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ABSTRACT OF DISSERTATION

EXAMINING CHILDHOOD OUTCOMES IN NEONATAL ABSTINENCE
SYNDROME
Rates of neonatal abstinence syndrome have been rising over the past several years,
alongside rising rates of opioid use disorder, propelled by the continuing Opioid Epidemic
ravaging the country. Children born withdrawing from opioids they were exposed to in
utero have known health complications through the first year of life that have been studied
in the current literature. Less is known, however, about the outcomes these children face
in childhood. As many of these children are progressing to childhood, there is an urgent
need for healthcare system to prepare to handle the health needs of these children; outcomes
related to child development for these children have not been well-established within the
literature.
Using data procured from the Kentucky Medicaid Management Information
System, a study population consisting of all Kentucky children born on Kentucky Medicaid
between 2014 and 2019 was created. This data was linked to select information available
on the child’s birth certificate from the Office of Vital Statistics, including indicators of
prenatal health and certain maternal health characteristics. This study population formed
the base population for the studies conducted within this chapter and provided a
homogenous group under a common set of healthcare policies administered by one public
insurance organization in one southern state.
Chapter 1 introduces the scope of the problem in Kentucky, as well as establishing
some background into the condition. In Chapter 2, a literature synthesis was conducted in
which outcomes in Medicaid populations were assessed and gaps in the literature were
determined. Chapter 3 provides overarching methodology for the dissertation as well as
basic demographic information for the entire study population.
Chapter 4 provided an assessment of socioemotional developmental factors for
children, which, in the context of this work, was defined as family characteristics and
structure. Specifically, a mother’s enrollment on Medicaid, the enrollment of siblings on
Medicaid, evidence of siblings with prenatal exposure to opioids, foster care involvement,
and whether a child was located at the same household as the mother were assessed. A
cross-sectional logistic regression analysis was designed to establish the odds of a child
with prenatal opioid exposure being in a different household than the mother, as well as a
discussion of the factors that contribute to a child being located at a different address than
the mother and the implications of that displacement.

In Chapter 5, physical health, here defined as gastrointestinal conditions and
respiratory conditions, were explored through a data exploration that led to a descriptive
study to establish evidence of whether such an association existed. Asthma created a signal
indicating that such an association may exist for children prenatally exposed to opioids in
utero. The population was subset to children born in 2016 through 2019 and a logistic
regression analysis was again conducted to ascertain whether there was evidence of such
an association existing that could be explored in later analyses.
Also in Chapter 5, cognitive development outcomes were assessed, here defined as
the diagnosis of a mental health condition identified in two previous works on the subject.
After assessing the prevalence of the conditions in the population of children born in 2014
and 2015, the population was subset again to only include children born in 2014 and with
one continuous year of enrollment in the database. Again, a logistic regression analysis was
conducted to ascertain the odds of a child with prenatal opioid exposure being diagnosed
with a mental health condition identified in two previous works.
Finally, in Chapter 6, a longitudinal data analysis was conducted to establish
whether the expenditures accrued by children with prenatal opioid exposure differed from
that of their peers over time. A linear mixed model with an exponential power decay
covariance structure, restricted maximum likelihood estimators, and model-based standard
errors was utilized in the analysis.
Chapter 7 provides overall conclusions and policy recommendations for the
Medicaid system based on the findings of the dissertation.
KEYWORDS: neonatal abstinence syndrome, child development, childhood outcomes,
Medicaid, Kentucky Medicaid, prenatal opioid exposure
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CHAPTER 1. INTRODUCTION
1.1

Background
With the expanding Opioid Epidemic continuing to impact communities across the

country in the years since approximately 2012, neonatal abstinence syndrome, or NAS, has
also seen a surge of interest in recent years. Neonatal abstinence syndrome refers to the
withdrawal symptoms that arise following in utero exposure to substances due to maternal
use. Recently the term has become synonymous with neonatal opioid withdrawal
syndrome, or NOWS, but this has not always been the case.
A simple PubMed search of the literature using the keyword “neonatal abstinence
syndrome” revealed that the earliest archived article on the subject dates back to 1974: a
literature review on the subject by Phyllis Burosch.1 Google Scholar could trace the interest
in the subject back even further, with a literature review by Cobrinik et al. published in
Pediatrics in 1959.2 A historical perspective published in 2018 in Frontiers of Pediatrics
traced documentation of the syndrome following exposure to opioids back to 18753;
Kocherlakota also identified these same origins in a review article published in 2014.4
Despite the long history, and given the acceleration of the Opioid Epidemic, the
literature on the subject began its expansion around 2012. 75 articles were archived on
PubMed in 2012, a 44.23% increase from the 52 articles in 2011. Even with a global
pandemic in 2020 disrupting academic research, the literature has remained consistently
above this threshold since 2012; 85 articles have been published between January 1, 2021
and May 23, 2021 alone.
Yet despite the increased interest in the subject, significant gaps in the literature
persist. Childhood outcomes following NAS remain a relatively understudied body of
work. To understand how a condition experienced in infancy could disrupt childhood
development, biological aspects at play behind the syndrome must first be understood.
1.2

Pathophysiology of NAS and Treatment
In 2014, Kocherlakota noted that the pathophysiological mechanisms of opioid

withdrawal are relatively unknown and “…is more complex in neonates as a result of
immature neurologic development, impaired neurologic processing, and complex
1

materno-feto-placental pharmacokinetics.”4 Opioids are central nervous system agents.5 In
fetal development, the central nervous system is one of the earliest systems to begin
developing6 and one of the last to complete development, with the prefrontal cortex
continuing its maturation far past infancy until around age 25.7
Pregnancy also complicates all aspects of drug action, from metabolism to
clearance.8 Transport of compounds to the fetus occurs through the maternal circulatory
system and synctiotrophoblasts5 acting as gatekeepers for the allowance of materials to
cross the placenta.9 Opioids, in general, have a profile that favors their transport across
both the blood-brain barrier and the placental barrier.10,11
While a substance use disorder is a biopsychosocial phenomenon that arises
following use of a substance of abuse12, tolerance and dependence are biological responses
to substance use.13 Tolerance refers to the need for increased dosage or administration of
a substance to elicit a previous effect, and dependence refers to the adaptation of the body
to a substance to fulfill a certain role.14 Tolerance and dependence are symptoms of a
substance use disorder, but not a substance use disorder themselves15; tolerance and
dependence arise following exposure to a substance.13
Drug withdrawal is a phenomenon that can arise following the cessation of
exposure to a substance.16 Opioids, both licit and illicit, prescribed and acquired through
alternative markets, can precipitate withdrawal symptoms.16 Detoxification from these
substances in adults requires medical supervision, as the withdrawal can be dangerous.17
For neonates who obtained exposure to a substance during gestation, this is also likely
true.
NAS is a multisystemic condition, with the central nervous system, gastrointestinal
systems, and respiratory systems absorbing the brunt of the burden.18 A large portion of
neonates with NAS are treated in the neonatal intensive care unit (NICU).19 Treatment
protocols for NAS vary between hospitals, from the tools used to assess an infant’s need
for treatment of NAS to the pharmacological treatments utilized in the treatment process
of the syndrome.20 One of the most popular tools used to assess the need for
pharmacological treatment in NAS is the Finnegan Score, first published by Dr. Loretta
Finnegan et al. in 1975.21,22 Another tool growing in popularity was first published in 2017
after several quality improvement implementation cycles at Yale University, known as Eat
2

Sleep Console.23–25 The goal of both tools is to provide an objective determination of the
severity of the withdrawal symptoms experienced by a neonate.21,23–25
In general, when withdrawal symptoms begin in a neonate, non-pharmacological
treatment therapies, such as swaddling and baby massage, are administered to the child.22
After repeated scoring, if the score cannot be held constant (i.e., “captured”) below a
threshold or continues to escalate, pharmacological treatment is administered to the
infant.22 In instances where the score continues to escalate following administration of a
pharmacological agent, treatment protocols either switch medications for NAS or add a
conjugant medication.22 When the score is captured and begins decreasing, a weaning
protocol off the pharmacological agent is initiated. Three common treatment agents for
NAS are morphine, a full opioid agonist; phenobarbital, a barbiturate; and clonidine, a
hypotensive agent.22 Other medications, such as methadone and buprenorphine, have also
been utilized in the treatment of NAS.22
Yet despite the dangers of withdrawal for a neonate, death rates in NAS remain
relatively low.26 Most of the children experiencing the syndrome in infancy will become
children. Despite a plethora of literature available on infant outcomes in NAS, relatively
little exploration on child development following NAS has been conducted.
1.3

Child Development
To speak of child development is to speak of the way a child grows and copes with

the world around them.27 Child development is not a straightforward, simple process, but
rather a result of all the biological, social, and psychological inputs to a child.27 Because
the process relies so heavily on the subjective experiences throughout a child’s life, no
child will ever develop in a perfectly optimal environment. Every child will face challenges
of varying magnitudes throughout their growth and development, with worst case scenario
being a traumatic experience, and each child will respond to such challenges and traumatic
events differently.28
Dr. Laura Berk identified three domains of child development in her textbook on
the subject: physical development, cognitive development, and socio-emotional
development.29 Physical development refers to biological and visually apparent indicators
of the growth trajectory of a child: body composition, pathogenesis, among others.29
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Cognitive development refers to the neurological and psychological aspects of the process
of maturation: for instance, the child’s mental health concerns, neurological conditions,
learning capacity, and communication capabilities.29 Socio-emotional development refers
to advances in relational milestones, such as the forming of friendships, attachment to
parents, and a child’s adaptation into societal norms, customs, and contexts.29 Childhood
outcomes, then, do not solely refer to health outcomes, but the holistic developmental
outcomes important to the child’s growth and maturity.
One of the assumptions throughout this work is that NAS results in biological
manifestations that have the potential to alter the developmental trajectories of the children.
Many biological inputs, such as prenatal opioid exposure, can be thought of as linear
processes, with the biological stimulus yielding a biological response30. These stimuli can
be interfered with and acted upon by other outside forces but, for the most part, the
consistent predictability of stimulus-response remains a necessary element to ensure
causality.30 This assumption lends itself to the examination of health utilization and
outcomes among children with NAS in order to understand the health outcomes of children
who had NAS.
Not only are biological factors important in the development of the child, but it is
well-known that the very social system the child exists also has the potential to alter the
child’s developmental trajectory.31 The biopsychosocial model of NAS is utilized as the
conceptual framework throughout this work, implying that the social system in conjunction
with the biologic input creates demonstrable differences in the development of children
throughout childhood.31 As such, the social (i.e., the familial) environment in which the
child develops within is an area of examination to understand the holistic development of
this population.
1.4

Purpose
The purpose of this dissertation is to examine childhood outcomes in neonatal

abstinence syndrome. Table 1.1 provides an overview of all the questions for research
within this dissertation, as well as their associated domains of development and hypotheses.
The analyses and studies within this work intend to provide a more holistic perspective of
child development by considering socioemotional components of development, physical
4

health-related components of development, and cognitive health components of
development for children undergoing this syndrome at birth. In Chapter 2, a literature
synthesis examining neonatal abstinence syndrome outcomes specifically assessed in
Medicaid populations was conducted. In Chapter 3, the data source and overarching
methodologies for the studies examined within this dissertation is discussed. In Chapter 4,
familial environments and guardianship factors are discussed for this population. Chapter
5 analyzes select health outcomes for this population. Chapter 6 examines healthcare
utilization and expenditures for this population. Finally, Chapter 7 provides some
concluding thoughts on all the studies conducted and policy recommendations based on
the discoveries of the preceding chapters.
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Table 1.1 Questions for research for the dissertation and associated domains of
development and hypotheses.
Question
Domain of
Hypothesis
Development
Are the family and social
SocioChildren with an NAS diagnosis
environments of children with
emotional
will be more likely to have
NAS diagnoses different from
siblings in the Medicaid system
that of other children?
and be enrolled in a different
household than their mother
than children without a
diagnosis of NAS.
Are children diagnosed with
Cognitive
Children with a diagnosis of
NAS also being diagnosed with
NAS will be more likely to be
mental health conditions at ages 1
diagnosed with a mental health
and 2 more frequently than other
condition at an early age
children?
compared to children without
the diagnosis.
Do children diagnosed with NAS
Physical
Children diagnosed with NAS
have more diagnoses of
will have more gastrointestinal
gastrointestinal conditions than
conditions diagnosed than
other children?
children without a diagnosis of
NAS.
Do children diagnosed with NAS
Physical
Children with a diagnosis of
have more diagnosed respiratory
NAS will have more respiratory
conditions diagnosed than other
conditions diagnosed than
children?
children without a diagnosis of
NAS.
Are children with a diagnosis of
Physical,
Children with a diagnosis of
NAS more expensive for the
cognitive,
NAS will have higher healthcare
Medicaid system than other
socio-emotional
expenditures than children
children?
without a diagnosis of NAS
through the duration of early
childhood.
Do children with NAS utilize
Physical,
Children with a diagnosis of
more health services than other
cognitive,
NAS will utilize more health
children?
socio-emotional services than children without a
diagnosis of NAS through the
duration of early childhood.
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CHAPTER 2. LITERATURE SYNTHESIS: NEONATAL ABSTINENCE SYNDROME IN MEDICAID
POPULATIONS
2.1

Background
In an American healthcare context, it is impossible to separate the provision of

healthcare from a person’s insurance coverage. Children, for the most part, are covered by
one of three mechanisms: as a dependent on a private insurance plan enrolled in by their
parents, Medicaid, or through the Children’s Health Insurance Program (CHIP).32 CHIP
began in 1997.32 States were charged to administer their own CHIP programs for infants
meeting 200% of the federal poverty line (FPL) threshold; states additionally have the
option to expand this coverage capacity and most do.32–34 CHIP insures children ages 1 to
18.34 The missing year in a child’s life before CHIP eligibility begins – the period from
birth until the first birthday – is most frequently covered as part of a Medicaid program.32,34
Medicaid as a program began in 1965.35 In its original role, the program existed to
cover low-income families, children, some older adults, and adults with disabilities.36
Following the passage of the Affordable Care Act (ACA), Medicaid expanded the coverage
to include adults without dependent children. Currently, 39 of the 50 States, as well as
Washington, D.C., have expanded their Medicaid coverage.36,37 Many state regulations and
state laws, such as Kentucky Revised Statute § 205.592 in Kentucky, require coverage of
the infant on Medicaid from birth through the first year of life.39
In NAS, Medicaid has been identified as an important payer source, with more than
80% of the burden of payment for NAS falling to the Medicaid system.39 Children on
Medicaid, because of factors related to social determinants of health, face unique
challenges. Low socioeconomic status, inherent to qualifying a child for Medicaid, has
been associated with suboptimal child development, particularly in cognitive
development.40 Thus, examination of Medicaid populations provides important context for
understanding NAS and child development overall. The purpose of this literature synthesis
is to synthesize the literature for published articles on NAS outcomes in Medicaid
populations and identify common themes throughout the published works.

2.2

Methods
A literature synthesis was conducted in the PubMed database using the keyword

“(neonatal abstinence syndrome OR prenatal expo* OR prenatal opioid expo*) AND
Medicaid” between March 3, 2020 and May 28, 2021. The literature was then filtered to
only include research identified as having been published within the past 10 years and in
English. Resulting articles were then reviewed at an abstract level to determine inclusion
in the literature synthesis. Following the abstract-level review, the full article was the
assessed and a determination for inclusion in the final review was made. Resulting articles
appearing in this synthesis were then compiled into a summary table and common thematic
elements from the literature were determined to form this literature synthesis.
2.3

Results
The initial search result yielded 135 results. Filtering for studies published within the

past 10 years narrowed the results to include 99 articles, and studies published in English
did not result in any excluded articles. Abstract review ascertained 66 articles as eligible
for full review. Full review of the discovered literature left 43 articles available for
inclusion in this literature synthesis. A flow chart depicting this process is available in
Figure 2.1.
The discovered literature ranged from publications in 2012 through 2021. A
summary of all the included literature with select findings is available in Table 2.1.
Following full review, four overall themes emerged in the literature synthesized within this
chapter: studies on prevalence and demographics, as well as validation studies used to
identify NAS in databases; analyses of infant outcomes; development-related studies; and
economic impact investigations.
Two papers had findings that did not match any of these extracted themes. A study
by Wen et al. published in 2021 found that exposure to prescription opioids in later
pregnancy (meaning the second and third trimesters) increased the risk of congenital
malformations.41 Additionally, findings in a health utilization paper by Corr et al. found
that infants with NAS in Medicaid systems were more likely to have respiratory diagnoses
and developmental delays than children without NAS.42
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2.3.1

NAS Primers: Prevalence, Demographics, and Validation Models

The prevalence of NAS has been an area of interest for states due to the increased
attention on the syndrome across the United States. The earliest estimates of this condition
were established by Patrick et al. in 2012.43 In this study, the authors identified that the
incidence of NAS between 2000 and 2009 had risen from 1.2 in every 1,000 births to 3.4
in every 1,000 births.43 In 2013, a study by Pan and Yi found increases in rates of NAS
between 1999 and 2008, coinciding with increases in rates of the use of opioids; during
this same time period, alcohol and cocaine use decreased within their study population.44
Patrick et al. revisited incidence rates of NAS in a 2015 study, finding that a region of the
United States consisting of Kentucky, Tennessee, Mississippi, and Alabama had the
highest incidence of NAS, closely followed by the New England states (identified as
Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut).39 In
2020, Alemu et al. looked at demographics, length of stay, and hospital characteristics
associated with NAS, finding that children with NAS were largely male, White, and had
more clinical conditions than other children; additionally, these children were more rural
than their counterparts and less likely to be at an urban non-teaching hospital.45 Consistent
with the findings of Patrick et al. in 2015, Alemu also found that rates of NAS were higher
in the South and in the Northeast.45 Another 2020 study by Ramphul et al. found that 0.8%
of all births were NAS births, with the majority of infants born with NAS being male,
White, and southern.46 A 2021 study by Hirai et al. also investigated changes in rates of
both NAS and maternal opioid-related diagnoses, both nationwide and for each state within
the United States, finding that, between 2010 and 2017, rates of NAS increased slightly
across the United States.47
Several studies focused solely on NAS in specific states. NAS in Wisconsin was
investigated by Atwell et al. in 2016, finding that the rate of both NAS and maternal
substance use was increasing, though maternal substance use was increasing faster than the
rate of NAS.48 In 2017, Okoroh et al. found that, between 2003 and 2013, rates of NAS
increased in Louisiana from 2.1 in every 1,000 births to 8 in every 1,000 births while rates
of exposure to opioids increased from 2.2 in every 1,000 births to 12.6 in every 1,000
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births.49 In Florida, consistent results were found, with increases in the rate of both NAS
and SUD diagnoses during the time period investigated by Wang et al.50
Stabler et al., in 2017, looked at rates of NAS and substance use trends in West
Virginia between 2007 and 2013, finding that NAS had increased during this time period;
of note, use of opioids had increased while use of cocaine had decreased.51 In 2018,
Rogerson et al. did a study on factors associated with NAS in West Virginia, finding that
areas with higher rates of Medicaid enrollment also had higher rates of NAS.52 In 2021,
Umer et al. found that the rate of NAS between 2017 and 2019 in West Virginia was higher
for infants covered by Medicaid, with the rate among the Medicaid population at 85.8 in
every 1,000 births compared to the state average of 52.4 in every 1,000 births.53
Hussaini and Garcia Saavedra, in a 2018 study, examined factors associated with
NAS in Arizona and New Mexico, finding that incidence rates increased in both states
between 2008 and 2013.54 Findings using data from infants born on Texas Medicaid
between 2010 and 2014 found that rates of death were increased among the infants with
known opioid exposure but without a diagnosis of NAS, with about a quarter of these
deaths due to sudden unexplained infant death.55 Incidence rates of NAS in Nevada were
also examined by Batra et al. in 2020, finding that, compared to previous 2013 estimates,
rates of NAS were consistently higher, despite a dip in the incidence rate of NAS in Nevada
between 2016 and 2018.56 A 2021 study using the population of infants in Oregon Medicaid
by Ko et al. found that the rate of NAS between 2008 and 2012 was 5.8 in every 1,000
births.57
In 2017, a methodology paper by Brogly et al. presented a novel method of
accounting for confounding that would not otherwise be available in administrative claims
data.58 Maalouf et al. also ascertained a PPV for the ICD-9 and ICD-10 codes associated
with NAS.59 ICD-9 code 779.5 had a positive predictive value (PPV) of approximately
91% while ICD-10 code P96.1 had a PPV of approximately 98.2%.59
2.3.2

Infant Outcomes

Infant outcomes, defined here as infants throughout the first year of life for a child,
have been one of the most widely assessed areas of research for children with this
condition. Many reasons are possible for the increased assessment of outcomes during this
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period of a child’s life. One potential explanation could be continuity of coverage and loss
to follow-up after the first year of a child’s life. Studies utilizing administrative claims data
to follow children, such as was used by Taylor et al., could see coverage for the child
interrupted following this period as the child is passed to other health insurance coverage
options or due to changes in parental health insurance coverage.60 Another reason could be
loss to follow-up from clinics as children age out of programs and providers making
follow-up or examination beyond this period of a child’s life difficult for researchers.
Nevertheless, whatever the reason, this period of life for children with NAS has garnered
significant attention.
A study by Parlett et al. in 2019 found that commercially-insured infants with NAS
often had more clinical characteristics suggestive of severe NAS and prescription opioid
use was more common among commercially-insured mothers of infants with NAS.61
Additionally, alcohol use and tobacco use seemed to be more common among mothers
with Medicaid than mothers with commercial insurance.61
NAS itself was frequently treated as an outcome of interest. In 2015, Desai et al.
assessed the risk of NAS based on how long a mother had been using an opioid medication
and the trimester with which the use was taking place, finding that long-term use increased
the risk of NAS as did use later in pregnancy.62 A similar finding was published in 2020
by Patorno et al., who examined gabapentin and neonatal outcomes, finding that later use
of gabapentin increased the risk of adverse neonatal events like neonatal malformations,
pre-eclampsia, preterm birth, small for gestational age, and NICU admission.63 In 2015,
Patrick et al. looked at the risk of NAS based on MMEs, finding that the risk of NAS
largely seems to ceiling among long-acting formulations as MMEs increase, though the
risk of NAS rises much quicker as MMEs of short-acting opioid formulations increases.64
Also in 2017, Charles et al. found that NAS was associated with male sex and that male
infants differed from female infants in several ways that have been shown to influence the
manifestation of NAS symptomologies.65 A 2020 study by Ma et al. found increased odds
of NAS and NICU admissions among mothers with serious mental illness and gestational
opioid use, with the group of mothers using buprenorphine or methadone and the group of
mothers with opioid use disorder having the highest odds; both of these groups also saw
increases in NICU admissions.66 Using Pennsylvania Medicaid data, Krans et al. in 2021
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found that 57.9% of infants were diagnosed with NAS following maternal use of MOUD.67
The findings of this paper also examined neonatal outcomes as they relate to the duration
of maternal use of MOUD.67 The authors found that longer duration of MOUD did increase
the odds of NAS, even after adjustment, but decreased the odds of low birthweight.67
Finally, in 2021, Patrick et al. published an article using Tennessee Medicaid data
proposing a model to predict NAS in both a general risk and high risk category.68
In 2019, Sanlorenzo et al. found that concurrent maternal use of benzodiazepines
increased the odds of an infant needing pharmacological treatment to relieve NAS
symptoms.69 Huybrechts et al. found something similar in 2017, adding that
antidepressants and gabapentin also increased the risk alongside benzodiazepines.70 These
two additional medications were not consistent with the findings from the Sanlorenzo et
al. paper.69,70
Treatment options for infants with NAS also produced several articles included
within this literature synthesis. Lee et al. published findings from a combined inpatient and
outpatient clinic for NAS treatment, finding that hospitals with more cases of NAS often
had lower lengths of stay than other hospitals, but the methadone program seemed to be
decreasing length of stay until a switch to morphine as the primary medication for the
treatment of NAS within the hospital occurred in 2013.71 In 2012, a study examining the
use of acupuncture in the treatment of NAS was published.72 In 2017, Lai et al. published
findings from a treatment program that allowed children to finish a wean from methadone
in an outpatient setting, finding that it took approximately 7 days for the infant to reach
every 24 hour dosing, but that the outpatient program did reduce length of stay in the NICU
from 12 days to 10 days.73 Maalouf et al. in a 2018 paper also examined outpatient
pharmacotherapy for these children, finding that phenobarbital is the most common
medication given for NAS in an outpatient setting, though the length of treatment for
infants in an outpatient setting is often much longer than patients in an inpatient setting (60
days of treatment compared to 19 days of treatment).74
A study by Rebbe et al. also examined hospital factors associated with reports to
CPS within 7 days of a child being born with prenatal opioid exposure, finding that opioids
were the most common substance for which a report was made and less prenatal care also
increased the risk.75 Additionally, serving more Medicaid patients also increased the odds
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of a report being made to CPS.75 In a similar line of thought, a study by Austin et al.
investigated diagnoses of injuries, maltreatment, and developmental delays among the
population of infants born with NAS, finding increased rates of maltreatment among opioid
exposed children, with 51.4% of maltreatment diagnoses being physical abuse.76
2.3.3 Childhood Cognitive Development
Childhood cognitive development has also attracted significant attention for
research in children with NAS. Cognitive development is a critical aspect of child
development and an element that underlies all other aspects of development for a child: the
psychiatric profile and integrity of development for a child can alter the progression of a
childhood experience, and that altered trajectory can impact adulthood. Fill et al. in 2018,
for instance, examined educational disabilities among Tennessee children diagnosed with
NAS.77 More children with a history of NAS diagnosis were diagnosed with educational
disabilities and referred for services than other children; additionally, more children with
NAS received additional educational services, such as occupational therapy and speech
therapy.77 The primary driver of these findings seemed to be developmental delays.77
Sherman et al. looked at diagnoses of mental health conditions for children with a history
of NAS diagnosis in 2019, finding elevated rates of all conditions for children with NAS.78
This work was extended by Conner et al. in 2020 to a commercially-insured population,
finding that the rate of NAS was much higher in the Medicaid population than in the
commercially-insured population79, as well as finding consistent results to the results found
by Sherman et al.78,79
2.3.4

Economic Impact

With the prevalence of NAS being significantly higher in Medicaid populations
compared to commercially insured populations, the economic impact of these children to
the Medicaid system has also been assessed. Patrick et al., in 2012, identified a 35%
increase in costs between 2000 and 2009 for infants with NAS compared to a 30% increase
among other infants.43 The study in Louisiana Medicaid by Okoroh found that the average
NICU costs for infants with NAS was almost 4 times higher than NICU costs for other
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infants between 2003 and 2013.49 In 2018, Winkelman et al. found that infants insured by
commercial insurance, except between 2011 and 2014, were more costly to treat than
infants covered by Medicaid, though the differences were not statistically significant.80
Clemans-Cope et al. found that, while methadone decreased the costs associated with NAS
treatment for infants, infant costs for all infants of mothers with SUD were higher than
infant costs for infants of mothers without SUD.81
In a seminal study on healthcare utilization of infants with NAS, Taylor et al. found
that infants with NAS had more ED visits and less outpatient visits than the comparator
group, though the differences seemed to diminish as clinical characteristics were
considered within analyses.60 This was consistent with the findings of Ko et al. in 2021
using Oregon Medicaid data, showing increased sick visits and emergency department
utilization at four weeks and one year.57 Another seminal study by Corr et al. following
this population of infants for 11 years found similarly, showing increased use of emergency
departments in the first two years of life for the infants in the study.42 Corr et al. observed
that differences among utilization between these two groups of infants diminished as the
children grew older.42
Dickes et al. in 2017 suggested a cost-saving model for Medicaid, estimating that,
without intervention, costs to the Medicaid system will continue to rise at a quick rate.82
2.4

Discussion
The literature review confirmed that rates of NAS have been rising since 200043, with

increased attention to the syndrome occurring largely because of the increase in the
utilization of prescription opioids and the escalation of the Opioid Epidemic64. The
demographic profile of children with NAS is also largely similar: majority male45,46,65,
majority White45,46, largely in the South39,45,46 or in New England45,64. A notable exception
to these findings were from the study of Arizona and New Mexico, in which NAS in New
Mexico had a different demographic profile than identified in other studies.54 Additionally,
every study in the literature synthesis that utilized a non-Medicaid data source identified
Medicaid as the most frequent payer source for NAS.43,52,53,61,75,78–80
Validation studies for the utilization of Medicaid administrative claims data to
analyze NAS59, as well as the development of a predictive model68, have also been
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published in the NAS literature. These studies were conducted using Tennessee Medicaid
data linked to vital records data as a source dataset59,68; medical records were also obtained
to ascertain a positive predictive value in the validation study for the Medicaid
population.59 Nevertheless, these studies provide sufficient evidence that utilizing
Medicaid administrative claims data with linked records from vital statistics provides a
sufficient dataset for examining childhood outcomes in NAS.
Investigation into the first year of life for a child was plentiful in the literature, with
many of the articles included in this synthesis being cross-sectional in nature.39,43–
49,51,52,54,56,71,75,79,80

This again emphasizes the need for additional investigation into

childhood outcomes for children with NAS to extend the literature in this area.
Childhood cognitive development received a significant amount of attention in the
discovered literature. Both Sherman et al. and Conner et al. investigated the development
of childhood mental health conditions in this population.78,79 However, the ages
investigated by both groups of researchers ranged from age one to age five and neither
analysis investigated the age at which a child was diagnosed. This suggests the potential
for a child aged one or two to be diagnosed with one of these conditions, which may
represent the need for additional investigation regarding the source of the diagnosis.
Largely, debates regarding diagnosing children with mental health conditions at an early
age has been an issue eliciting much attention83,84; many of the diagnoses obtained by oneand two-year-old children should be developmental delays, with estimates for these
diagnoses at ages 9 and 24 months being as high as 13%.85 Additional investigation is
warranted to ensure the appropriateness of diagnoses of mental health conditions for these
populations.
While a significant amount of literature was found concerning the cognitive
development of children with a history of NAS, little information on the physical health of
children with NAS was ascertained in the literature review.41 NAS has been identified as a
condition that affects multiple physical systems in an infant’s body: the central nervous
system, the respiratory system, and the gastrointestinal system. Additionally, the brief
insight by Conner et al. into most frequently prescribed medications for this population
identified antiasthmatic and bronchodilator agents as a commonly prescribed medication.79
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Additionally, Corr et al. identified increased rates of respiratory diagnoses among children
with a history of NAS42, warranting additional investigation.
Finally, children with NAS have a significant economic impact for the Medicaid
system. The paper by Taylor et al. showing long-term healthcare utilization of children
with a diagnosis of NAS is a seminal paper in studies of the economic impact of NAS.60
This paper showed that differences in healthcare utilization largely decreased over time for
the group of children with NAS, with clinical characteristics of the children diminishing
the gap in expenditures even further.60 However, while the work conducted in this analysis
is exemplary and should be held as the standard for analyses regarding NAS, the period
examined within this study ranged between 1999 and 2011, prior to the beginning of the
Opioid Epidemic.60 This may represent a different generation of substance use disorder and
different ideas surrounding the treatment and continued care of infants with NAS.
Additionally, the states investigated in the analysis consisted solely of New York and
Texas60; the findings from these two states may not be generalizable to other populations
and merits additional investigation in different populations in more recent data. In another
seminal study, Corr et al. filled some of these gaps by evaluating an eleven-year cohort
from 2003 to 2013, the longest cohort examined in the literature synthesis.42 These authors
found similar findings, showing that healthcare utilization among children diagnosed with
NAS ceased to be statistically different from the comparator group after age 3.42 However,
like in the Taylor et al. study60, the last year of data in the study population is 2013,
representing an early period of the Opioid Epidemic42, and thus may not be generalizable
to the current population of children diagnosed with NAS.
The work in the next chapters of this dissertation will attempt to fill many of the gaps
identified within the course of this literature synthesis.
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Figure 2.1 Flow chart depicting inclusion and exclusion criteria for the literature
synthesis.
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Table 2.1 Summary of literature included in the literature synthesis.
Year of
Publication

Authors

Journal

Title

Data

Design

Outcomes

Years
Examined

Notable Findings

2012

Stephen
W.
Patrick,
et al.

JAMA

Neonatal
Abstinence
Syndrome and
Associated
Healthcare
Expenditures:
United States,
2000-2009

Kids’
Inpatient
Database;
National
Inpatient
Sample

Crosssectional

Length of
stay,
hospital
charges

2000 to
2009

2012

Amanda
C.
Filippelli,
et al.

Global
Advances
in Health
and
Medicine

Non-insertive
Acupuncture
and Neonatal
Abstinence
Syndrome: A
Case Series
From an Innercity Safety Net
Hospital

Boston
Medical
Center
Pediatric
Ward

Retrospective
chart review

Sleeping;
feeding;
adverse
events

May 26,
2009 to
October
30, 2010

2013

I-Jen Pan
and
Hsaio-ye
Yi

Maternal
and Child
Health
Journal

Prevalence of
hospitalized live
births affected
by alcohol and
drugs and
parturient
women
diagnosed with
substance abuse
at liveborn
delivery: United
States, 19992008

Nationwide
Inpatient
Sample

Crosssectional

Live births
affected by
transfer of
substances
across the
placenta;
maternal
substance
use disorderrelated
diagnoses;
estimated
costs;
lengths of
stay

1999 to
2008

78.1% of children with
NAS are covered by
Medicaid. The rate of
NAS rose between 2000
and 2009 from 1.2 per
1,000 births to 3.4 in
1,000 births, concurrent
with an increase in total
costs (an increase of
35% for expenditures
associated with NAS,
30% for all others).
Length of stay
associated with NAS
was consistent for the
duration of the study
period.
87% of the infants in the
study were covered by
Medicaid. Study
population consisted of
157 infants with NAS,
among which 54 got
acupuncture. The entire
study population had a
total of 92 acupuncture
treatment sessions. 28
infants slept through the
treatment or fell asleep
upon completion of the
treatment while better
feeding was reported
among 8 of the infants.
Neonates affected by
alcohol and cocaine
trended down during the
study period while
neonates affected by
narcotics,
hallucinogens, NAS,
and unspecified
substances of abuse
trended up. Diagnoses
related to maternal
alcohol use remained
consistent throughout
the study period while
maternal cocaine-related
diagnoses trended
down. All other drugs
trended up. In 2001,
64.3% of the neonates
affected by substances
of abuse were covered
by Medicaid; by 2008,
this had risen to 77.9%.
60% of the mothers with
a substance-related
diagnosis were covered
by Medicaid.
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Table 2.1 Continued.
2015

Rishi J.
Desai, et
al.

BMJ

Exposure to
prescription opioid
analgesics in utero
and risk of neonatal
abstinence
syndrome:
population based
cohort study

Medicaid
Analytic
eXtract

Cohort

Diagnosis of
NAS within
30 days of
birth

2000
to
2007

2015

Stephen
W.
Patrick,
et al.

Journal of
Perinatology

Increasing
incidence and
geographic
distribution of
neonatal abstinence
syndrome: United
States 2009 to 2012

Kids’ Inpatient
Database and
Nationwide
Inpatient
Sample

Serial
crosssectional

Incidence
rates of NAS;
geographic
variation in
rates of NAS;
healthcare
utilization

2009
to
2012

2015

Jerry
Lee, et
al.

Population
Health
Management

Neonatal
Abstinence
Syndrome:
Influence of a
Combined
Inpatient/Outpatient
Methadone
Treatment Regimen
on the Average
Length of Stay of a
Medicaid NICU
Population

AmeriHealth
Caritas
Pennsylvania’s
Medicaid
members
managed by
Progeny
Health

Serial
crosssectional

Length of
stay,
differences
between
hospitals,
contributing
factors
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Among the women included in
the study, 1.7% of women in
the study had a diagnosis
related to opioid misuse or
dependence while all other
forms of substance use
disorders (including alcohol)
were around 9.8% of the
population. Long-term opioid
use increased the risk of a
child being born with NAS
compared to short-term opioid
use. Use of opioids later in
pregnancy increased the risk of
NAS compared to use earlier
in pregnancy.
The East South Central region
of the United States
(Kentucky, Tennessee,
Mississippi, and Alabama) and
New England (Maine, New
Hampshire, Vermont,
Massachusetts, Rhode Island,
and Connecticut) had the
highest incidence of NAS. The
average length of stay for
infants with NAS was
approximately 16 days; with
assumed pharmacological
treatment (defined as any
length of stay exceeding 6
days), the average length of
stay rose to 23 days. 82% of
the births with a diagnosis of
NAS were covered by
Medicaid; Medicaid also bore
the costs of most births in the
study.
Rates of NAS rose in the
population between 2007 to
2013 from 0.2% to 7.3%. The
most common treatments for
NAS included morphine and
morphine with adjuvant
phenobarbital. Length of stay
was decreased for the
population treated with
methadone. Across hospitals,
the more cases of NAS a
hospital handled, the lower the
length of stay tended to be.
Length of stay increased when
a switch to morphine was
made in May 2013. Among
readmissions in the outpatient
weaning program, there was
only one readmission related
to NAS (specifically due to
missed methadone doses in the
outpatient weaning).

Table 2.1 Continued.
2015

Stephen
W.
Patrick,
et al.

Pediatrics

Prescription
opioid
epidemic and
infant outcomes

Tennessee
Medicaid
with linked
Vital
Statistics
data

Cohort

NAS diagnosis

2009
to
2011

Approximately 41.8%
of the population
evaluated utilized
tobacco while 0.8% of
the population during
this study period had a
diagnosis related to
opioid dependency. The
rate of NAS increased
during this period. The
risk of NAS seemed to
reach a ceiling as MMEs
increased and the
number of daily
cigarettes increased, but,
overall, trended upward.
Short-acting opioids
increased the risk of
NAS much faster for the
MMEs evaluated,
however, the MMEs
evaluated were also
much lower compared to
the long-acting
formulations.

2016

Karina
A.
Atwell,
et al.

Wisconsin
Medical
Journal

Neonatal
Abstinence
Syndrome and
Maternal
Substance Use
in Wisconsin,
2009-2014

Wisconsin
Hospital
Discharge
Data

Crosssectional

Newborn
substance
exposure;
maternal
substance use;
length of stay;
hospital
charges;
adverse
neonatal
clinical
characteristics
and
demographics

2009
to
2014

Rates of NAS and
maternal substance use
both increased during
the study period, but
maternal substance use
increased at a faster rate
than NAS. 82% of the
deliveries resulting in
NAS were covered by
Wisconsin Medicaid.
Substance use was
higher in the Medicaid
population than the
other population.

2017

Andrew
Lai, et
al.

Population
Health
Management

An Outpatient
Methadone
Weaning
Program by a
Neonatal
Intensive Care
Unit for
Neonatal
Abstinence
Syndrome

Hospital data
from a
hospital in
southeastern
Pennsylvania

Retrospective
chart review

Demographics;
length of stay
in the NICU;
time to dosing
weaned down
to every 24
hours;
readmissions

20

The population was
majority male (58.5%)
and majority white
(71.2%). Medicaid was
the payer for the
majority of the births.
Length of stay was
approximately 12 days.
For infants on the
methadone treatment
regimen, length of stay
was approximately 10
days prior to discharge.
The average length of
stay to reach 24-hour
dosing was 7 days.
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M.
Katherine
Charles,
et al.

Hospital
Pediatrics

Male Sex
Associated With
Increased Risk of
Neonatal
Abstinence
Syndrome

Tennessee
Medicaid
linked to Vital
Statistics

Cohort

Diagnoses of
NAS; length
of stay

2009 to
2011

2017

Maegan
E.
Stabler,
et al.

Journal of
Rural Health

Neonatal
Abstinence
Syndrome in
West Virginia
Substate Regions,
2007-2013

Hospital
inpatient
discharge data
from West
Virginia

Serial
crosssectional

Incidence
rates of NAS
and substance
exposure

2007 to
2013

2017

Ekwutosi
M.
Okoroh,
et al.

Maternal and
Child Health
Journal

Neonatal
Abstinence
Syndrome: Trend
and Expenditure
in Louisiana
Medicaid, 20032013

Louisiana
Medicaid
linked to vital
records

Serial
crosssectional

Incidence
rates of NAS
and substance
exposure;
healthcare
costs

2003 to
2013

2017

Susan B.
Brogly,
et al.

American
Journal of
Epidemiology

Neonatal
Outcomes in a
Medicaid
Population With
Opioid
Dependence

Massachusetts
Analytic
eXtract paired
with
prospective
cohort data

Descriptive;
prospective
cohort

Preterm
births, low
birth weight,
length of stay

2006 to
2011 for
Medicaid
data;
2015 to
2016 for
cohort
data
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Mothers of infants born
male tended to be older and
heavier smokers. Male
infants with NAS were born
earlier (i.e., more preterm),
but had higher birthweights
than infants with NAS born
female. The overall risk of
NAS was insignificant in
the unadjusted model but
became significant when
adjusted.
85% of the births in the
study had Medicaid as the
payer source. Most of the
diagnoses were related to
exposure to opioids (i.e.,
narcotics) and this increased
over time while the rate of
cocaine-exposed births
decreased over time.
During the study period, the
rate of exposure to
substances of abuse rose
from 2.2 in every 1,000
births to 12.6 in every 1,000
births while the rate of NAS
rose from 2.1 in every 1,000
births to 8 in every 1,000
births. 20.1% of the mothers
of the substance exposed
infants had a diagnosis
related to opioid use
disorder or dependence;
33.2% of those mothers had
a concurrent mental illness.
25.1% of mothers of infants
with NAS had a prescription
for hydrocodone. 81% of
the infants with NAS were
treated in the NICU. The
NICU costs for infants with
NAS were roughly four
times higher than the NICU
costs for infants without
NAS.
After adjusting for solely
confounders from the
Massachusetts MAX data,
infants with mothers on
buprenorphine had lower
risk of both preterm birth
and low for gestational age
birthweight compared to
infants of mothers on
methadone; after adjustment
with data from the
prospective cohort study,
the risk of preterm birth for
infants whose mothers were
treated with buprenorphine
was lower than mothers
treated with methadone, but
the risk of low for
gestational age birthweight
increased.
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Lori
Dickes, et
al.

Population
Health
Management

Potential for
Medicaid
Savings: A
State and
National
Comparison of
an Innovative
Neonatal
Abstinence
Syndrome
Treatment
Model

South
Carolina
inpatient
discharge
data

Cohort

Average
inpatient
charges; 3
expansion
scenarios
based on
variations in
the scope of
the program
and the length
of stay for
neonates

2006
to
2014

2017

Krista F.
Huybrechts,
et al.

BMJ

Risk of
neonatal drug
withdrawal
after
intrauterine coexposure to
opioids and
psychotropic
medications:
cohort study

Medicaid
Analytic
eXtract

Cohort

NAS; proxy
measures for
withdrawal
severity

2000
to
2010

2017

Xi Wang, et
al.

Pharmacotherapy

Trends of
Neonatal
Abstinence
Syndrome
Epidemic and
Maternal Risk
Factors in
Florida

Florida
Medicaid
Analytic
eXtract
linked to
birth
certificates

Cohort

Opioid
prescription
90 days
before
delivery;
NAS;
antidepressant
use; SUD
diagnoses;
tobacco use

2000
to
2010

22

Costs related to NAS
largely increased
between 2006 and
2014 in South
Carolina, with
Medicaid bearing the
brunt of the costs. NAS
rates were projected to
continue rising
between 2015 and
2025, which will lead
to a concurrent fast rise
in costs with no
intervention.
Increasing eligibility
into the treatment
model for NAS studied
here was projected to
produce significant
annual cost savings for
Medicaid programs.
Concurrent use of
antidepressants,
benzodiazepines, and
gabapentin seemed to
increase the risk of
neonatal withdrawal
compared to opioids
alone; use of 2 or more
psychotropics also
increased the risk of
withdrawal. The risk
rations were higher for
all with added
psychotropic
utilization.
Mothers of infants with
NAS tended to be
slightly older than
other mothers, with the
majority falling
between 25 to 29 years
old compared to 18 to
24 years for mothers of
infants without NAS.
Infants with NAS also
tended to be born more
preterm than other
infants. No significant
differences in prenatal
care. Tobacco use
(57.2% vs. 13.7%) and
antidepressant use
(13.7% vs. 2.7%) were
higher among mothers
of infants with NAS.
NAS rates increased
during the study period
as did SUD diagnoses.
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MaryMargaret A.
Fill, et al.

Pediatrics

Educational
Disabilities
Among Children
Born With
Neonatal
Abstinence
Syndrome

Tennessee
Medicaid
and birth
certificate
data linked
to
Tennessee
Department
of
Education
special
education
data

Cohort

Referrals for
evaluation;
eligibility for
services;
receipt of
therapies or
services

2018

Taylor
Rogerson,
et al.

Journal of
Opioid
Management

Factors
associated with
the prevalence of
neonatal
abstinence
syndrome in
West Virginia

Various
sources of
data related
to West
Virginia

Crosssectional

Rates of NAS

2018

Tyler N. A.
Winkelman,
et al.

Pediatrics

Incidence and
Costs of Neonatal
Abstinence
Syndrome
Among Infants
With Medicaid:
2004-2014

National
Inpatient
Sample

Serial
crosssectional

Rates of NAS;
rate of transfer
to other
facilities;
length of stay;
cost of birth
hospitalization
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2008
to
2011

2004
to
2014

No children with a diagnosis
of NAS had a recorded
intellectual disability
recorded as being
intellectually gifted during
the study period. Infants with
NAS had lower birthweights,
were more preterm, and were
more likely to have been in
the NICU. Mothers of infants
with NAS received less
prenatal care. More children
with NAS were referred for
evaluation of intellectual
disability (19.3% vs 13.7%)
and more were considered
eligible than other infants
(15.6% vs 11.6%); among
the reasons for eligibility,
developmental delays were
highest (5.3% vs 3.5%).
More infants with NAS also
received services (15.3% vs.
11.4%).
The data seemed to suggest
that higher concentrations of
Medicaid coverage
correlated to increases in
rates of NAS, and this
seemed to hold at a national
level as well. Increased
access to opioid treatment
centers seemed to decrease
the rates of NAS.
Rates of NAS increased
between 2004 and 2014.
Infants with a diagnosis of
NAS covered by Medicaid
are more male and more
likely to live in
socioeconomically
disadvantaged and/or rural
areas. Infants with a
diagnosis of NAS and
covered by Medicaid also
seemed to have more
diagnoses of clinical
characteristics indicative of
the condition. Infants with
NAS covered by Medicaid
had more hospital transfers
than infants with private
insurance. Between 2011 and
2014, hospital costs related
to NAS were higher for
infants with private
insurance.
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Khaleel
S.
Hussaini
and
Luigi F.
Garcia
Saavedra

Maternal
and Child
Health
Journal

Neonatal
Abstinence
Syndrome (NAS)
in Southwestern
Border States:
Examining
Trends,
Population
Correlates, and
Implications for
Policy

Hospital
inpatient
discharge
data from
Arizona and
New Mexico

Crosssectional

NAS

2008
to
2013

2018

Faouzi I.
Maalouf,
et al.

Journal of
Pediatrics

Outpatient
Pharmacotherapy
for Neonatal
Abstinence
Syndrome

Tennessee
Medicaid
and linked
vital records

Cohort

Length of stay;
length of
treatment;
hospitalizations
in 30 days and
6 months;
emergency
department
visits in 30
days and 6
months

2009
to
2011

2019

Lauren
Parlett,
et al.

Medical
Care

Drivers of
Hospital Length
of Stay in
Medicaid and
Commercially
Insured MotherInfant Pairs With
a Diagnosis of
Neonatal
Abstinence
Syndrome

HealthCore
Integrated
Research
Environment

Caseseries

Length of stay

24

Rates of NAS rose between
2008 and 2013 in both
Arizona and New Mexico,
though rates were higher in
Arizona. Coverage by
Medicaid was high in both
areas (77.7% in Arizona and
87.5% in New Mexico).
Infants born with NAS in
Arizona were largely white
and infants born with NAS in
New Mexico were largely
Hispanic. Median costs of
births were $28,000 and
$23,000 higher for infants
with NAS in Arizona and
New Mexico respectively.
Low birthweight was
significantly different in New
Mexico. Lengths of stay were
13 and 14 days for infants
with NAS in Arizona and
New Mexico.
Infants with NAS treated
inpatient were most
frequently treated with
morphine while infants with
NAS treated outpatient were
more frequently treated with
phenobarbital. The length of
stay for infants treated
outpatient was 11 days
compared to 23 days for
infants treated inpatient.
Length of treatment for
infants treated outpatient was
60 days compared to 19 days.
85% success in linking
mother-infant dyads within
Medicaid; 88% success
within commercial insurance.
79% of infants with NAS
were covered by Medicaid.
Mothers covered by
Medicaid had more frequent
alcohol and tobacco related
diagnoses while mothers
covered by commercial
insurance had more
prescription opioid use.
Infants with NAS covered by
commercial insurance had
indicators indicating more
severe NAS than infants with
NAS covered by Medicaid.
Similar lengths of stay. Use
of buprenorphine was more
common among the
commercially insured
population. NICU stays for
infants with NAS covered by
commercial insurance were
longer for males but shorter
for females.
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Rebecca
Rebbe, et
al.

Journal of
Pediatrics

Hospital
Variation in
Child Protection
Reports of
Substance
Exposed Infants

Washington
State birth
records
linked to
hospital
data and
child
protective
services
data

Crosssectional

Reports to CPS
within first 7
days of life

2006
to
2013

2019

Lauren A.
Sanlorenzo,
et al.

Hospital
Pediatrics

Tennessee
Medicaid
linked to
vital
records

Cohort

Pharmacological
treatment of
NAS

2009
to
2011

2019

Laura J.
Sherman,
et al.

Psychiatric
Services

Increased
Severity of
Neonatal
Abstinence
Syndrome
Associated With
Concomitant
Antenatal
Opioid and
Benzodiazepine
Exposure
Mental
Disorders
Among
Children Born
With Neonatal
Abstinence
Syndrome

TruVen
Health
Analytics’
Multi-State
Medicaid
Database

Cohort

Mental health
condition
diagnoses

2019

Faouzi I.
Maalouf, et
al.

Pediatrics

Tennessee
Medicaid
with
medical
records

Chart
review

Positive
predictive value

Positive
Predictive Value
of
Administrative
Data for
Neonatal
Abstinence
Syndrome

25

2009
to
2011,
2016

High rates of substance
exposure among Native
American infants and
Black infants. Opioids
were the most common
substance exposure.
The odds of a report to
CPS were 1.32 times
higher for infants with
NAS with less prenatal
care compared to
infants with more
prenatal care and were
1.25 higher in hospitals
with higher percentages
of Medicaid coverage
compared to hospitals
with more private
insurance coverage.
Public payer sources
increased the odds of a
report to CPS by 1.74
compared to other
payer sources.
Benzodiazepines and
sustained-release
opioids increased the
odds of
pharmacological
treatment for NAS; the
other substances
examined were not
significant. Infants had
more respiratory
complications.
Rates of mental health
conditions were
elevated in the
population of children
diagnosed with NAS.
Developmental delays
were the highest
percentage of
diagnosed with mental
health conditions;
conduct disorders,
ADHD, and adjustment
reactions were also
high.
The positive predictive
value of NAS using
779.5 from ICD-9 had
a PPV of 91% while
the PPV of P96.1 in
ICD-10 was 98.2%.
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Lisa
ClemansCope, et
al.

Drug and
Alcohol
Dependence

Pregnant women
with opioid use
disorder and their
infants in three
state Medicaid
programs in
2013-2016

Medicaid
data from
three states
linked to
birth
certificate
records

Cohort

Healthcare
utilization;
healthcare
expenditures;
SUD treatment by
type; months of
treatment;
neonatal outcomes

2013
to
2016

2020

Elisabetta
Patorno,
et al.

PLOS
Medicine

Medicaid
Analytic
eXtract

Cohort

Neonatal
malformations;
pre-eclampsia;
preterm birth;
small for
gestational age;
NICU admission

2000
to
2013

2020

Walter
M.
Taylor, et
al.

Journal of
Pediatrics

Gabapentin in
pregnancy and
the risk of
adverse neonatal
and maternal
outcomes: A
population-based
cohort study
nested in the US
Medicaid
Analytic eXtract
dataset
Long-term
Healthcare
Utilization by
Medicaid
Enrolled Children
with Neonatal
Abstinence
Syndrome

Medicaidenrolled
children in
New York
and Texas

Cohort

Total inpatient
days; outpatient
office visits; ED
visits; total filled
prescriptions

Infants with NAS had more
ED visits and less outpatient
visits than other infants.
Findings were insignificant
for inpatient days and filled
prescriptions. Clinical
characteristics decreased the
differences among the
groups.

2020

Kailyn L.
Conner,
et al.

Psychiatric
Services

IBMWatson
MarketScan
Database

Crosssectional

Mental health
diagnoses; use of
select
pharmacotherapies
in population

1999
to
2011
for
New
York;
1999
to
2010
for
Texas
2009
to
2015

2020

Jifeng
Ma, et al.

Journal of
Perinatology

Medicaid
data from a
large
southern
state

Cohort

NAS diagnoses;
NICU admissions

2014
to
2018

Among mothers with a
severe mental illness,
approximately 25% of those
mothers had an opioidrelated diagnosis, compared
to 11%. After adjustment,
buprenorphine and
methadone use increased the
odds of NAS by 168.93; for
OUD, aOR of 46.87. All
opioid diagnoses increased
the odds of a NICU
admission. Urban residence
increased the odds of NAS
but decreased the odds of a
NICU admission.

Neonatal
Abstinence
Syndrome and
Childhood
Mental Health
Conditions, 20092015:
Commercial
Versus Medicaid
Populations
Adverse neonatal
outcomes
associated with
maternal severe
mental health
diagnoses and
opioid use
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The prevalence of SUD was
8.1%, with the prevalence of
OUD being 2.2% and 5.9%
for other types of SUD.
72.8% of mothers received
treatment in the year before
or after delivery for SUD.
Mothers receiving
methadone began their
prenatal care later compared
to other mothers; however,
methadone also seemed to
decrease infant costs, though
infant costs were higher for
all infants of a mother with
an SUD compared to
mothers without an SUD.
No evidence of any
association with adverse
events for gabapentin use in
early pregnancy. Use of
gabapentin in later
pregnancy increased the risk
of adverse neonatal
outcomes in later pregnancy.

The rate of NAS was much
higher in the Medicaidinsured population than in
the commercially insured
population. Findings were
consistent with Sherman et
al. Some psychotropics
being used in the population
of children ages 1 to 5.
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Brook T.
Alemu, et
al.

Southern
Medical
Journal

Patient and
Hospital
Characteristics
of Newborns
with Neonatal
Withdrawal
Syndrome

Kids’
Inpatient
Database

Crosssectional

Demographics;
length of stay;
total charges

2016

2020

Anna E.
Austin, et
al.

Child
Maltreatment

Incidence of
Injury,
Maltreatment,
and
Developmental
Disorders
Among
Substance
Exposed Infants

Medicaid
Analytic
eXtract
data for
North
Carolina,
Georgia,
and Texas

Retrospective
cohort

2006
to
2011

2020

Kamleshun
Ramphul,
et al.

Hospital
Pediatrics

An Update on
the Burden of
Neonatal
Abstinence
Syndrome in the
United States

KID Data

Crosssectional

Injury
diagnoses in
the first year
of life;
maltreatment
diagnoses in
the first year
of life;
developmental
delay
diagnoses in
the first year
of life
Incidence of
NAS; length of
stay; total
charges

2021

Kavita
Batra, et
al.

International
Journal of
Environmental
Research and
Public Health

Incidence of
Neonatal
Abstinence
Syndrome
Epidemic and
Associated
Predictors in
Nevada: A
Statewide Audit,
2016-2018

Nevada
hospital
discharge
data

Serial crosssectional

NAS

2016
to
2018

27

2016

83% of the population
was covered by Medicaid.
Infants with NAS were
more likely to be treated
in a rural hospital than
other infants and less
likely to be treated in an
urban non-teaching
hospital; the percentage
was approximately the
same for both groups
regarding urban teaching
hospitals. Infants with
NAS were more Southern
or Northeastern than other
infants.
Most common diagnoses
indicative of substance
exposure among the
infants were cocaine
exposure and NAS.
Maltreatment diagnoses
were elevated amongst
infants with prenatal
opioid exposure. Physical
abuse comprised 51.4% of
maltreatment diagnoses.
NAS births comprised
0.8% of all the births in
2016. Most NAS births
were male, White, and
Southern. 83.8% of NAS
births were covered by
Medicaid. The mean
length of stay for infants
with NAS was 16.5 days,
with a median length of
stay of 12 days; being
preterm increased the
length of stay. 45 infant
deaths in this group in
2016, with 60% of the
deaths among preterm
infants.
NAS rates decreased
between 2016 and 2018
but remained higher than
2013 estimates. Higher
rates of NAS among
white infants and among
infants insured by
Medicaid. Higher in urban
areas and higher in more
socioeconomically
disadvantaged areas.
Hospital factors were not
associated with rates of
NAS.
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Ashley
H. Hirai,
et al.

JAMA

Neonatal
Abstinence
Syndrome and
Maternal OpioidRelated Diagnoses
in the US, 20102017

2021

Stephen
W.
Patrick,
et al.

The Journal
of Pediatrics

Development and
Validation of a
Model to Predict
Neonatal
Abstinence
Syndrome

2021

Elizabeth
E. Krans,
et al.

Addiction

Outcomes
associated with the
use of medications
for opioid use
disorder during
pregnancy

2021

Jean Y.
Ko, et al.

Drug and
Alcohol
Dependence

Maternal opioid
exposure, neonatal
abstinence
syndrome, and
infant healthcare
utilization: A
retrospective
cohort analysis

National
Inpatient
Sample, state
inpatient
discharge
databases
from 47
states and
Washington,
D.C.
Tennessee
Medicaid
linked to
vital records

Serial crosssectional

NAS; maternal
opioid-related
diagnoses;
length of stay;
hospital costs

2010
to
2017

Retrospective
cohort

NAS

2009
to
2014

Pennsylvania
Medicaid

Retrospective
cohort

Overdose;
continuation of
MOUD in the
postpartum
period; low
birth weight in
the infant; NAS

2009
to
2017

Oregon
Medicaid
with linked
birth
certificate
data

Retrospective
cohort

4 groups of
combined
known opioid
exposure and
NAS diagnoses;
demographics;
infant birth
outcomes;
infant
hospitalizations;
healthcare
utilization

2008
to
2012
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Medicaid covered
approximately 84% of NAS
discharges and 77.1% of
maternal opioid-related
diagnosis discharges. The
overall number of births
nationwide remained
relatively stable while the rate
of NAS and maternal opioidrelated diagnoses increased.
Creation of a risk
stratification model for NAS.
Lower birthweight and female
sex at birth reduced the odds
of developing NAS;
sustained-release opioids also
associated with increased risk
of NAS. Additional evidence
that gestational age in the
high-risk model is predictive
of NAS; in both models,
increased birth weight seems
to be protective. Hepatitis C
in the mother also increases
risk of NAS in both models.
7.6% of infants had low birth
weight in the study. 57.9% of
infants of mothers on MOUD
were diagnosed with NAS.
The risk of low birth weight
decreased as duration of
MOUD treatment increased,
but longer treatment duration
with MOUD also increased
the odds of NAS. The
increased risk for NAS was
non-linear.
Maternal opioid exposure
occurred in approximately
123.1 in every 1,000 births for
the study population; the rate
of NAS was 5.8 in every
1,000 births. Children with
opioid exposure and/or NAS
had increased hospitalizations
at four weeks and one year;
sick visits and emergency
department visits were also
increased for these groups.
Well-child visits had more
mixed results.
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Xuerong
Wen, et
al.

JAMA
Network
Open

Association of
Gestational
Opioid Exposure
and Risk of
Major and Minor
Congenital
Malformations

Rhode
Island
Medicaid
and linked
vital
statistics
data

Retrospective
cohort

Major of
minor
congenital
malformations;
10 specific
categories of
malformations

2008 to
2016

2021

JoAnna
K.
Leyenaar,
et al.

JAMA
Pediatrics

Infant Mortality
Associated With
Prenatal Opioid
Exposure

Texas
Neonatal
Intensive
Care
Project
(consists of
infants
born on
Texas
Medicaid)

Retrospective
cohort

Infant
mortality

2010 to
2014
with
mortality
data
through
2015

2021

Tammy
E. Corr,
et al.

The Journal
of Pediatrics

Longitudinal
Health Care
Utilization of
MedicaidInsured Children
with a History of
Neonatal
Abstinence
Syndrome

Medicaid
Analytic
eXtract

Retrospective
cohort

Number of
claims and
costs
associated
with claims

2003 to
2013

2021

Amna
Umer, et
al.

Paediatric
and Perinatal
Epidemiology

Disparities in
neonatal
abstinence
syndrome and
health insurance
status: A
statewide study
using non–
claims real-time
surveillance data

Project
WATCH
data from
West
Virginia

Populationbased cohort

NAS

2017 to
2019
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Appeared to be an
increased risk of
congenital malformations
when the fetus was
exposed to opioids later
in pregnancy (i.e., the
second and third
trimesters).
Musculoskeletal
malformations appeared
to have a dose-response
association.
In a study population of
1,129,032 infants, 7,207
had known prenatal
opioid exposure. 4,238 of
those infants had an NAS
diagnosis consistent with
prenatal opioid exposure.
The group of infants with
the highest risk of infant
death was the group of
infants with prenatal
opioid exposure but
without a diagnosis of
NAS. 25% of the deaths
were due to sudden
unexplained infant death.
54% of the NAS cases
were diagnosed in the last
four years of the study.
Healthcare utilization for
children with NAS was
much higher for infants
with NAS in the first year
of life and remained
different through age 3,
then similar after age 3
for the children. More
preventative care and
vaccines in the group of
children with NAS.
West Virginia Medicaid
covered approximately
52.6% of all births during
the study period. The rate
of NAS among children
covered by West Virginia
Medicaid was 85.8 in
every 1,000 births; the
overall state average rate
of NAS was 52.4 in every
1,000 births. After
adjustment for other
variables, the risk of NAS
in infants covered by
Medicaid was 3 times
higher than infants
insured by commercial
insurance. The adjusted
excess risk of NAS for
infants covered by
Medicaid was an excess
20.3 in every 1,000
births.

CHAPTER 3. METHODOLOGY AND DEMOGRAPHICS: NEONATAL ABSTINENCE SYNDROME IN
THE KENTUCKY MEDICAID ADMINISTRATIVE CLAIMS DATABASE
3.1

Data Sources and Acquisition
As Chapter 2 revealed, Medicaid is an important stakeholder in the assessment of

NAS and children in Medicaid systems have social determinants of health that impact their
overall wellbeing that differ from children insured through other means. This identifies
Medicaid as an important data source for the monitoring of children with NAS in claimsbased analyses.
The Opioid Epidemic has had a palpable impact across the United States, but some
of the hardest hit areas have borne an extensive burden under the weight of the crisis. In
Do No Harm, author Wiland identifies Kentucky as one of the hardest hit areas of the
United States, and one of the states specifically targeted by Purdue Pharma in their
advertisement of pain relief medications.86 Kentucky has seen rates of maternal opioid use
disorders rise 273% between 2010 and 2017 and rates of NAS rise 196% during the same
period.47
Kentucky was one of the first states to expand their Medicaid system under the
provisions allowed in the Affordable Care Act87; the expansion occurred at the beginning
of the study period88. The increase from 135% of the federal poverty line (FPL) to 139%
FPL grew the Medicaid system significantly.88 In June 2021, enrollment in Kentucky
Medicaid was approximately 1.7 million89; in a state where the estimated population is 4.5
million90, this creates an estimated 38% of the population of Kentucky that is enrolled in
the Kentucky Medicaid system, or 19 in every 50 Kentuckians. The percentage of
Kentucky children is estimated to likely be higher.91
In October 1990, Kentucky passed KRS205.592, which specifically defines
pregnancy and infant eligibility criteria for the Kentucky Medicaid system to 185% FPL.39
KRS205.592 covers infants through their first year of life.38 Estimates for the annual birth
rate in Kentucky remain stable at around 65,000 births per year92; under the criteria laid
out in this law, Medicaid covers approximately 30,000 of those births each year, as
demonstrated in Table 3.1.
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After the first year of life, children then become eligible for the Children’s Health
Insurance Program, or CHIP, which covers children under age 19.34 While CHIP is a
federal program, each state is permitted to expand the program.93 Under 907 KAR 4:020
and 4:030, the Kentucky Children’s Health Insurance Program, or KCHIP, was formed.95,96
KCHIP in Kentucky is under the purveyance of Kentucky Medicaid96, which allows many
of the children born on Medicaid to be retained for long durations throughout childhood.
This policy feature in Kentucky allows the creation of long-term cohorts among children
in the Medicaid system. This feature creates a continuity of service for low-income children
that is unique to the structure of the Cabinet of Health and Family Services (CHFS) within
Kentucky, which houses the Kentucky Department for Medicaid Services (DMS).96
Furthermore, the Office of Vital Statistics (OVS), which compiles and stores information
from birth certificates and death certificates for citizens of the Commonwealth of
Kentucky, is also housed within CHFS.97 This multi-department approach to structuring a
governmental cabinet creates a ripe and rich environment for data sharing and linkage
across many of these units.
Deidentified data from the Kentucky Medicaid Management Information System
(MMIS) was obtained from the Office of Health Data and Analytics (OHDA) within CHFS
consisting of children born on Kentucky Medicaid between January 1, 2014 and December
31, 2019. Within OHDA, this data was linked to data from the birth certificate. This period
was chosen because data sharing between OHDA and OVS dates to birth certificate records
in 2014 and continues to the present. To maintain deidentification of the linkages between
the Medicaid data and the OVS data, data linkage was provided and reviewed by OHDA.
Furthermore, Kentucky Medicaid data has a 6-month lag between the filing of the
claim and the appearance and distribution from the database. The data was obtained in the
form of an annual summary; to allow for an entire year to pass in a child’s life, the youngest
children in this study were born in 2019. Furthermore, because the data required a full year
of annual summaries, the data was current to the first run of the data, which occurred in
October and November 2020 and likely does not fully account for all children born in 2019.
Indeed, in a refresh of the data that was obtained in May of 2021, an additional 257 children
appeared in this secondary dataset. These 257 children are not accounted for in the analyses
within this study.
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An initial discussion surrounding the dissertation data occurred with OHDA in
February 2020. The acquisition of the data required a completion of a Memorandum of
Understanding, completed in October 2020. All study protocol were approved by both the
University of Kentucky (UK) Institutional Review Board (IRB), protocol number 58851,
and by the CHFS IRB, letter dated June 30, 2020. To safeguard against the potential of
data being re-identified, and per the terms required within the Memorandum of
Understanding, cell values less than 10 were suppressed.
Data processing by OHDA occurs in iterative steps with safeguards in place at each
level to ensure data quality and accuracy. First, a project manager within OHDA assigns
an analyst to the data pull; the analyst then communicates with the requestor to clarify
confusion, express concerns, or suggest changes to the variables being requested. After the
data pull is completed, the analyst then passes the data off to another analyst for code
review. Following code review, the data is then passed to the project manager for release
to the requestor. At each stage, the data analyst documents the processes involved and
specifics of the data pull. This information is passed along to the requestor in addition to
the data. The requestor is then tasked with reviewing the data obtained from OHDA for
accuracy or confusion on variables requested; OHDA relies on communication from the
requestor and the subject-matter expertise of the requestor to ensure that the data being
delivered is accurate.
3.2

Created Database
The study population consisted of all children born on Kentucky Medicaid between

January 1, 2014 and December 31, 2019. Children were included in the analysis if they
were enrolled in Medicaid at the time of their birth. The children were then followed
forward, and annual summary figures were obtained for each year of life a child remained
enrolled in the Medicaid system. The children remained in the study population either the
end of the study period, no longer remaining enrolled, or death resulted in a loss to followup. Reason for loss-to-follow-up was not examined and represents a limitation to the study
methods.
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3.2.1

Exposure

The exposure of interest within this work was a diagnosis of NAS at birth. Because
the data was designed from administrative claims data, a diagnosis of NAS was defined
using International Classification of Diseases (ICD) diagnosis codes, created and
classified by the World Health Organization. Of note, the transition from International
Classification of Diseases, 9th Revision (ICD-9) to International Classification of Diseases,
10th Revision (ICD-10) occurred in October 2015 in the United States, within the study
period; as a result, both ICD-9 and ICD-10 codes are utilized throughout this work.
The way in which an exposure is defined has the potential to alter the findings in any
statistical work, often through the introduction of misclassification bias into the work itself.
In most of work surrounding NAS, the definition of NAS used has only included two codes
to identify the population of interest: in ICD-9, 779.5; in ICD-10, P96.1. This definition of
NAS has been identified to have high positive predictive value (PPV) in identifying NAS
and validated by a study in a NICU population at Vanderbilt University.59 779.5 is defined
under ICD-9 as “Drug withdrawal syndrome in newborn.”99 P96.1 is defined under ICD10 as “Neonatal withdrawal symptoms from maternal use of drugs of addiction.”100
However, a study population by Gangopadhyaya et al. identified an additional code
within ICD-9 and ICD-10 for identifying neonates prenatally exposed to opioids in utero:
760.72 and P04.49.100 760.72 is defined under ICD-9 as “Narcotics affecting newborn via
placenta or breast milk”101. P04.49 is defined under ICD-10 as “Newborn (suspected to be)
affected by maternal use of other drugs of addiction”.102
The synonymity of NAS with neonatal opioid withdrawal syndrome (NOWS) is a
relatively recent phenomenon. The term NAS was first utilized in the literature synthesized
within the PubMed database in 19741; the term NOWS was first utilized in the literature
compiled in the PubMed database in 1963.103 Prior to the ambiguity of the Opioid
Epidemic, NAS could be used to refer to any number of substances, licit and illicit, in utero
and ex utero, to which a neonate is exposed and subsequently suffers withdrawal from.104
Within the diagnosis code manuals used by billers in filing administrative claims
within a clinical setting, both 779.5 and 760.62 and P96.1 and P04.49 have exclusions for
the other code within the definition in the manual, meaning that the two codes usually are
not submitted simultaneously (Wendroth, personal communication). However, a biller
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noted that if the provider denotes both diagnoses, the codes can be submitted together on
the same claim. (Wendroth, personal communication) Thus, a child identified as in
withdrawal may carry both diagnoses, but a child prenatally exposed may only carry the
latter diagnosis.
The utilization of the NAS code is triggered when the child begins exhibiting
withdrawal symptoms (Wendroth, personal communication), thus beginning the process of
documenting Finnegan scoring, initiated by a clinician, most usually a neonatal intensive
care unit (NICU) nurse, and the application of non-pharmacological treatment
interventions to ease the infant through the withdrawal. Otherwise, if the infant is known
to be exposed to opioids but no withdrawal symptoms are identified or observed, the
neonate receives the other code. (Wendroth, personal communication) Studies examining
the effects of NAS on long-term childhood health outcomes are frequently implicitly
examining whether opioids cause longer term effects on children. To examine the studies
focusing solely on the 779.5/P96.1 coded infants (or the infants with NAS) leaves a
population of children with similar exposure in the comparator group (infants with
exposure), when not explicitly excluded from the study population.
However, these exposed infants did not experience withdrawal in the same manner
that the NAS infants. The literature suggests that neonates undergoing withdrawal have
more frequently experienced greater concentration of opioid exposure64 and were more
likely to be exposed during the later trimesters63, which is a critical period of rapid fetal
development.29,105 Thus, based on claims made previously in the literature, the exposure
experience in the infants with NAS likely varies from the exposure experience in the infants
with exposure.
Because of the co-existence of these codes, an opportunity arises to examine
whether long-term effect impact these two groups differently and create a more unexposed
referent group for comparison. It is worth noting that several other codes, such as 760.75
in ICD-9106 and P04.41 in ICD-10 for cocaine exposure107, exist in the codex. Polydrug use
is also a known common occurrence for people who use substances of abuse.108 Several of
these infants with other codes remain within the comparator population and represent a
limitation to this analysis.

34

3.2.1.1 Iatrogenic Withdrawal
ICD-10 contributed P96.2 to the classification system, defined as “Withdrawal
symptoms from therapeutic use of drugs in newborn”.109 This code is used to explicitly
identify infants undergoing iatrogenic withdrawal. No such equivalent exists in ICD-9, as
noted by Maalouf et al.59 In the ICD-9 system, 779.5 was also used to identify infants
undergoing withdrawal due to ex utero exposure to substances for treatment of medical
conditions.59 However, rates of iatrogenic withdrawal appear low, with a study by Maalouf
et al. only identifying 1.2% of NAS codes as iatrogenic withdrawal in a chart review
conducted at Vanderbilt University.59 Thus, because the rate was assumed to be low,
additional attempts at identifying these children were not taken and are considered an
additional limitation to the methodology in these studies.
3.2.2

Additional Variables

Additional variables obtained for analysis from the Medicaid MMIS system
included demographic information for the child, summary information on healthcare
utilization, and select diagnoses of interest. Summary information on the created dataset
can be found in the Appendix (Appendix 1). Demographic information (sex at birth, race,
county at the beginning of the year, county at the end of the year, etc.) were obtained from
the child’s enrollment record.
Currently, race is not a required field to be reported for enrollment in Kentucky
Medicaid. OHDA categorizes the population within Kentucky Medicaid into three
categories: White, Black, and Other. Persons who self-identified, or, in the case of children,
were identified by a caretaker on their enrollment into Kentucky Medicaid as White were
included in the White category while persons who self-identified in enrollment as Black
were categorized as Black. All other races, including observations in which no race was
reported, was included as Other. This means the Other category contains populations of
Pacific Islander descent, Asian descent, Native American descent, and Alaskan native
descent. Additionally, because the population of individuals for whom race is a missing
category is including in the Other category, some misclassification could be occurring
because of this categorization, though the capacity to explore such a misclassification is
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not currently possible given the current inability of Kentucky to mandate the reporting of
race on the enrollment form.
A child’s county location was then matched to the associated Rural-Urban
Continuum code (RUC code) as determined by the USDA in 2013; these codes assisted in
identifying whether children resided in metro (RUC codes 1 through 3) or non-metro (RUC
codes 4 through 9) areas of Kentucky.110 The information on county residence was also
used to create an Appalachian identifier for the children, using the counties identified as
Appalachian by the Appalachian Regional Commission.111 Information on the RUC code
as noted by the USDA and a listing of counties identified as Appalachian can be found in
the Appendix (Appendix 2 and Appendix 3). Appalachian status was particularly identified
within the context of the analysis given the impact the condition has had on the region in
recent years, especially within rural Appalachia.112
Information on healthcare utilization was derived across all the claims databases
(inpatient, outpatient, pharmacy, etc.) and summarized for each child within the respective
category. Respiratory, gastrointestinal, and mental health diagnoses were also investigated
within this dissertation. Diagnoses were also pulled from across the administrative claims
databases and summarized into two forms: one, a dichotomous indicator variable for each
child indicating whether that child had received a diagnosis in the category; and two, a
separate dataset for each category of diagnoses (respiratory, gastrointestinal, and mental
health) with the child’s unique identifier, each diagnosis code associated with the unique
identifier, and a dichotomous indicator variable for the age at which each child was
diagnosed. Mental health variables were identified using the ICD-9 codes identified by
both Sherman et al.78 and Conner et al.79 Respiratory and gastrointestinal diagnoses were
identified using the codes from the Healthcare Costs and Utilization Project (HCUP)
Clinical Classifications Software Refined (CCSR) code lists.113 The categories identified
by CCSR were also utilized within analyses.113
Variables obtained from OVS through OHDA included gestational age, maternal
smoking status, the number of prenatal visits, infant Hepatitis C status, maternal gestational
diabetes status, and maternal gestational hypertension status. Additionally, information
from vital statistics was used to link infants to their mothers and additional siblings,
allowing the investigation of other family members (mother and siblings) on Medicaid
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from 2014 forward, as well as other siblings (from 2014 forward) that were diagnosed with
one of the prenatal exposure or NAS codes used within this study. Siblings were not linked
within this analysis, nor were mothers included for analysis; utilization of these two dyads
represents a future direction for investigation.
Many of the variables obtained within the study were obtained in a cross-sectional
manner, as many of the outcomes of interest within the chapters needed preliminary
exploratory analyses prior to larger works being conducted. Some variables, however, were
obtained longitudinally, including the annual summary of healthcare utilization as well as
the foster care indicator. Variables obtained longitudinally permit investigation into
changes over time; for healthcare utilization, this is necessary to identify clear patterns in
healthcare utilization differences between the exposure groups.
Foster care status was also obtained as a longitudinal variable. Foster care was
intended by the Adoption and Safe Families Act to be a temporary status for children; as
such, the law dictates that when a child spends 15 of 22 months out of the custody of the
parent in foster care, a termination of parental rights occurs.114 Thus, foster care status was
designed to have a “ticking clock” associated with the status; children spending extended
time in foster care may be representing children who were not adopted or children entering
and exiting the foster care system.114 Foster care involvement has been identified as an
ACE115 and source of trauma in a child’s life and foster care involvement has been shown
to be associated with several adverse health outcomes, such as hypertension and asthma.116
Additionally, it is important to the children within this analysis are largely children younger
than the age at which school and education becomes a factor in a child’s life; teachers are
one of the most important mandatory reporters of childhood abuse and neglect117, and
Kentucky is known to have a high report rate to the Department of Community-Based
Services (DCBS)118, which, in Kentucky, is charged with investigating all reports of child
maltreatment.119 Therefore, in this age group, much of the abuse and neglect may not be
identified because children at this age have limited contact with mandatory reporters.
Outcomes of interest for each chapter are explained in greater detail in each chapter
of this dissertation. All statistical analytics were conducted using SAS v9.4. Geospatial
information system (GIS) analyses were conducted using ArcGIS with shape files of
Kentucky county boundaries obtained from the Kentucky GIS server, KyGeoNet.120 An
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alpha threshold of 0.05 was utilized; a p-value less than 0.05 indicated a statistically
significant result.
3.3

Demographics
A total of 192,379 children born on Kentucky Medicaid were available for analysis

within this dissertation. Demographics for the entire study population were assessed using
frequency analyses and measures of central tendency. Statistically significant differences
among these strata were identified using chi-square analyses for ordinal variables and
ANOVA analytics for continuous variables.
Table 3.1 presents demographic information for the entire study population stratified
by opioid-related diagnoses. Between 2014 and 2019, 8,232 children (4.28%) were
diagnosed with NAS while 5,854 children were diagnosed with prenatal opioid exposure
(3.04%). Around 2016, after the ICD-10 code switch occurred in October 2015, the
percentage of children diagnosed with the prenatal exposure code jumped from 1 to 2% in
2014 and 2015 to approximately 4% in 2016 through 2018. An exception to this occurred
in 2019 when the percentage fell to 2.61% of children receiving an opioid exposure
diagnosis code; however, it is also worth noting that the number of children diagnosed with
NAS also fell that same year to 3.69%.
Annually, approximately 31,000 children were born on Kentucky Medicaid each
year between 2014 and 2019 (lowest: 31,083 in 2019; highest: 32,956 in 2015). The overall
population of Medicaid children are majority male (51.27%), majority White (65.87%),
largely located in a metropolitan area of the state (53.79%), and largely non-Appalachian
region of the state (69.06%).
A choropleth map of the raw number of children residing in each county in Kentucky
at birth over the five-year period is available in Figure 3.1. This map was generated using
ArcGIS and Arc Map 10.8. Delineation of the categories in the color gradient were
ascertained using Jenks’ natural breaks. For comparison, a map of the 2010 population
estimates for Kentucky by county is available in Appendix 4. Of note, many regions of the
state that, in the 2010 population estimates, do not have large concentrations of the overall
population of Kentucky, such as areas in the eastern and southeastern portions of the state
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near the Tennessee and Virginia border, do have large numbers of children born on
Kentucky Medicaid in those areas.
One such area is Laurel County, located toward the southern border in the eastern
portion of the state. In the map in the Appendix, Laurel County is in the same category as
its neighbor, Pulaski County. In the map in Figure 3.1, however, the concentration of
children born on Kentucky Medicaid in this county is higher than its neighbor, Pulaski
County. Laurel County is composed of both London, Kentucky and Corbin, Kentucky;
Pulaski County’s county seat is Somerset, Kentucky. Though both counties have large
hospital systems available within them (Lake Cumberland Regional Hospital in
Somerset121 and CHI Saint Joseph Hospital in London122), the median income for Laurel
County123 actually exceeds the median income for Pulaski County, Kentucky124, making
this finding particularly interesting and worth additional examination in future studies.
Of interest, children with prenatal opioid exposure largely resemble the comparator
group population demographically. Children diagnosed with NAS, however, have some
important deviations. The group of children diagnosed with NAS are more White (76.82%
compared to 66.81% in the opioid exposed group and 65.34% in the comparator group),
much less Black (2.65% versus 11.26% and 11.95%), were born in more non-metropolitan
counties (62.03% compared to 42.35% and 45.61%), and more Appalachian (55.93%
compared to 31.07% and 29.78%). There are several possible explanations for these
differences. One possible explanation is racial differences in drugs of abuse; another could
be underdiagnosis of this syndrome in non-White children.
Figure 3.2 presents a choropleth map of NAS rates across the state across all years,
based on the number of children within each county during the five-year period, created
using
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For instance, in Jefferson County, a total of 32,704 children from 2014 to 2019 were born
residents of that county; among those children, a total of 796 children were diagnosed with
NAS, creating a rate of NAS for 2014 to 2019 within that county of 24.34 in every 1,000
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births. The delineations between the categories were determined using Jenks’ natural
breaks.
NAS rates in Kentucky for this five-year period ranged from 0 in every 1,000 births
(Livingston County and Lyon County both had 0 NAS births from 2014 to 2019) to 150.55
in every 1,000 births (the rate in Clay County, Kentucky). As shown in the figure, rates of
diagnoses of NAS were high in the state in the southeastern portion of the state, or near the
Tennessee and Virginia borders. The western portion of the state saw the lowest rates of
NAS within the Kentucky Medicaid population.
Statistically significant clusters of these rates of NAS were confirmed by the GetisOrd Gi* hotspot analysis shown in Figure 3.3. The cluster identified a statistically
significant hotspot of NAS at the Virginia border, stretching up into the more centralized
eastern portions of the states. Statistically significant cold spots were shown in the western
portions of the state. Also of interest, in Figure 3.3, neither of Kentucky’s two largest
counties, Jefferson or Fayette Counties, were identified as either a cold spot or a hot spot
for rates of NAS during this time. Also interesting is that the area surrounding Warren
County, the Bowling Green metro area and home of Western Kentucky University, was
also identified as a cold spot in the analysis. Factors related to these low rates of NAS in
these metropolitan areas are likely related to social determinants of health and sociocultural
factors in these areas that make the risk of NAS lower in such areas in Kentucky.
As previously mentioned, the unique placement of CHIP within Medicaid allows
for high retention rates to the Medicaid system, as shown in Table 3.2. Retention ranged
from approximately 78.3% for a child’s fifth year of life for the 2014 birth year cohort to
94.3% for the child’s second year of life for the 2018 birth year cohort. Across all birth
year cohorts, and consistent with expectation, retention diminished as the child grew older,
but most children could be identified in the Medicaid database for the duration of the study
period.
Continuous enrollment by HEDIS standards125 is shown in Table 3.3. Results in
this table reinforce that most children are being retained to the Medicaid system at a high
rate and most children also maintain continuous enrollment within the Medicaid system.
Combining results between Tables 3.2 and 3.3, in the fifth year of a child’s life (or the age
up to the child’s sixth birthday), for the 2014 birth year cohort, 24,995 children remained
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in the dataset; of these children, 22,134 (88.55%) were continuously enrolled for that year
of their life. These large percentages are consistent across the table.
Just because a child is born in a certain county does not necessarily mean that the
child stays in that county for the duration of their childhood. Moving and relocation for the
Medicaid population during childhood is assessed in Table 3.4. A total of 42,393 moves
occurred between 2014 and 2019 for the children in the study population with 32,333 ever
relocating, or 16.81% of children in the study population. Extrapolating, that means 10,060
relocations during this period were duplicate (multiple) relocations of the children to other
counties; relocations within a county could not be identified by this dataset but may
represent a future direction for research. As children enter school age, consistency and
stability become crucial components of ensuring that a child has an optimal environment
to learn and develop within. Though the data cannot elucidate as to the reason for the
relocations, a policy recommendation for Medicaid could be additional monitoring and
managed care engagement for children with multiple relocations to ensure that the child
has re-established connections with healthcare resources in the new area.
Maternal and gestational health factors affecting the fetus, as noted from the birth
certificate, were also available for analysis and are presented in Table 3.5. The data shows
a wide gap between maternal smoking rates for infants with evidence of in utero opioid
transfer (i.e., an NAS or opioid exposure diagnosis) compared to the comparator group
(72.19% and 60.33% compared to 26.02%). Interestingly, rates of maternal hypertension
and maternal diabetes were lower for the opioid transfer groups than the comparator group.
This could be due, in part, to the lower number of prenatal visits for the in utero opioid
transfer groups compared to the comparator group (mean of 9.02 and 9.54 compared to
11.62), as missing input and an input of unknown were also slightly higher for these groups.
However, these findings are consistent with recent work showing lower rates of infants
with NAS among women with diabetes.126 A finding of concern is the number of infants
noted as having been exposed to hepatitis C during gestation; among infants with an NAS
diagnosis, 27.58% were identified as exposed to hepatitis C while 14.18% of infants with
an opioid exposure diagnosis were identified as exposed to hepatitis C compared to 1.51%
of the comparator group. As hepatitis C can be transferred through the placenta and has a
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long latency period, this is an alarming finding that merits further investigation in future
analyses.
Gestational age, within the dataset, also presented a challenge. The means and
medians presented in Table 3.5 are the untransformed gestational ages available from the
dataset. OHDA censored gestational age greater than 47 weeks but conducted no censoring
at the bottom of the data. According to the literature, a fetus is considered viable once the
fetus reaches between 22-25 weeks gestation127; however, survival of neonates born prior
to this period of viability has been reported, though probability of survival is low.128 In a
study out of Canada on outcomes related to the use of methadone as a medication for opioid
use disorder (MOUD) during pregnancy, the authors censored neonates noted as having a
gestational age less than 23 weeks.129 Additionally, a meta-analysis on survival after
resuscitation and intensive care of infants born at 22 weeks was conducted by an author
team in the United States, finding a pooled survival rate of 29% for this group of
neonates.130
Approximately 21 children had a gestational age coded as less than 23 weeks in the
dataset obtained from OHDA (0.01% of children in the dataset). The method used by the
authors in Canada129 was utilized to bottom censor the data, with neonates coded as having
a gestational age of 22 weeks or less recoded as missing data due to the low probability of
survival prior to this period and inability to verify if the data is factual or erroneous. The
pre-censored measures of central tendency and censored measures of central tendency are
available in Table 3.6. After censoring, the values did not change significantly.
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Table 3.1 Demographics of the population of infants born on Kentucky Medicaid
between 2014 and 2019, stratified by opioid-related diagnoses status.
Demographic
Characteristic

NAS Diagnosis

Opioid
Exposure
Diagnosis
n=5,854

Comparator

Total Population

P-Value

n=8,232
n=178,293
N=192,379
Birth Year
<0.0001
Cohort
2014
1,340 (4.20%)
399 (1.25%)
30,201 (94.56%)
31,940
2015
1,420 (4.31%)
626 (1.90%)
30,910 (93.79%)
32,956
2016
1,393 (4.32%)
1,303 (4.04%)
29,547 (91.64%)
32,243
2017
1,529 (4.73%)
1,355 (4.19%)
29,445 (91.08%)
32,329
2018
1,404 (4.41%)
1,359 (4.27%)
29,065 (91.32%)
31,828
2019
1,146 (3.69%)
812 (2.61%)
29,125 (93.70%)
31,083
Sex at Birth
<0.0001
Male
4,388 (53.30%)
3,018 (51.55%)
91,221 (51.16%)
98,627 (51.27%)
Female
3,843 (46.68%)
2,836 (48.45%)
87,071 (48.84%)
93,750 (48.73%)
Unknown
Supp.
Supp.
Supp.
Supp.
Race
<0.0001
White
6,324 (76.82%)
3,911 (66.81%) 116,491 (65.34%)
126,726 (65.87%)
Black
218 (2.65%)
659 (11.26%)
21,302 (11.95%)
22,179 (11.53%)
Other
1,690 (20.53%)
1,284 (21.93%)
40,500 (22.72%)
43,474 (22.60%)
Rural-Urban
<0.0001
Continuum
Classification
Metro
3,126 (37.97%)
3,375 (57.65%)
96,979 (54.39%)
103,480 (53.79%)
Non-metro
5,106 (62.03%)
2,479 (42.35%)
81,314 (45.61%)
88,899 (46.21%)
Appalachian
4,604 (55.93%)
1,819 (31.07%)
53,097 (29.78%)
59,520 (30.94%)
<0.0001
at Birth
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49.
**Birth year cohort was determined based on the year of the date of birth of the infant. Sex at birth was extracted from
the Medicaid enrollment data in the first year of life. Race was extracted from the Medicaid enrollment data. RUC
codes were determined based on the county from the address the infant used to enroll in Medicaid at birth, linked to a
driver containing the 2013 RUC codes as determined by the USDA; a list of Kentucky counties with their associated
RUC code can be found in the Appendix. Appalachian status at birth was determined based on the list of 54
Appalachian counties identified by the Appalachian regional commission; a list of the counties considered Appalachian
can be found within the Appendix.
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Table 3.2 Overall retention, continuous enrollment not considered, within the Kentucky
Medicaid system for the population of infants born on Kentucky Medicaid between 2014
and 2019 between each year of life, stratified by birth year cohort.
Year of
2014
2015
2016
2017
2018
2019
Total
Life
Population
Birth to 1
31,940
32,956
32,243
32,329
31,828
31,083
192,379
1 to 2
30,544
31,678
30,862
30,755
30,013
-153,852
2 to 3
28,799
29,537
28,491
27,724
--114,551
3 to 4
27,730
28,108
26,767
---82,605
4 to 5
26,457
26,466
----52,923
5 to 6
24,995
-----24,996
Overall
78.26%
80.31%
83.02%
85.76%
94.30%
100%
-Retention
*Infants were included in a year of life if the infant was enrolled at any time during the year of life. Follow-up
discontinued for the infant if the infant was not enrolled in the Medicaid system during an entire year of life.
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Table 3.3 Continuously enrolled infants by year of life by HEDIS standards for the
population of infants born on Kentucky Medicaid between 2014 and 2019 for each year
of a child’s life, stratified by birth year cohort.
Year of
Life

2014

2015

2016

2017

Total
Population
n=31,940
n=32,956
n=32,243
n=32,329
n=31,828
n=31,083
N=192,379
Birth to 1
29,067
30,882
29,933
29,893
29,069
28,165
177,009
1 to 2
25,646
26,329
25,311
24,265
23,580
-125,131
2 to 3
24,807
25,669
24,097
23,751
--98,324
3 to 4
24,203
23,937
23,162
---71,304
4 to 5
22,724
23,501
----45,775
5 to 6
22,134
-----22,134
*HEDIS: Healthcare Effectiveness Data and Information Set. HEDIS continuous enrollment standards allow no more
than a 45-day gap (e.g., 87.6% covered days) in coverage within a given year. Infants meeting this criterion were
considered continuously enrolled in the Medicaid system for that year of life.
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2018

2019

Table 3.4 Frequency of relocation within the state for children born on Kentucky
Medicaid between 2014 and 2019 in each year of a child’s life, stratified by birth year
cohort.
Year of
Life

2014

2015

2016

2017

2018

2019

Total
Population
N=192,379
11,141
11,982
7,481
6,213
3,917
1,659
32,333

n=31,940
n=32,956
n=32,243
n=32,329
n=31,828
n=31,083
Birth to 1
1,805
1,044
1,398
2,187
2,508
2,199
1 to 2
2,724
1,859
2,309
2,837
2,253
-2 to 3
1,064
1,988
2,449
1,980
--3 to 4
1,900
2,368
1,945
---4 to 5
2,117
1,800
----5 to 6
1,659
-----Ever
7,610
6,589
6,081
5,647
4,207
2,199
Relocated
*Children were considered to have relocated if the county of the enrollment address at the beginning of the year of their
life was different than the county of the enrollment address at the end of the year of their life.
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Table 3.5 Maternal and gestational health characteristics of children born on
Kentucky Medicaid, 2014 to 2019, stratified by opioid-related diagnosis status.
Characteristic

NAS Diagnosis

Opioid
Exposure
Diagnosis
n=5,854
3,532 (60.33%)

Comparator

Total Population

P-Value

n=8,232
n=178,293
N=192,379
Maternal
5,943 (72.19%)
46,393 (26.02%)
55,868 (29.04%)
<0.0001
Smoking
85 (1.03%)
32 (0.55%)
1,093 (0.61%)
1,210 (0.63%)
Unknown
Missing
786 (9.55%)
451 (7.70%)
11,860 (6.65%)
13,097 (6.81%)
Gestational
38.40 (1.75)
38.14 (2.26)
38.63 (1.74)
38.60 (1.76)
<0.0001
Age, mean
(S.D.)
Missing
849
484
14,671
16,004
Number of
9.02 (5.79)
9.54 (5.21)
11.62 (4.29)
11.45 (4.44)
<0.0001
Prenatal
Visits¸mean
(S.D.)
Missing
1,227
830
19,592
21,649
Gestational
404 (4.91%)
396 (6.76%)
13,567 (7.61%)
14,367 (7.47%)
<0.0001
Hypertension
103 (1.25%)
51 (0.87%)
1,006 (0.56%)
1,160 (0.60%)
Unknown
Missing
786 (9.55%)
450 (7.69%)
11,858 (6.65%)
13,094 (6.81%)
Gestational
184 (2.24%)
229 (3.91%)
9,740 (5.46%)
10,153 (5.28%)
<0.0001
Diabetes
Unknown
103 (1.25%)
51 (0.87%)
1,006 (0.56%)
1,160 (0.60%)
Missing
786 (9.55%)
450 (7.69%)
11,858 (6.65%)
13,094 (6.81%)
Infant Exposed 2,270 (27.58%)
830 (14.18%)
2,686 (1.51%)
5,786 (3.01%)
<0.0001
to Hepatitis C
Unknown
132 (1.60%)
83 (1.42%)
1,403 (0.79%)
1,618 (0.84%)
Missing
786 (9.55%)
450 (7.69%)
11,858 (6.65%)
13,094 (6.81%)
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49.
**All maternal and gestational health characteristics were extracted from information available on the infant’s birth
certificate. Missing variables in categorical analyses were considered as a category. Categorical variables coded with a
“9” were assumed to be unknown and were counted as different than missing to indicate that the field was populated.
Missing variables coded as “NULL” were later recoded to be missing.
***OHDA censored and marked as missing gestational ages greater than 45 weeks. Number of prenatal visits coded as
“99” were assumed to be missing.
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Table 3.6 Measures of central tendency for gestational age in the population of
children born on Kentucky Medicaid between 2014 to 2019, before and after
censoring of the variable, stratified by opioid exposure status.
NO CENSORING
NAS
Prenatal
Opioid
Exposure
Comparator
Total
Population**

Mean

Median

Minimum

Maximum

P-Value

39
39

Stan.
Dev.
1.75
2.26

38.40
38.14

23
23

44
43

<0.0001

38.63
38.60

39
39

1.74
1.76

9
9

47
47

Mean

Median

Minimum

Maximum

P-Value

38.40
38.14

39
39

Stan.
Dev.
1.75
2.26

23
23

44
43

<0.0001

38.63
38.61

39
39

1.73
1.75

23
23

47
47

AFTER CENSORING
NAS
Prenatal
Opioid
Exposure
Comparator
Total
Population***

*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code
P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72
and ICD-10 code P04.49. Censoring of the gestational age variable required
censoring cells with gestational age input as 22 weeks or less.

**A total of 16,004 observations (8.32% of the entire population) were missing. Among children with NAS, 10.31%
were missing; among children with a diagnosis of prenatal opioid exposure, 8.27% were missing; and among the
comparator group, 8.23% were missing.
***A total of 16,025 observations (8.33% of the entire population) were missing. Among children with NAS, 10.31%
were missing; among children with a diagnosis of prenatal opioid exposure, 8.27% were missing; and among the
comparator group, 8.24% were missing.
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Figure 3.1 Distribution of the children born on Kentucky Medicaid between 2014
and 2019 by county at birth.
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Figure 3.2 Rates of neonatal abstinence syndrome among children born on
Kentucky Medicaid between 2014 and 2019 by county at birth.
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Figure 3.3 Getis-Ord Gi* hotspot analysis of rates of neonatal abstinence syndrome
among children born on Kentucky Medicaid between 2014 and 2019 by county at
birth.
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CHAPTER 4. SOCIO-EMOTIONAL DEVELOPMENT: OTHER FAMILY MEMBERS ON MEDICAID
AND ENROLLMENT ADDRESS IN NEONATAL ABSTINENCE SYNDROME
4.1

Background
The importance of the role a child’s family and home environment plays in a child’s

life cannot be understated.131 These elements of a child’s life become the cornerstone of a
child’s developmental trajectory, with exposure to these environments becoming the first
relationships a child ever builds.29,131,132 Children emerge into the world as completely
dependent creatures; they cannot identify or serve their own needs for the duration of a
critical period of learning and adapting in early life29,131. The efficacy of the family in
serving the child’s physical, mental, and emotional wellness become paramount in that
child maintaining optimal physical health, mental health, and emotional health for the rest
of their life.131
When a child is neglected in any one of these areas in these vital periods of life, the
child faces a significant obstacle in their early development. As such, many adverse
childhood experiences (ACEs) are associated with the family life of a child.115,133 ACEs
have known adverse health outcomes.133 While these early experiences do not decide a
child’s future, they alter the trajectory of that future and place barriers in a child’s pathway
toward wellness. At the extreme end of ACEs, foster care involvement becomes
inevitable.115,133 Involvement in the foster care system itself has been identified as an ACE
and a significant source of trauma, as well as associated with adverse health outcomes,
both physical and mental, later in a child’s life.115,116
Current evidence, however, is adamant that children tend to thrive when the
connection with their mother can be maintained in the hours following birth.134 Even in the
presence of a suboptimal developmental environment, when a child and their mother can
bond and connect, the child’s developmental trajectory is different than when such
connections are not possible.132,134 Children of mothers with substance use disorder,
however, have a significant disadvantage in this instance. Anecdotal evidence of substance
use disorders speaks to the consuming nature of the disorder135–139; though a mother could
be physically present in a child’s life, the mother is not necessarily mentally or emotionally
present with the child, creating an area of neglect in the child’s development that the child
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will be tasked with overcoming later in life if the child wants to establish thriving
relationships with their peers.140
The family lives of children with NAS have not been well studied. Thus, the purpose
of this chapter is to examine family life factors associated with NAS, including other family
members on Medicaid, other siblings with NAS, the household where a child received mail
among children with NAS, and involvement with the foster care system.
4.2

Methods
The entire study population identified in Chapter Three was utilized in the analysis

to obtain information regarding the families and family life of children with NAS. The
entire study population was used in this instance due to the nature of the outcomes
analyzed. Much of the source of the outcomes assessed stemmed from information
available in the enrollment data available within the Kentucky Medicaid administrative
claims database and the cross-sectional nature of many of the outcomes, as discussed
further below. This information was largely considered consistent for the entire annual
period, regardless of continuous enrollment status for that child.
Dichotomous, cross-sectional indicator variables available for analysis included
whether the child ever had a sibling in the Medicaid system, whether a sibling was also
diagnosed with either NAS or opioid exposure, maternal Medicaid status, and whether the
child was enrolled in Medicaid at the same address as the mother (assumed to reflect the
household location of the child). A longitudinal, dichotomous indicator variable reflecting
foster care status within the year of child’s life was also available for analysis; if the child
entered the foster care system at any point during that year of life, the variable identified
such a switch occurred.
Frequency analyses were conducted to identify differences among the strata, with chi
square analyses being utilized to identify statistically significant differences among the
strata for categorical variables.
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4.2.1

Statistical Analyses

Following the ascertainment of the frequencies of family characteristics, a logistic
regression analysis was conducted among the population of children with a mother enrolled
on Medicaid to ascertain the likelihood of a child being enrolled at the same household
location as the mother based on opioid exposure status. Because children with foster care
involvement are inherently placed outside parental custody, these children were excluded
from the logistic regression analysis.
A directed acyclic graph (DAG) was designed using DAGitty v.3.0 to identify factors
associated with both enrollment status and opioid exposure status. Following the bivariable
and multivariable logistic regression analysis using the factors and minimal sufficient
adjustment set identified by the DAG, additional logistic regression models were run post
hoc using both a fully adjusted model composed of all the variables identified in the DAG
and backwards selection to optimize variable selection to optimize model fit. Model
selection criteria utilized the c-statistic, Akaike information criterion, and -2 log likelihood
statistics to identify optimal model fit. Following the selection of a logistic regression
model, model assumptions were checked to ensure all assumptions to ensure a valid logistic
regression analysis were met. All statistical analyses were conducted using SAS v9.4
(Cary, NC). An α-threshold of 0.05 was utilized; p-values less than 0.05 were considered
statistically significant.
4.3

Results
Demographic information for the study population included in this study are

provided in Chapter 3. Additionally, linkage of the databases to identify the mother and
any siblings in the Medicaid claims data was explained in greater detail in Chapter 3. Table
4.1 provides frequency analyses of family characteristics of the children in the study
population. Between 89.8% to 91.6% of children on Medicaid have a mother that could be
identified in the Medicaid database; between 44.3% and 48.7% of children also had a
sibling that could be identified in the database. Among children with some evidence of
prenatal opioid transfer, 27.8% of children with NAS and 19.1% of children with prenatal
opioid exposure have a sibling that also acquired one of these codes at birth.
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Two findings regarding the child’s association with the mother are worth noting. For
children with a diagnosis of NAS, only 46.44% were always enrolled in Medicaid at the
same address as the mother; for children with prenatal opioid exposure, this rises slightly
to 55.96%. This is largely different than the 72.39% of children enrolled at the same address
as the mother in the comparator group.
Table 4.2 and Table 4.3 investigate age at entry into the foster care system for these
children. Table 4.2 investigates age at entry for children based on birth year cohort. Overall,
it seems that most children in the analysis involved in foster care during this age period
become involved prior to their first birthday; this is also consistent with the findings of
Table 4.3. Of note, however, is that, because of the recency of the data (birth cohorts 2014
to 2019 with information spanning through 2020) means that many of the children in the
cohort have not yet aged past early years and thus may not have had time to interact with
the foster care system, so results should be interpreted with caution.
4.3.1

Logistic Regression Analysis

The study population was then subset to the population of children with a mother
able to be identified in the MMIS system (91.12% of the children in the dataset). This
subset occurred because the outcome of interest for these analyses, enrollment at an address
different than the mother’s, is not possible to ascertain if the mother could not be identified
in the Medicaid claims data. Additionally, because of the high likelihood that a child in
foster care will be located outside parental custody and thus enrolled at a different address,
these children were excluded from this analysis.
Following the inclusion and exclusion criteria being applied to the population of
children born on Kentucky Medicaid between 2014 and 2019, a total of 167,384 children
of the original 192,379 children remained in the study population (i.e., 87.00% of the full
population). Table 4.4 presents the demographics of this newly created study population,
stratified by whether a child is enrolled at the same or different address during the study
period. The children at a different address than the mother were more frequently diagnosed
with NAS (approximately 7.1% compared to 2.7%) or prenatal opioid exposure
(approximately 4.2% compared to 2.4%) than the group of children always enrolled at the
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same address as the mother. Children enrolled at different addresses were also more likely
to have a sibling with one of the prenatal opioid exposure diagnoses than children located
at the same household, with 6.8% compared to 2.7% having this characteristic,
respectively.
The DAG utilized to identify the minimum sufficient adjustment set is shown in
Figure 4.1. Code for the DAG is included in the Appendix. Table 4.5 provides logic and
justification for the inclusion of variables within the DAG, as well as identified proxy
variables within the model. The minimal sufficient adjustment set identified by the DAG
included physical location for a child, sex, race, birth year cohort, continued substance use,
and indicators of poverty. The results in Table 4.6 present the results of a logistic regression
analysis conducted to ascertain the odds of a child with evidence of in utero opioid transfer
being enrolled in an address different than the mother using this minimal sufficient
adjustment set, as well as unadjusted (or bivariable) analyses. The adjusted equation
modeled by the logistic regression analysis in Table 4.6 was
𝑦𝑦 = −0.68 + 0.39𝑥𝑥1 + 0.10𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7

− 0.09𝑥𝑥8 + 0.14𝑥𝑥9 − 0.01𝑥𝑥10 − 0.01𝑥𝑥11 − 0.07𝑥𝑥12 − 0.08𝑥𝑥13 + 0.39𝑥𝑥14

where

+ 𝜖𝜖

x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS,
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal
opioid exposure,
x3 is a dichotomous variable indicating whether a child was born in 2014,
x4 is a dichotomous variable indicating whether a child was born in 2015,
x5 is a dichotomous variable indicating whether a child was born in 2016,
x6 is a dichotomous variable indicating whether a child was born in 2017,
x7 is a dichotomous variable indicating whether a child was born in 2018,
x8 is a dichotomous variable indicating whether a child’s race is identified as Black,
x9 is a dichotomous variable indicating whether a child’s race is identified as Other,
x10 is a dichotomous variable indicating whether a child’s sex at birth was female,
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x11 is a dichotomous variable indicating whether a child was born a resident of a
county identified as Appalachian,
x12 is a dichotomous variable indicating whether a child was born a resident of a
county identified as non-metropolitan,
x13 is a dichotomous variable indicating whether a child had a sibling on Medicaid,
and x14 is a dichotomous variable indicating whether a child had a sibling diagnosed
with a diagnosis indicating prenatal opioid exposure.
Odds ratios are ascertained from logistic regression models by exponentiating each
of the covariates in the model. SAS provides these odds ratios as part of the analytic output
for the model.
In the unadjusted analyses, children with a diagnosis of NAS had 2.81 (95% CI: 2.66,
2.96) times higher odds of being enrolled at a different address than their mother than the
comparator group; among children with a diagnosis of prenatal opioid exposure, these odds
remained elevated, at 1.87 (95% CI: 1.77, 2.01) times higher odds than the comparator
group; following the adjustment, these odds remained inflated, at 2.39 (95% CI: 2.26, 2.53)
and 1.78 (95% CI: 1.67, 1.91).
Consistent with the decreasing frequencies shown in Table 4.4, birth year cohort also
saw decreasing odds of enrollment at a different address as the recency of the birth
increased in both the unadjusted and adjusted models. Also consistent with the table, in
both the bivariable and multivariable analyses, having a sibling on Medicaid seemed to be
protective against enrollment at a different address while having a sibling diagnosed with
prenatal opioid exposure seemed to have a large effect on enrollment at an address different
than the mother’s address (bivariable odds 2.64 times higher than not having a sibling
diagnosed with prenatal opioid exposure and odds in the multivariable analysis 2.17 times
higher than not having a sibling diagnosed with prenatal opioid exposure, holding all other
variables constant).
In the bivariable analyses, sex at birth failed to obtain statistical significance,
consistent with the lack of statistical significance showing difference between the strata in
Table 4.4. However, standard procedures in epidemiology regarding evaluating the effect
of sex on various conditions mandated the variable remaining in the analysis, despite its
lack of statistical significance.
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In the bivariable analyses, Appalachian status was statistically significant; in the
adjusted model, the variable ceased being statistically significant. Additionally, nonmetropolitan status in the adjustment saw a slight shift, moving from 0.90 in the unadjusted
to 0.87 in the adjusted model. These two facts in tandem provides suggestion that
collinearity may exist between these two variables and merits additional investigation in
the assessment of model assumptions.
Race produced an interesting finding from the analysis, indicating that being enrolled
in Medicaid as Black was protective against being located at a different address than the
mother compared to children identified as White (unadjusted odds ratio of 0.94 with 95%
CI of 0.91 to 0.98; adjusted odds ratio of 0.95 with 95% CI of 0.92 to 0.99). This did not
hold for children identified as being of an Other race in the analysis, as these children had
inflated odds compared to children identified as White (unadjusted odds ratio of 1.15 with
95% CI of 1.12 to 1.19; adjusted odds ratio of 1.21 with 95% of 1.17 to 1.25).
4.3.2

Model Fit Assessment and Assumptions

To ensure adequate modeling of the exposure and outcome in this analysis, model fit
statistics were considered to identify an optimal model for the assessment of the total effect
of prenatal opioid exposure on enrollment at a different address than the mother. The model
given in Table 4.6 had a c-statistic of 0.62. The c-statistic for a logistic regression model is
equivalent to the area under of the curve of a ROC model, which models the predictive
quality of a data; these areas range from 0 to 1.141 In general, models are considered
reasonable fits for data if the c-statistic is greater than or equal to 0.7; a model is strongly
predictive if the c-statistic is 0.8 or higher.142 The c-statistic for the model given in Table
4.6 indicates a model that is acceptable, but shows significant room for improvement. Thus,
an attempt was made to optimize the model fit of the data. Because the DAG was selected
using human assumptions of relationships between variables, it is possible that a better
model exists to explain the data over all; backwards selection allows SAS to select
prespecified variables based on statistical significance until a reasonably parsimonious
model is created.
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Table 4.7 presents the results of post hoc analyses conducted to optimize model fit.
In the first model, every variable identified by the DAG, regardless of its identification as
part of the minimal sufficient adjustment set, was included in the analysis; this model was
referred to as the “Fully Adjusted” model and is given by the equation,
𝑦𝑦 = 1.71 + 0.39𝑥𝑥1 + 0.08𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7 − 0.10𝑥𝑥8
+ 0.14𝑥𝑥9 − 0.01𝑥𝑥10 − 0.01𝑥𝑥11 − 0.07𝑥𝑥12 − 0.07𝑥𝑥13 + 0.39𝑥𝑥14
− 0.06𝑥𝑥15 + 𝜖𝜖

where,

x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS,
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal
opioid exposure,
x3 is a dichotomous variable indicating whether a child was born in 2014,
x4 is a dichotomous variable indicating whether a child was born in 2015,
x5 is a dichotomous variable indicating whether a child was born in 2016,
x6 is a dichotomous variable indicating whether a child was born in 2017,
x7 is a dichotomous variable indicating whether a child was born in 2018,
x8 is a dichotomous variable indicating whether a child’s race is identified as Black,
x9 is a dichotomous variable indicating whether a child’s race is identified as Other,
x10 is a dichotomous variable indicating whether a child’s sex at birth was female,
x11 is a dichotomous variable indicating whether a child was born a resident of a
county identified as Appalachian,
x12 is a dichotomous variable indicating whether a child was born a resident of a
county identified as non-metropolitan,
x13 is a dichotomous variable indicating whether a child had a sibling on Medicaid,
x14 is a dichotomous variable indicating whether a child had a sibling diagnosed
with a diagnosis indicating prenatal opioid exposure,
and x15 is a continuous variable for each additional week of added gestational age for
a child.
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Additionally, backward selection was applied to this fully adjusted model, resulting
in a model given by the equation,
𝑦𝑦 = 1.71 + 0.39𝑥𝑥1 + 0.08𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7 − 0.10𝑥𝑥8
+ 0.14𝑥𝑥9 − 0.07𝑥𝑥10 − 0.07𝑥𝑥11 + 0.39𝑥𝑥12 − 0.06𝑥𝑥13 + 𝜖𝜖

where,

x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS,
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal
opioid exposure,
x3 is a dichotomous variable indicating whether a child was born in 2014,
x4 is a dichotomous variable indicating whether a child was born in 2015,
x5 is a dichotomous variable indicating whether a child was born in 2016,
x6 is a dichotomous variable indicating whether a child was born in 2017,
x7 is a dichotomous variable indicating whether a child was born in 2018,
x8 is a dichotomous variable indicating whether a child’s race is identified as Black,
x9 is a dichotomous variable indicating whether a child’s race is identified as Other,
x10 is a dichotomous variable indicating whether a child was born a resident of a
county identified as non-metropolitan,
x11 is a dichotomous variable indicating whether a child had a sibling on Medicaid,
x12 is a dichotomous variable indicating whether a child had a sibling diagnosed
with a diagnosis indicating prenatal opioid exposure,
and x13 is a continuous variable for each additional week of added gestational age for
a child.
This model was referred to as the “Backward Selected Model.” Backwards selection
removed both sex and Appalachian status from the model. For the most part, results
between the fully adjusted and adjusted model were largely consistent, with the only
significant alteration occurring in the non-metropolitan status following the removal of
Appalachian status from the model (odds ratio of 0.87 in the fully adjusted model and 0.86
in the backward selected model).
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The c-statistic for both the fully adjusted model and the backward selected model
was 0.63, indicating slight improvement in model fit. Considering other model fit statistics,
the AIC for the adjusted model in Table 4.6 was 160,544.09; for the fully adjusted model,
the AIC was 159,886.39; and for the backward selected model, the AIC was 159,885.21.
In general, when selecting an optimal model, smaller AIC indicates better fit143, and thus,
based on the AIC criterion, the backward selected model is the more optimal model for the
data. Contrastingly, considering -2 log-likelihood as a model fit statistic, the adjusted
model had a -2 log-likelihood of 160,514,09; the fully adjusted model had a -2 loglikelihood of 165,444.44; and the backward selected model had a -2 log-likelihood statistic
of 159,857.21. For -2 log-likelihood, in contrast to the AIC, higher values indicate more
optimal model fits, and thus the -2 log-likelihood statistic indicated the fully adjusted
model as the optimal model fit. Most importantly, however, none of the model fit statistics
identified the model adjusted using the minimal sufficient adjustment set from the DAG as
the optimal dataset.
The results in Table 4.8 show the c-statistics from the bivariable analyses for each of
the variables in the study to show the relative strength of each variable in predicting
whether a child would enroll at an address different than the mother. Overall, the variables
had c-statistics around 0.5, indicating that the variables were quite neutral individually in
predicting; none were strong predictors of such an outcome on their own. The “strongest”
of the variables seemed to be birth year cohort, with a bivariable c-statistic of 0.59; the
second “strongest” variable was prenatal opioid exposure, with a bivariable c-statistic of
0.53.
Model assumptions were also considered to identify the optimal model for the
association between prenatal opioid exposure and enrollment at an address different than
the mother’s address. Model assumptions for a logistic regression analysis require that the
outcome variable be ordinal, observations be independent, lack multicollinearity, the log
odds be linear, and a large sample size is obtained for analysis.144,145
First, multicollinearity was considered, as previous analyses indicated that two of the
models (the adjusted and fully adjusted models) may violate this assumption. Usually, a
chi-square analysis is sufficient to ascertain multicollinearity between variables in models.
However, the ability to detect statistical significance is largely dependent upon the
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statistical power of a model146; in the case of big data analytics, as are utilized within the
dissertation, analyses may be overpowered to detect significant differences and thus result
in analyses very sensitive to slight changes; indeed, a chi-square analysis between
Appalachian status and non-metropolitan status provided a p-value of <0.0001, indicating
that Appalachian status and non-metropolitan status were likely associated with one
another. This was deemed to be insufficient evidence, and a bivariable logistic regression
analysis was conducted, utilizing metropolitan status as the outcome of interest and
Appalachian status as the exposure of interest. Results from this analysis provided an odds
ratio of 0.03 with a very narrow 95% confidence interval. This indicates a relatively strong
inverse correlation between Appalachian status and metropolitan status: the more likely an
observation is to the Appalachian, the less likely the observation is to be in a metropolitan
area. This is confirmed by the maps of the counties identified as metropolitan and
Appalachian available in the Appendix; there are very few, if any, overlaps between these
counties.
Based on the findings in Chapter 3, we also know that prenatal opioid exposure status
is also associated with several of the variables in the study, which may suggest that
multicollinearity is a problem in the model. One variable that is likely very associated with
prenatal opioid exposure status is the variable indicating whether a child had a sibling with
NAS. The logistic regression model may be violating this assumption because of these
associations between variables. There is no sufficient fix for this violation as prenatal
opioid exposure is the effect of interest in the model. Thus, to best safeguard against
multicollinearity, the backwards selected model was determined to be the final model for
the remaining investigations into model assumptions.
Most variables included in the model are ordinal variables as opposed to continuous
variables, and thus do not likely contribute significant outliers that influence the model.
The notable exception to this is gestational age. With gestational age, in chapter 3, the
censoring that took place by both OHDA and during the methodological overview are
likely preventing significant outliers from influencing the data. A histogram of gestational
age for the study population can be found in Appendix 6. For the most part, while the data
is not perfectly normally distributed, the data is largely consistent with the overall
distribution that would be expected of a normally distributed variable, with a significant
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amount of clustering occurring around 38 weeks and with tails on both ends. Below 30
weeks gestational age, observations are rare, only contributing a small percentage of the
overall distribution. Above 42 weeks, observations are also rare. As noted in Chapter 3,
OHDA censored data at the top at 47 weeks gestational age. Also noted in Chapter 3 was
the bottom censoring that occurred as part of the overall study methodology, censoring
observations less than 23 weeks.
To check for linearity in the logit, gestational age was considered as a categorical
variable in a bivariable analysis and odds were ascertained to ensure that increasing
gestational age continued decreasing the odds of enrolling at a different address than the
mother’s address. The full results of this assessment can be found in Appendix 7. The
model does seem to be linear as far as it related to log odds, until the very tail end of the
data when the weeks exceed 42 gestation and the data heads in the opposite direction of
the trend of the remainder of the data. This may be due, in part, to small sample sizes rather
than a violation in the model assumptions. If such a violation does exist in the model, a
way to safeguard against both significant outliers and nonlinearity in the logit would be to
categorize gestational age rather than keeping the variable as a continuous variable in the
analysis, and thus eliminate the need for examination into continuous variables altogether.
However, categorizing a variable like gestational age could result in the loss of granularity
of information arising during the analysis.
4.4

Discussion
The logistic regression analysis identified that children with prenatal opioid

transference had 3.6 and 2.5 times the odds of enrolling in Medicaid at an address different
than the comparator group. This could be a result of several policies. Punitive policies for
mothers with prenatal opioid exposure could explain the relocation of a child to a different
household, whether foster care or otherwise, when prenatal exposure is identified. One
method Kentucky has already begun utilizing to make progress in this area is through plans
of safe care. Plans of safe care were established within Kentucky were created to assist in
fostering the development of relationships between family and children following prenatal
opioid exposure and ensuring a safer home environment for the neonate.147 Additionally,
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programs such as START exist within Kentucky to create plans to keep families together
following substance involvement.148
The data also shows that approximately 91% of children in the study population have
a mother also covered by Medicaid and a large percentage of children have a sibling that
is covered by Medicaid. This suggests that there are a significant number of whole families
that Medicaid is covering simultaneously. Health is symbiotic to the environment in which
it is being experienced; one shift for a family member can change the trajectory of the entire
family.149 Thus, any prophylactic measures and additional monitoring Medicaid creates for
children has the potential to influence the entire family. Medicaid therefore has a
significant opportunity for influence in the health of families by strategically targeting
interventions toward the children covered by Medicaid.
The data suggested that there seems to be a birth cohort effect among the children in
this analysis, as the frequency of a child being enrolled at a different address decreased as
the birth year cohorts became more recent. This birth cohort effect could be occurring for
many reasons. One reason, and likely a large contributor to this effect, is that children born
earlier have more time to be enrolled at a different address than their mothers, thus
increasing the likelihood of such an event occurring; another reason, and likely a more
minor contributor, could be increased efforts by social and child protective services to keep
families together whenever possible.150
The consensus among child development literature is that, when safe and
appropriate, the optimal environment for child development occurs when a child can
remain with their family.151,152 The relationship between a child and parent is critical to
ensuring the child develops healthy relationships later in life; this relationship, as one of
the earliest relationships formed by the infant, sets the stage for attachment for the child
throughout their life.29,131,132 In instances where healthy, secure attachment with the parent,
and in particular the mother, can be fostered, the infant is shown to have improved
outcomes across several sectors of development.131
However, it is not always safe for an infant to maintain this connection; the best
option for a child may be extraction and separation for a period until it can be determined
that it is safe for the child to return to the custody of the parent. First, in these instances,
best practice requires investigation to see if there is another family member or close family
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friend that could raise the child temporarily until parental custody can be safely
reinstated151; if such a relation cannot be found, or it is determined that the best course of
action for the child is complete removal and relocation, then the child enters the foster care
system152, at which time, under the Adoption and Safe Families Act, a clock for the
complete revocation of parental rights to the child begins ticking.114
Children in the foster care system in Kentucky are covered by the Medicaid
system153 until the child ages out of foster care, can return to the parent, or is adopted
following the termination of parental rights to the child. Children with foster care
involvement face unique challenges compared to their peers, and involvement with foster
care has been shown to be associated with greater risk of mental health conditions, as well
as other conditions.154 The utilization of antipsychotics in this population has also been
established as an area for concern.155
The results of this chapter also indicate that around 19.6% of children with a
diagnosis of NAS and 15.5% of children with prenatal opioid exposure were ever involved
in foster care, compared to 3.3% of the comparator group; this large gap indicates that
foster care is a notable consideration for future analyses regarding this population. This
indicates that prenatal opioid exposure is a large driver of the overall population increase
to 4% of children overall. Thus, foster care is an important consideration when analyzing
children with a history of prenatal opioid exposure, whether the child has experienced
withdrawal or not. The data also trends toward a stark drop-off in first-time foster care
involvement following the child’s first birthday. Medicaid, therefore, has a responsibility
to ensure that these children are obtaining the needed healthcare and preventative visits to
prophylactically intervene in adverse health outcomes for these children. All children in
the foster care system have a standard for pediatric care visits established by the American
Academy of Pediatrics that foster parents should adhere to.156 Children with a diagnosis of
NAS involved with foster care are also designated as medically fragile157 and have a more
stringent set of requirements.154 Medicaid bears a responsibility to ensure that children are
being provided with adequate care and a safe environment for the child to develop in.
Partnerships with DCBS could be utilized to create targeted interventions for these groups
to optimize the health of the children in the foster care system.
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4.4.1

Limitations and Future Directions

It should be noted that, within this analysis, reason for displacement from the
mother’s household was not explored. Reasons outside foster care and kinship care,
meaning the care of a child by a relative or family friend known to the child and facilitated
by child protective services, could be contributing to the child’s displacement from the
mother’s household address. Indeed, the child could be in primary custody of a father,
either having always been in the custody of the father from birth or in the custody of the
father following a divorce. Additionally, the child may be in the care of a grandparent for
reasons unrelated to substance use159, or the mother could be in a substance use disorder
treatment program and be unable to bring her child with her to the treatment program, as
programs that allow mothers to bring children with them remain rare.160 It may also be
likely that the child and the mother are located within the same household, but one or both
parties may have not provided a current address to Medicaid, thus creating the appearance
of a different household when, in truth, the dyad is together. Additionally, one cannot
discount the possibility of the dyad being homeless161, and the discrepancy in address being
a result of finding addresses to register so that healthcare could be received. Future research
should focus on reasons for this discrepancy and the socioemotional developmental impact
of these specific reasons for displacement.
Additionally, paternal relationships of children with neonatal abstinence syndrome
were not explored within this analysis. Older siblings of children with prenatal opioid
exposure (meaning siblings born before 2014) were not able to be identified in the analysis.
Currently, OHDA does not house data from OVS prior to 2014; historical information on
children in the Kentucky Medicaid MMIS database does date back beyond 2014. By
obtaining information from these two offices separately, it may be feasible to examine
these historic relationships beyond 2014, though such a linkage would require the
ascertainment of protected health information, such as social security numbers, to verify
such a linkage.
Third, this analysis proved the capability of OHDA to examine dyads, both for
mother-infant pairs and siblings. The analysis did determine that approximately a quarter
of children with a diagnosis of NAS have a sibling that was born with a diagnosis indicating
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prenatal opioid exposure. Such a relationship was not examined within the context of this
analysis and presents a limitation to this analysis. Little information is available in the
literature on sibling pairs with a history of NAS. Given the large sample size available for
analysis, a sibling study with prenatally exposed children compared against an unexposed
comparator group could be feasible and represents an interesting future direction for
research.
Siblings born before 2014 could not be directly identified, as OVS data prior to this
period was not available, and thus the siblings identified here were siblings born between
2014 and 2019. It is likely, therefore, that many of the children with siblings have a sibling
in the study population; however, these siblings were not linked for this analysis.
Additionally, these findings were extracted from children born on a Medicaid
program from one state within the United States. It is possible that the findings of these
analyses may not be generalizable to other populations.
Finally, it is also worth noting that, within this chapter, many aspects of foster care
among children with prenatal opioid exposure remained unexplored. Future directions for
this population could include a time-to-event analysis of entrance and exit from the foster
care system, additional investigation of the relationship between NAS and foster care, and
more careful examination of other family members of children with prenatal opioid
exposure, including investigation into fathers of children with prenatal opioid exposure and
health characteristics of mothers of children with prenatal opioid exposure and the
incidence of foster care when such a relationship or connection can be determined.
Additionally, further investigation into mothers with multiple children born with NAS
represents an understudied area for future research.
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Table 4.1 Cross-sectional frequencies of family characteristics of the children born on
Kentucky Medicaid between 2014 and 2019, stratified by opioid exposure level.
Characteristic

NAS Diagnosis

Opioid
Exposure
Diagnosis
n=5,854
5,364 (91.63%)

Comparator

Total Population

P-Value

n=8,232
n=178,293
N=192,379
Mother on
7,393 (89.81%)
162,534 (91.16%) 175,291 (91.12%)
<0.0001
Medicaid
Sibling (2014
3,798 (46.14%) 2,850 (48.68%)
78,892 (44.25%)
85,540 (44.46%)
<0.0001
to 2019) on
Medicaid
Sibling (2014
2,286 (27.77%) 1,118 (19.10%)
3,948 (2.21%)
7,352 (3.81%)
<0.0001
to 2019) with
Diagnosed
Evidence of In
Utero Opioid
Transfer
Ever in Foster
1,612 (19.58%)
906 (15.48%)
5,808 (3.26%)
8,326 (4.33%)
<0.0001
Care
Enrolled at a
4,409 (53.56%) 2,578 (44.04%)
49,229 (27.61%)
56,216 (29.22%)
<0.0001
Different
Address as the
Mother
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. Mother’s Medicaid status was obtained
by obtaining identifiers for the mother from the infant’s birth certificate and scanning to see if a match ever existed in
the Medicaid system. Siblings on Medicaid were obtained by using the mother’s identifiers from the infant’s birth
certificate and looking for other children in the Vital Records data available from 2014 to 2019 with the same mother
listed. Siblings with diagnosed evidence of in utero opioid transfer were obtained by identifying the siblings in the
Medicaid data and looking into the administrative claims data for one of the qualifying codes (ICD-9: 779.5 and
760.72; ICD-10: P96.1 and P04.49). Ever in foster care was a dichotomous variable created to identify any child that
had ever been in foster care from the longitudinal variable obtained from OHDA identifying if a child had been in
foster care in each year of life available for analysis. An infant was determined to be enrolled in a different household
than the mother by first identifying the mother listed on the infant’s birth certificate and then identifying if the infant
was ever enrolled in Medicaid at a different address than the address listed in the mother’s enrollment data.
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Table 4.2 Age at earliest entry into the foster care system for children born on Kentucky
Medicaid between 2014 and 2019, stratified by birth year cohort.
Year of
Life

2014

2015

n=1,763
n=1,600
Birth to 1
655
669
1 to 2
260
261
2 to 3
234
274
3 to 4
254
242
4 to 5
228
154
5 to 6
132
-*Overall table p-value of <0.0001.

2016

2017

2018

2019

n=1,496
749
287
296
164
---

n=1,391
863
337
191
----

n=1,255
1,021
234
-----

n=821
821
------
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Total
Population
N=8,326
4,778
1,379
995
660
382
132

Table 4.3 Age at earliest entry into the foster care system for children born on Kentucky
Medicaid between 2014 and 2019, stratified by opioid exposure level.
Year of Life
NAS
Opioid
Comparator
Total
Diagnosis
Exposure
Group
Population
Diagnosis
Birth to 1
1,230
634
2,914
4,778
1 to 2
156
148
1,075
1,379
2 to 3
105
64
826
995
3 to 4
71
43
546
660
4 to 6***
50
17
447
514

*Overall table p-value of <0.0001.
**A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49.
***Cell values less than 10 were required to be suppressed per the Memorandum of Understanding. To minimize
potential for reidentification of children, as column totals were noted in other tables (i.e., Table 4.1), these ages were
combined.
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Table 4.4 Demographics of the population of children born on Kentucky Medicaid
between 2014 and 2019, not involved with foster care, and with a mother able to be
identified in the Medicaid data, stratified by different household status.
Characteristic

Opioid Exposure
NAS Diagnosis
Opioid Exposure
Comparator
Race
White
Black
Other
Sex at Birth
Male
Female
Birth Year
2014
2015
2016
2017
2018
2019
Appalachian
Metropolitan
Metro
Non-Metro
Gestational Age,
mean (S.D.)**
Sibling on Medicaid
Sibling with in
Utero Opioid
Transfer

Same Address as
the Mother
n=135,050

Different Address
than the Mother
n=32,784

Total Population

3,647 (2.70%)
3,187 (2.36%)
128,216 (94.94%)

2,324 (7.09%)
1,364 (4.16%)
29,096 (88.75%)

5,971 (3.56%)
4,551 (2.71%)
157,312 (93.73%)

90,598 (67.08%)
16,405 (12.15%)
28,047 (20.77%)

21,459 (65.46%)
3,669 (4.16%)
7,656 (23.35%)

112,057 (66.77%)
20,074 (11.96%)
35,703 (21.27%)

69,096 (51.16%)
65,954 (48.84%)

16,956 (51.72%)
15,828 (48.28%)

86,052 (51.27%)
81,782 (48.73%)

21,134 (74.36%)
21,309 (75.78%)
21,995 (78.84%)
22,598 (81.04%)
23,486 (84.56%)
24,528 (88.45%)
41,958 (31.07%)

7,289 (25.64%)
6,810 (24.22%)
5,905 (21.16%)
5,288 (18.96%)
4,289 (15.44%)
3,203 (11.55%)
9,978 (30.44%)

28,423
28,119
27,900
27,886
27,775
27,731
51,936 (30.94%)

71,064 (52.62%)
63,986 (47.38%)
38.66 (1.63)

18,096 (55.20%)
14,688 (44.80%)
38.43 (2.13)

89,160 (53.12%)
78,674 (46.88%)
38.61 (1.74)

65,378 (48.41%)
3,653 (2.70%)

15,072 (45.97%)
2,240 (6.83%)

80,450 (47.93%)
5,893 (3.51%)

N=167,384

P-Value
<0.0001

<0.0001

0.07
<0.0001

0.03
<0.0001
<0.0001
<0.0001
<0.0001

*An infant was determined to be enrolled in a different household than the mother by first identifying the mother listed
on the infant’s birth certificate and then identifying if the infant was ever enrolled in Medicaid at a different address
than the address listed in the mother’s enrollment data. A diagnosis of NAS was determined using ICD-9 code 779.5
and ICD-10 code P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72 and ICD-10
code P04.49. Siblings on Medicaid were determined by linking children of common mothers through data available
from the infant’s birth certificate; these figures represent identified siblings from 2014 forward. A sibling with in utero
opioid transfer was determined based on the identified siblings and then identifying if the sibling had one of the
prenatal opioid exposure diagnoses (ICD-9: 779.5 and 760.72; ICD-10: P96.1 and P04.49).
**A t-test was used to test for significant differences. The test for equality of variances yielded a p-value of <0.0001;
because the variances were determined to be significantly different from one another, the Satterthwaite method of
ascertaining a p-value was utilized and reported.
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Table 4.5 Factors identified by the DAG, proxy variables available within the data,
and justification for the logistic regression analysis evaluating the association
between prenatal opioid exposure and being in a different household than the
mother.
Identified Factor
Proxy Variable
Justification
Physical Location*

Appalachian Status;
Metropolitan Status

Sex*

Sex at Birth

Abuse**

N/A

Birth Year*

Birth Year Cohort

Race*

Race

Continued Substance
Use*

Sibling with in Utero
Opioid Transfer
Diagnosis

Foster Care

Foster Care

Gestational Age

Gestational Age

Poverty*

Sibling on Medicaid

The physical location, or the county in which a
child resides, has a significant impact on the
availability of services as well as the culture the
child is exposed to. Additionally, access to care
issues are known for Appalachian162 and rural
areas.163
There may be sex differences in children
involved with child protective services or
displaced from families.164
Abuse and neglect are significant factors in the
involvement of child protective services and
may be relevant to a child being displaced from
their parents.165
The data seems to have a birth cohort effect
where children born later in the data are less
likely to be in a different household than their
mother. This is likely because children born
earlier have more time to be displaced than
children born later. Additionally, renewed effort
has contributed to additional efforts to keep
families united whenever possible.148
There may be racial differences among children
who are displaced from their families.166,167
Having a sibling born with one of the prenatal
opioid exposure codes indicates continued
substance use among the parents of children,
which could lead to displacement and/or child
protective services involvement.168
Children in foster care have been removed from
parental custody for a period due to the
environment being created by the parent being
deemed unsafe for the child.
Evidence in the literature suggests that infants
born preterm are more likely to be abused than
infants carried to term.169
Poverty is considered an ACE170 and has been
shown to be a contributing factor to children
being raised by grandparents or caretakers other
than the parents.171,172

*Identified as part of the minimal sufficient adjustment set for estimating the total effect based on the DAG in Figure
4.1. Code for the DAG can be found in the Appendix.
**No sufficient proxy variable for abuse was available within the dataset.
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Table 4.6 Logistic regression analysis of likelihood that a child born on Kentucky
Medicaid between 2014 and 2019 was enrolled in Medicaid at a different address than
their mother.
Strata
Opioid
Exposure Level
NAS Diagnosis
Opioid Exposure
Birth Year
2014
2015
2016
2017
2018
Race
Black
Other
Sex at Birth
Female
Appalachian
Metro Status
Non-Metro
Gestational Age
Sibling on
Medicaid
Sibling with in
Utero Opioid
Transfer

Unadjusted
Odds Ratio
95% CI

Adjusted*
Odds Ratio
95% CI

2.81
1.87

(2.66, 2.96)
(1.77, 2.01)

2.39
1.78

(2.26, 2.53)
(1.67, 1.91)

2.64
2.45
2.06
1.79
1.40

(2.52, 2.76)
(2.34, 2.56)
(1.96, 2.15)
(1.71, 1.88)
(1.33, 1.47)

2.74
2.50
2.09
1.81
1.40

(2.61, 2.86)
(2.38, 2.61)
(1.99, 2.19)
(1.72, 1.90)
(1.33, 1.47)

0.94
1.15

(0.91, 0.98)
(1.12, 1.19)

0.95
1.21

(0.92, 0.99)
(1.17, 1.25)

0.98
0.97

(0.96, 1.002)
(0.95, 0.997)

0.98
0.99

(0.96, 1.01)
(0.96, 1.02)

0.90
0.93
0.91

(0.88, 0.92)
(0.93, 0.94)
(0.89, 0.93)

0.87
--0.85

(0.84, 0.90)
--(0.83, 0.87)

2.64

(2.50, 2.78)

2.17

(2.04, 2.30)

¶ A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49.
*Adjusted for physical location (Appalachian status and metropolitan status), sex at birth, birth year cohort, race,
continued substance use (sibling with a prenatal opioid exposure diagnosis), and poverty (sibling on Medicaid).
Referent group for opioid exposure is the comparator group; for birth year cohort, being born in 2019; for race, White;
for sex at birth, male; for Appalachian status, non-Appalachian; for metropolitan status, metropolitan; for sibling on
Medicaid, no sibling on Medicaid; for sibling with in utero opioid transfer, no evidence of in utero transfer. Gestational
age was treated as a continuous variable. All other variables were considered categorical.
**The c-statistic for the adjusted model is 0.621. The -2 log likelihood for the adjusted model is 160,514.09. The AIC
for the model is 160,544.09.
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Table 4.7 Post hoc sensitivity analyses of logistic regression models of the odds that a
child born on Kentucky Medicaid between 2014 and 2019 was enrolled in Medicaid
at a different address than their mother.
Strata
Opioid
Exposure Level
NAS Diagnosis
Opioid Exposure
Birth Year
2014
2015
2016
2017
2018
Race
Black
Other
Sex at Birth
Female
Appalachian
Metro Status
Non-Metro
Gestational Age
Sibling on
Medicaid
Sibling with in
Utero Opioid
Transfer
C-Statistic
-2 Log
Likelihood
AIC

Fully Adjusted*
Odds Ratio
95% CI

Backwards Selection**
Odds Ratio
95% CI

2.35
1.73

(2.22, 2.49)
(1.62, 1.85)

2.35
1.73

(2.22, 2.49)
(1.62, 1.85)

2.74
2.51
2.10
1.82
1.41

(2.62, 2.87)
(2.40, 2.63)
(2.00, 2.20)
(1.73, 1.91)
(1.34, 1.48)

2.74
2.51
2.10
1.82
1.41

(2.62, 2.87)
(2.40, 2.63)
(2.00, 2.20)
(1.73, 1.91)
(1.34, 1.48)

0.95
1.20

(0.91, 0.99)
(1.17, 1.24)

0.95
1.20

(0.91, 0.99)
(1.17, 1.24)

0.98
0.98

(0.96, 1.01)
(0.95, 1.02)

---

---

0.87
0.94
0.88

(0.84, 0.90)
(0.93, 0.95)
(0.85, 0.90)

0.86

(0.84, 0.88)

0.88

(0.85, 0.90)

2.18

(2.05, 2.32)

2.18

(2.05, 2.32)

0.625
165,444.44

0.625
159,857.21

159,886.39

159,885.21

*The fully adjusted model accounts for all the factors identified in the DAG in Figure 4.1, regardless of statistical
significance in the bivariable analyses.
**Backwards selection identified opioid exposure diagnosis level, birth year cohort, race, metropolitan status, sibling
on Medicaid, and sibling with in utero opioid transfer as the optimal model fit; Appalachian status and sex at birth were
eliminated. In other models, sex at birth was kept in the model due to standard epidemiology protocol of keeping sex in
the model. However, in this selection technique, the variable was removed, as statistical protocol would deem given the
lack of evidence in Table 4.4 and Table 4.6 of any association between sex at birth and a child enrolling at a different
household than their mother.
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Table 4.8 The c-statistics associated with each variable included in the logistic
regression models of the odds that a child born on Kentucky Medicaid between 2014
and 2019 was enrolled at a different address than their mother.
Variable
C-Statistic in the Bivariable Analyses
Opioid Exposure Level
0.53
Birth Year Cohort
0.59
Race
0.52
Sex at Birth
0.50
Appalachian Status
0.50
Metro Status
0.51
Gestational Age
0.52
Sibling on Medicaid
0.51
Sibling with in Utero Opioid Transfer
0.52
*An infant was determined to be enrolled in a different household than the mother by first identifying the mother listed
on the infant’s birth certificate and then identifying if the infant was ever enrolled in Medicaid at a different address
than the address listed in the mother’s enrollment data. A diagnosis of NAS was determined using ICD-9 code 779.5
and ICD-10 code P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72 and ICD-10
code P04.49. Siblings on Medicaid were determined by linking children of common mothers through data available
from the infant’s birth certificate; these figures represent identified siblings from 2014 forward. A sibling with in utero
opioid transfer was determined based on the identified siblings and then identifying if the sibling had one of the
prenatal opioid exposure diagnoses (ICD-9: 779.5 and 760.72; ICD-10: P96.1 and P04.49).
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Figure 4.1 Directed acyclic graph (DAG) hypothesizing the relationship between
prenatal opioid exposure and residing in a different household than the mother.
(Code in the Appendix)
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CHAPTER 5. PHYSICAL AND COGNITIVE DEVELOPMENT: GASTROINTESTINAL,
RESPIRATORY, AND MENTAL HEALTH CONDITIONS IN NEONATAL ABSTINENCE SYNDROME
5.1

Background
Identifying specific health outcomes in childhood for children with NAS has become

an area of urgent need. Though the rate of death in this population is elevated, the death
rate for NAS overall remains relatively low.55 Many of the children diagnosed with this
condition at birth, and part of this study, are now children living their lives in Kentucky,
involved in school systems and building relationships with others in their communities.
Each number in this dissertation corresponds to an actual, real child with actual, real
experiences utilizing healthcare services and real issues to overcome. It is important, then,
for healthcare practitioners and healthcare systems to be anticipating the needs of this
population.
The intent of this Chapter is to further specify some exact health outcomes that could
be associated with NAS in later childhood and determine whether associations exist in this
population, as well as provide some possible biologic mechanisms for the development of
such conditions. Two sides of health outcomes will be examined: physical health outcomes
and mental health outcomes.
5.2

Physical Development
NAS is a set of multisystem symptomologies, with known impacts to the central

nervous system (or the CNS, manifested in the emergence of symptoms such as seizures,
jerking, and pedaling in the infant), the gastrointestinal system (diarrhea being a common
symptom of NAS), and the respiratory system.4,18,104 CNS involvement is ubiquitous in
many conditions173 and the emergence of exact conditions indicating adverse CNS health
outcomes may take longer periods of time to develop than could be readily identified within
the first five years of life174. Conditions that could readily be identified within the first five
years of a child’s life, however, could be gastrointestinal conditions and respiratory
conditions.
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5.2.1

Gastrointestinal Conditions

In the usual timeline of fetal development, the gastrointestinal system is one of the
earliest organ systems to complete development.29,175 Exposure to opioids in adults is
known to create chronic gastrointestinal dysfunction, the most well-known of which is
chronic constipation following long-term opioid exposure.176 In adults, this constipation
must be treated with medication for a significant period even following abstinence from
the substance that created the condition.176 Because opioids are known to readily cross the
placenta11 and knowing that opioids create alterations with long chronicity in the
gastrointestinal function of adults176, it is plausible that opioid exposure during this critical
period of development could impact the development of the GI tract in the fetus, which
could manifest in gastrointestinal conditions in childhood.
5.2.2

Respiratory Conditions

One of the most discussed outcomes of adult opioid use is opioid overdose.177
Though opioid overdose involves many systems, one of the most dangerous aspects of the
overdose is respiratory depression.177 This depression arises from the area of the brain
targeted by opioids, with opioid receptors in the pons activated178, leading to the slowing
of breathing in the user; in the case of an overdose, this loss of breath can eventually lead
to a loss of life when intervention is not taken by bystanders and emergency responders.177
In fetal development, the respiratory system is one of the systems with the longest
periods of development.29,179,180 The respiratory system begins developing within weeks of
conception.29,179,180 In very early fetal development, the system has a gill-like manner of
obtaining oxygen; as gestation continues, the gills give way to the lung and airway system
that will become vital organs for life once the child is delivered into the world.29,179,180 At
delivery, the respiratory system is still developing, with the infant’s first cries indicative of
the healthy functioning of the system and the capability of the system in intaking oxygen.
NAS has been more commonly associated with use of substances in the second and
third trimesters of pregnancy.62 Because the respiratory system is still developing in this
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trimester29,179,180, the added insult from the substances of abuse could manifest alterations
in the function of the system in later childhood.
5.2.3

Methods

The study population was subset to the last observation available in a continuously
enrolled year in the population of children born in birth year cohorts 2016, 2017, 2018, and
2019. These children were specifically identified because of the ICD-10 code switch that
occurred in October 2015 to create a homogenous population for analysis under a common
code set. Children were stratified as in previous analyses based on in utero opioid exposure
status.
First, a data exploration occurred within categories of diagnoses identified within
the dataset to identify signals for potential analyses. Gastrointestinal conditions and
respiratory conditions were chosen for this analysis because of the relationship between
NAS and these two systems. Explanation of hypothesized mechanisms for these
relationships were discussed earlier in the chapter. The intent of this exploration was to
identify signals in a relatively unexplored domain of development for the children to merit
additional analyses. As such, the intent of this study was to simply identify whether an
association could possibly exist, not to quantify the magnitude of the association itself.
Diagnosis codes from the Healthcare Cost and Utilization Project (HCUP)’s
Clinical Classification Software Revised (CCSR)113 were used to identify gastrointestinal
conditions, which included disorders of the teeth and mouth, and respiratory conditions113,
which served as the primary outcomes of interest. The diagnosis codes identified by the
CCW consisted of 1,103 ICD-10 codes for gastrointestinal conditions and 441 ICD-10
codes for respiratory conditions. An additional dataset was also provided from OHDA
identifying the diagnosis code associated with the condition for each unique child and the
age at which the child was diagnosed.
Following obtaining the number of diagnoses for each category, a proportion was
calculated to identify signaling. The proportion was calculated as,

𝑥𝑥 =

𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑐𝑐ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖 𝑡𝑡ℎ𝑒𝑒 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑡𝑡ℎ𝑒𝑒 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
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Signaling was considered for analysis if the signal indicated a stepwise increase of
a considerable amount in the proportion (i.e., if the proportion among the NAS children
exceeded the proportion among the children with prenatal opioid exposure which exceeded
the proportion among the children in the comparator group). In addition to the stepwise
increase, the increase in the proportion also had to be considerably large, and the category
well-defined to merit further evaluation.
Following the determination of signaling, a dichotomous indicator variable for the
condition was created and merged back into the original dataset, which served as the
outcome of interest in the formal analysis. Frequency analyses were conducted to describe
the strata of children in the newly created study population, as well as to describe the strata
of the children with the signal compared to other children. Chi-square analyses were
conducted to ascertain statistically significant differences. A DAG was created using
DAGitty v3.0 to identify variables confounding the relationship between prenatal opioid
exposure and the signaling variable of interest. A logistic regression analysis was then
conducted to ascertain the odds of children with prenatal opioid exposure being diagnosed
with the signaling variable. All statistical analyses were conducted using SAS v9.4 (Cary,
NC). An α-threshold of 0.05 was utilized; p-values less than 0.05 were considered
statistically significant.
5.2.4

Results

After the exclusion criteria was applied, the population consisted of 127,403 unique
children available for analysis. Among these children, a total of 80,105 (62.84%) children
were diagnosed with any gastrointestinal condition identified by the CCSR diagnosis
codes113 and 104,698 children (82.13%) were diagnosed with any respiratory identified by
the CCSR diagnosis codes.113 Raw counts of unique diagnoses in the CCSR categories
determined by HCUP113 are shown in Table 5.1 and Table 5.3. Of note, in a deviation from
the standards for the algorithm, only one diagnosis was sufficient to be included in the
analysis, as the intent of the study was not to quantify the magnitude of an association, but
merely to determine the possibility for such an association to exist.
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Proportions for each of the categories of diagnoses were then calculated, as shown
in Table 5.2 and Table 5.4. Based on these analyses, the large proportion of children with
respiratory conditions is likely a result of the large percentage of acute bronchitis and other
specified upper respiratory infections, for which it seems that, among children who
received this diagnosis, received several different diagnoses within this category, as the
results for these proportions were greater than one.
Based on the results of the analysis, though several items in the gastrointestinal
conditions list could merit further investigation, no strong signal was detected. Among
respiratory conditions, however, two categories seemed to indicate that a signal could be
identified: asthma and respiratory failure, insufficiency, and/or arrest. Corr et al. identified
increased rates of respiratory diagnoses among the population of children with a history of
NAS42. Additionally, Conner et al. found a high percentage of children with NAS
prescribed antiasthmatic and bronchodilator agents in a finding in their analysis.79 Based
on these two findings, asthma was chosen as a potential signal to investigate for additional
associations in further analyses.
The demographics of the study population stratified by prenatal opioid exposure
status is shown in Table 5.5. The overall prevalence of NAS in this group was largely
reflective of the percentage from the overall population analyzed in Chapter 3. The
percentage of children with a diagnosis of prenatal opioid exposure were slightly higher.
One reason for this discrepancy could be the ICD-10 code switch that occurred in October
2015; the utilization of the prenatally exposed code rose in 2016, as shown in Chapter 3.
This may be due to a dichotomization of infants with NAS from the group prenatally
exposed following awareness of this code in the new codex. The remainder of the
demographics for this population were largely reflective of the demographics provided in
Chapter 3.
Demographics stratified by evidence of an asthma diagnosis shown in Table 5.6.
This population of children were more male than the population of children without a
diagnosis of asthma and more Appalachian than the population of children without a
diagnosis of asthma. Additionally, it seems the proportion of children who are Black and
have a diagnosis of asthma is greater than the proportion of children who are Black and do
not have a diagnosis of asthma.
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An exploratory logistic regression analysis was then undertaken to gain additional
evidence as to whether such an association exists. The DAG for the exploratory analysis is
shown in Figure 5.1. Code for the DAG is available in the Appendix (Appendix 8). Overall,
the DAG identified 6 covariates and one causal pathway in the relationship between
prenatal opioid exposure and asthma. According to the results from the DAG, the minimum
sufficient adjustment set to estimate the effect consists of gestational age, maternal
smoking, physical environment, race, and sex. Physical environment in this analysis will
be proxied by Appalachian status at birth and metropolitan status at birth, as was the case
in Chapter 4.
Univariable logistic regression analyses based on the findings of the DAG are
shown in Table 5.7. Overall, not accounting for other factors, the odds of a child with a
diagnosis of NAS being diagnosed with asthma were 1.77 times higher than children
without a diagnosis of either NAS or prenatal opioid exposure; among children with a
diagnosis of prenatal opioid exposure, these odds were 1.34 times higher. Odds were also
higher among children born in Appalachian county and children born in a non-metro
county of residence. Black children also saw increased odds compared to White children,
though being of a race that fell under the category of “Other”, as described in Chapter 3,
was protective against a diagnosis of asthma. Finally, one unit increases in gestational age
also were incrementally protective against a diagnosis of asthma.
Results from the adjusted logistic regression analysis are also shown in Table 5.7.
These results were largely consistent with the findings from the univariable analyses with
relatively few major shifts in the overall finding. Children with a diagnosis of NAS and
children with a diagnosis of prenatal opioid exposure both had greater odds of being
diagnosed with asthma compared to the comparator group, with adjusted odds ratios
(aORs) of 1.40 and 1.19 respectively with all other factors held constant. The largest shift
occurred among children who are Black in the analysis, increasing from 1.24 in the
unadjusted to 1.63 in the adjusted compared to children who are White, all other factors
held constant. This increase was not quite as pronounced among children whose race was
categorized as “Other.” This indicates that race is likely related to another factor in the
analysis, allowing the bias within the result from the univariable analyses to be removed,
causing a right-shift in the variable.
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5.3

Cognitive Development
In 2019, an analysis by Sherman et al. found elevated rates of mental health

conditions in children ages 1 to 5 in a national population of Medicaid-insured children
after being diagnosed with NAS.78 This analysis was extended by Conner et al. to a
commercially insured population with similar findings.79 These findings mimic earlier
work in this area that suggest that children with NAS face significant challenges in their
cognitive development in childhood.77,181 Less discussed, however, has been the fact that
many children in these population could have been diagnosed with mental health
conditions very early in childhood, such as at ages 1 and 2.78,79 Indeed, neither Sherman et
al. nor Conner et al. explored age at diagnosis or factors associated with these early
diagnoses of mental health conditions.78,79 Thus, the intent of this analysis is to expand the
findings of Sherman et al.78 and Conner et al.79 using the mental health conditions identified
by Sherman et al.78 diagnosed in the Kentucky Medicaid population to children to identify
the prevalence of these diagnoses at early ages and to identify factors associated with the
diagnosis of these conditions at early ages.
5.3.1

Methods

To replicate the tables produced by Sherman et al.78 and Conner et al.,79 the study
population was subset to include only children born in birth year cohorts 2014 and 2015.
These two birth year cohorts were chosen because there were the only two birth year
cohorts to be eligible to be diagnosed with the ICD-9 codes identified by Sherman et al.78
given the code switch that occurred in October 2015. This reduced the overall study
population from to 64,896 children. Diagnosis codes identified by Sherman et al.78 were
used to identify mental health conditions, which were then categorized based on the three
leading numbers of the diagnosis. An additional dataset was also provided from OHDA
identifying the diagnosis code associated with the mental health condition for the child and
the age at which the child was diagnosed.
To analyze factors associated with diagnoses of mental health conditions, the study
population was then subset again to only include the observations available in year 1 among
the continuously enrolled population of children born in birth year cohort 2014. This
additional exclusion criterion was applied to provide a minimum of one year for a child to
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have a sufficient period of enrollment to interact with the healthcare system and obtain one
of these diagnoses. As was noted previously, children born in 2014 were specifically
identified because of the ICD-10 code switch that occurred in October 2015 to create a
homogenous population for analysis under a common code set; the codes identified by
Sherman et al. consisted solely of ICD-9 codes, and thus children born in later birth year
cohorts were either ineligible to be diagnosed with one of the identified codes or may not
have had sufficient time to be diagnosed with one of the identified diagnosis codes.
Children were stratified as in previous analyses based on in utero opioid exposure status.
Frequency analyses were conducted to identify differences between the strata of
children. Chi-square analyses were conducted to ascertain statistically significant
differences between the strata for ordinal variables and ANOVA models were utilized to
assess statistically significant differences between the strata for continuous variables.
A DAG was created using DAGitty v3.0 to predetermine variables of interest based
on hypothesized relationships between prenatal opioid exposure and one of the diagnosed
mental health conditions. Logistic regression analyses were then conducted to obtain the
odds of a child with in utero opioid exposure being diagnosed with one of the identified
mental health conditions. Univariable logistic regression analyses were conducted for each
of the identified variables, as well as two adjusted models: a model containing all the
variables and proxy variables identified by the DAG and a model containing only the
minimum sufficient adjustment set identified by the DAG. In a post hoc analysis,
backwards selection was also run on the logistic regression model to create a more
parsimonious model for analysis, and the c-statistic was examined to compare this model
to the fully adjusted and DAG adjusted models. Additionally, post hoc frequency analyses
of variables of interest from the logistic regression analyses were conducted to further
describe a population and adjusted variable from the analysis. All statistical analyses were
conducted using SAS v9.4 (Cary, NC). An α-threshold of 0.05 was utilized; p-values less
than 0.05 were considered statistically significant.
5.3.2

Results

Table 5.8 replicates the table produced by both Sherman et al.78 and Conner et al.79
in their respective analyses for the population of children born in Kentucky Medicaid in
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2014 and 2015, with the added strata of children with a diagnosis of prenatal opioid
exposure extracted from the comparator group. Overall, per the Memorandum of
Understanding signed to be able to acquire the data, many of the cell values for this table
were less than 10, and thus suppressed; additionally, zeros were not presented in this table,
despite an impossibility of reidentifying a population in which nothing occurred, to
minimize the potential for reidentification in another strata. Overall, approximately 8.44%
of children with a diagnosis of NAS were diagnosed with any of the mental health
conditions identified by Sherman et al., compared to 5.07% of children with prenatal opioid
exposure and 3.29% of children from the comparator group. These percentages were
largely being driven by delays in development.
The study population was then further subset to include only those children born in
birth year cohort 2014 and continuously enrolled by HEDIS standards for the first year of
life. This reduced the study population further to a population of 29,067 children available
for analysis.
Demographics for the population identified are presented in Table 5.9, along with
the frequency of mental health conditions in the 2014 birth year cohort in these early years
of life. Consistent with the findings in both Sherman et al.78 and Conner et al.79, the
prevalence of mental health conditions in this population are nearly three times that of the
comparator group of children for both children diagnosed with NAS and children
diagnosed with in utero opioid exposure (approximately 11% and 10% compared to 4%).
This finding is also consistent with the supplement table with one year of continuous
enrollment provided by Conner et al. showing elevated rates of mental health conditions in
the population of children with only one year of continuous enrollment79, as opposed to the
five years of continuous required by Sherman et al. and by Conner et al. in the primary
analysis.78,79
A DAG was then utilized to identify factors and hypothesized relationships between
variables relevant to the association between prenatal opioid exposure and mental health
conditions. The resultant DAG is available in Figure 5.2 with justification for each of the
variables and the minimal sufficient adjustment set further explained in Table 5.10.
This result was further validated by the logistic regression analysis in Table 5.11.
In the unadjusted analysis, the odds of a child with a diagnosis of NAS being diagnosed
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with a mental health condition was 3.08 times higher compared to the comparator group,
while the odds of a child diagnosed with opioid exposure in pregnancy was 2.69 times
higher compared to the comparator group. After adjusting for race, sex, metropolitan status,
Appalachian status, foster care, different household, mother on Medicaid, sibling on
Medicaid, gestational age, sibling with NAS, and foster care, the odds fell considerably,
but remained elevated compared to the comparator group, at 1.46 and 1.39, respectively.
Eliminating siblings with NAS from the adjustment, as shown in the DAG adjusted model,
resulted in a further decline of the odds ratio to 1.42 and 1.36. Unadjusted and adjusted
odds ratios for all other variables are also shown in Table 5.11.
Interestingly, from the adjustment in the logistic regression analysis, holding all
other variables constant, foster care resulted in extremely high elevated odds ratios
compared to the children not in the foster care system in the first year of life. In Chapter 4,
we ascertained that children entering the foster care system most frequently have their first
contact with the foster care system in the first year of life. Unadjusted, the odds of a child
in foster care being diagnosed with a mental health condition were 14.41 times higher than
the odds of a child not engaged with the foster system; with the adjustments in the fully
adjusted and DAG adjusted models, these odds ratios fell to 9.79 and 9.72. This indicates
that a large burden of the conditions being diagnosed in this analysis were borne by the
children in the foster care system.
Model fit statistics were also assessed for the models to determine the final model
resulting from the analysis. The c-statistic for both the fully adjusted model and the DAG
adjusted models was 0.720. This represents a decent fit for a statistical model, as a cstatistic of 0.70 is generally thought to be adequate while a c-statistic of 0.8 is generally
considered to be strong.
An additional model in Table 5.12 was created post hoc using the backwards
selection process within the SAS software. Interestingly, this model had a c-statistic of
0.718, slightly less than the manually identified model. The results of this analysis are
available in Table 5.12 and are largely consistent with the findings in the other tables.
While this model is more parsimonious, the fully adjusted and DAG adjusted models are
likely accounting for some confounding that is not present in the backwards selected
model. Thus, given the negligible difference identified by equal c-statistics between the
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fully adjusted and DAG adjusted model, the final model for this analysis was determined
to be the DAG adjusted model.
The DAG adjusted model was chosen due to the exclusion of the sibling with NAS
variable in the model, which reversed in the fully adjusted model to become protective.
One reason for this reversal may be due to the inclusion of the variable indicating a sibling
on Medicaid and likely collinearity between these two variables. This created a final model
of
𝑦𝑦 = 6.52 + 0.13𝑥𝑥1 + 0.08𝑥𝑥2 − 0.18𝑥𝑥3 + 0.11𝑥𝑥4 − 0.11𝑥𝑥5 − 0.06𝑥𝑥6 + 0.21𝑥𝑥7
+ 1.14𝑥𝑥8 + 0.24𝑥𝑥9 + 0.03𝑥𝑥10 − 0.21𝑥𝑥11 − 0.22𝑥𝑥12

where

x1 is a dichotomous indicator variable indicating whether an observation had a
diagnosis of NAS,
x2 is a dichotomous indicator variable indicating whether an observation had a
diagnosis of prenatal opioid exposure,
x3 is a dichotomous indicator variable indicating whether an observation was
identified as Black on the enrollment form,
x4 is a dichotomous indicator variable indicating whether an observation had a race
identified as Other,
x5 is a dichotomous indicator variable indicating whether an observation was
identified as being female,
x6 is a dichotomous indicator variable indicating whether an observation was born
a resident of a non-metropolitan county,
x7 is a dichotomous indicator variable indicating whether an observation was born
a resident of an Appalachian county,
x8 is a dichotomous indicator variable indicating whether an observation was
involved with foster care in their first year of life,
x9 is a dichotomous indicator variable indicating whether an observation resided in
a different household than their mother,
x10 is a dichotomous indicator variable indicating whether an observation did not
have a mother on Medicaid,
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x11 is a dichotomous indicator variable indicating whether an observation did not
have a sibling on Medicaid,
and x12 is a variable corresponding with each additional week of added gestational
age for an observation.
In Chapter 4, model assumptions for a logistic regression analysis were identified
as requirements for the outcome variable be ordinal, observations be independent, lack
multicollinearity, the log odds be linear, and a large sample size is obtained for
analysis.144,145 For this analysis, the outcome variable was a dichotomous indicator
variable, thus fulfilling the requirement for ordinality. Additionally, we have no reason to
assume that the observations violate the independence assumption for logistic regression,
as each child within this analysis is a unique child situated within unique circumstances. A
sufficiently large sample size is also utilized within the analysis, with a population of
29,067 children supplying the figures for the analysis.
As in Chapter 4, there is potential that the multicollinearity assumption has been
violated, as many of the variables identified here seem to be significantly associated with
prenatal opioid exposure. This is due in part to the large sample size in the analysis and the
potential for the study to be overpowered. Nonetheless, the utilization of sensitivity
analyses and backwards selection helps protect against the potential for multicollinearity
to bias the result. As such, inference for the model is approximately equivalent for each of
the model selection methodologies assessed.
Regarding the requirement that log odds be linear, for the overall model, the log
odds do appear to provide a linear equation for analysis; within each variable, the only
variable for which a violation could be occurring is gestational age. However, based on the
results here, it seems that the log odds are linear, as the odds ratio estimate is the estimated
change based on a one unit change in gestational age. It is worth noting that the range for
the gestational age variable is a bounded number, meaning that the variable has defined
lower limits and defined upper limits. Therefore, while these log odds may be linear, not
all numerical values are available for analysis. A way to protect against this would be to
create a categorical variable for gestational age to utilize within the analysis rather than
utilizing the continuous variable, given this bounded criterion established in the
methodology in Chapter 3. However, as was noted in Chapter 4, use of a categorical
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variable removes a level of granularity from the analysis. During gestation, a week
represents a significant and rapid period of development for a fetus.29 Therefore, each week
becomes an important unit of measure for an infant, and thus provides the justification for
the utilization of the continuous variable within the scope of this analysis. However,
utilizing a categorical variable in this manner would further safeguard against violations of
this assumption.
Finally, following the model selection, and given the highly influential nature of
foster care in the analysis, the population of children within the study involved with foster
care in the first year of life were examined. These demographic features are available in
Table 5.13. The prevalence of NAS among the children born in 2014 and engaged with the
foster care system was approximately 29%. This is a rate seven times higher than the
prevalence of NAS in the entire study population. These children were also majority White,
majority male, and largely from metropolitan and non-Appalachian regions of the state.
Additionally, the prevalence of mental health conditions in this population was
approximately 36%. Among children with NAS engaged in foster care, approximately 42%
were diagnosed with one of the mental health diagnoses; among children in the comparator
group, this approximately 34% were diagnosed with a mental health condition from this
population of children.
5.4

Discussion and Policy Implications
After the exploration of the data related to gastrointestinal and respiratory conditions,

asthma appeared as a diagnosis meriting further exploration. The intent of this analysis was
not to establish an exact quantified impact of the effect of neonatal abstinence syndrome
on the development of asthma, but rather to describe whether such an association exists.
For the purposes of this dissertation, this analysis was purely exploratory and descriptive
rather than analytical in nature.
Nonetheless, it does seem that the association between diagnoses of childhood
asthma and prenatal opioid exposure merits additional investigation. In the general
pediatric population, the prevalence of asthma is estimated to be 7%.182 In our population,
the prevalence of asthma in the comparator group, based on one diagnosis of a code
identified as part of the asthma category in the CCSR system113, was approximately 15%;
89

in the group of children with prenatal opioid exposure, this prevalence was higher, at
around 21%, and among children with a diagnosis of NAS, this was closer to 25%.
Childhood asthma is frequently connected to many environmental triggers, from
unclean household allergens to parental smoking.183 Pediatric asthma has also been
associated with elevated costs to healthcare systems when compared to children without
such a diagnosis.184 For Medicaid, this presents a significant area meriting further
investigation into the costs associated with asthma in these populations of children. Policy
could also be implemented to curtail many of the lifestyle-oriented factors associated with
pediatric asthma, and renewed efforts targeting parental smoking may be needed in these
populations183, given the high rates of maternal smoking among children with history of
NAS and the high rates of asthma among children with a history of NAS.
Regarding cognitive development, in 2021, Velasco et al. delved into the impact of
prenatal opioid exposure on myelin generation and developmental brain physiology,
concluding that prenatal exposure has the potential to create late myelination that persists
within the prefrontal cortex for children through young adulthood.185 This reduced
myelination has been connected with developmental delays in children.186 If the hypotheses
supplied by both of these articles are valid, the findings of this chapter show novel
consistency in connecting and explaining the biological mechanism behind the elevated
rates of developmental delays among children with NAS identified within this chapter.
In Chapter 4, it was discovered that a large percentage of children with in utero opioid
exposure enter into the foster care system early in life. In this chapter, the results seem to
indicate that not only are these children entering the foster care system early in life, children
in foster care are also being diagnosed with mental health conditions earlier in life
compared to other children. Many of these conditions require pharmacological treatment
interventions to manage, such as stimulants to treat attention deficit hyperactivity disorder
(ADHD)187 and antipsychotics for the management of more severe mental health
conditions188. At a stage of critical brain and physical development for these children, the
children are potentially facing exposure to medications designed to alter neurochemical
function in the brain189, as well as medications that can alter physical health outcomes.190
Overutilization of medications for ADHD191 and the overdiagnosis of ADHD192 has
been a topic of discussion in the literature, with more emphasis placed on the impact such
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diagnoses have on males compared to females193. For all neurodivergent, the literature has
traditionally focused on identifying and managing the conditions in young boys, though
young girls also face challenges from such conditions.194
Identifying the child with such conditions early in life creates many challenges. For
one, many of the children in the foster care system have undergone serious trauma in their
lives.195 The externalizing symptoms used to identify the conditions within these
populations could be the result of the trauma experienced, not necessarily a chronic mental
health condition itself.155 Children at these young ages lack autonomy and the efficacy to
vocalize their needs, depending entirely on the caretaker to identify when such need
meeting.29 In the absence of that caretaker recognizing and aiding the child, the child then
adapts to survive the harsh environment in which they have been placed.29 The
externalizing realities of this adaptation are frequently either withdrawal from the
environment in which they have been placed (despondency) or lashing out (i.e., aggression,
hyperactivity, alluding authority).196 These characteristics are not as much indicative of a
“bad kid” as much as a child that has learned how to survive in their environment by
exhibiting these characteristics to gain the attention of the caretaker or avoid further harm
and/or hurt.196
Overwhelmingly, children regress in behavior when under duress29, a fact that also
makes the need for designated diagnostic tools that differentiate the characteristics and
behaviors of full-term infants from that of preterm infants197. Providers should ask
additional questions before applying a mental health diagnosis onto the children in
question, especially if the provider becomes aware of an extenuating circumstance in the
child’s life that could be impacting the environment in which a child develops.
A prime example of this, as illustrated by the data, are for children involved with the
foster care system. Foster care has been associated with many adverse cognitive and
physical health outcomes for children.115,154,198 This study, through the current chapters,
has highlighted the importance of considering the role foster care plays in the health
outcomes of children with a history of NAS; the results of the analyses largely suggest that
it may not be possible to separate the compounding effects of both in the overall
development of a child.
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The role of Medicaid in such instances should be to provide extra monitoring to
children who obtain such diagnoses early in life and carefully follow up with parents and
guardians of these children to ensure adequate treatment and safety for these children.
Under managed care infrastructure, Medicaid has the power to assess children more
vigilantly with these conditions and ensure more optimal development continues for the
child. Because of the long retention of children to the Kentucky Medicaid system,
Kentucky Medicaid has greater impetus to intervene in child development issues to subvert
additional, greater health issues for these children later in life.
Additionally, as previously noted, this chapter also highlights the need for increased
vigilance for the population of children involved with the foster care system. Because these
children remain on the Medicaid system, Medicaid has the capability to monitor and
surveille this population of children for potentially problematic patterns of healthcare
utilization or evidence of adverse health outcomes. By renewing their focus on these
children, Medicaid has the potential to prophylactically curtail added healthcare
expenditures later in life through early intervention. Physical and cognitive health
outcomes have the potential to become sources of high utilization of healthcare resources
and generate large healthcare expenditures among children. Additional investigation into
the healthcare utilization of children with prenatal opioid exposure will be explored in
greater detail in Chapter 6.
5.4.1

Limitations and Future Directions

Within this analysis, diagnoses were defined as the appearance of any diagnosis
code on a child’s record. This is not consistent with algorithms established for evaluating
conditions frequently diagnosed in outpatient settings, requiring the appearance of two
outpatient claims for a diagnosis or one inpatient claim. This represents a limitation to this
analysis for both the physical health and cognitive health sections of these analyses, as the
diagnoses indicated here may not be reflective of actual diagnosed conditions.
Nonetheless, these analyses were largely considered exploratory, and sought to
explore and describe associations rather than quantify an effect; the goals of such studies
were descriptive as opposed to analytic. The reason for this was to provide a foundational
layer for the literature to build upon. In the hierarchy of evidence, descriptive studies sit
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below analytic studies.199 To be able to progress to more formal analytic works, the nature
of such an association should already be established through descriptive literature.199 The
intent of this chapter was to provide descriptive evidence of associations that merit
additional analysis.
A future direction for all the studies in this chapter would be a more formalized
study that is not cross-sectional in nature, but rather longitudinal. Causal inference
methodologies could be utilized in an observational study design to aid in assessing
whether prenatal opioid exposure causes the development of asthma or the mental health
condition diagnoses listed here. Additionally, this study also highlights the need for
additional research on the impact of foster care on these diagnoses, as well as foster care
as it relates to NAS.
Finally, the results within this chapter represent a homogenous population under
common policy actions and within a common state. As such, results in these analyses may
not be generalizable to other populations.
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Table 5.1 Number of diagnoses in the categories of gastrointestinal conditions of
children born on Kentucky Medicaid between 2016 and 2019, stratified by opioid
exposure status.

Any gastrointestinal
diagnosis
Abdominal hernia
Anal and rectal conditions
Appendicitis and other
appendiceal conditions
Biliary tract disease
Diseases of the mouth
(excludes dental)
Diseases of teeth and
gingiva
Diverticulosis and
diverticulitis
Esophageal disorders
Gastritis and duodenitis
Gastroduodenal ulcer
Gastrointestinal and biliary
perforation
Gastrointestinal hemorrhage
Hemorrhoids
Hepatic failure
Intestinal infection
Intestinal obstruction and
ileus
Noninfectious
gastroenteritis
Noninfectious hepatitis
Other specified and
unspecified disorders of the
stomach and duodenum
Other specified and
unspecified gastrointestinal
disorders
Other specified and
unspecified liver disease
Pancreatic disorders
(excluding diabetes)
Peritonitis and intraabdominal abscess
Postprocedural and
postoperative digestive
system complication
Regional enteritis and
ulcerative colitis

NAS
Diagnosis
(n=5,472)
3,720

Exposure
Diagnosis
(n=4,829)
3,106

Comparator
Group
(n=117,182)
73,279

(N=127,483)
80,105

495
43
Supp.

503
55
Supp.

8,376
1,186
56

9,374
1,284
Supp.

25
1,726

22
1,497

289
33,244

336
36,467

1,127

835

19,571

21,533

Supp.

Supp.

Supp.

Supp.

1,474
52
Supp.
Supp.

1,062
51
Supp.
Supp.

26,220
1,130
29
99

28,756
1,233
Supp.
Supp.

103
Supp.
Supp.
782
94

97
14
11
602
88

2,504
288
68
16,281
1,213

2,704
Supp.
Supp.
17,665
1,395

710

463

13,173

14,346

Supp.

Supp.

Supp.

Supp.

1,459

1,360

32,350

35,169

26

43

347

416

Supp.

Supp.

105

Supp.

17

Supp.

318

Supp.

69

81

829

979

Supp.

Supp.

29

Supp.

80

56

94

989

Total

1,125

Table 5.2 Proportion of diagnoses in the categories of gastrointestinal conditions to
children born on Kentucky Medicaid between 2016 and 2019, stratified by opioid exposure
status, expressed as percentages.
Any gastrointestinal
diagnosis
Abdominal hernia
Anal and rectal conditions
Appendicitis and other
appendiceal conditions
Biliary tract disease
Diseases of the mouth
(excludes dental)
Diseases of teeth and
gingiva
Diverticulosis and
diverticulitis
Esophageal disorders
Gastritis and duodenitis
Gastroduodenal ulcer
Gastrointestinal and biliary
perforation
Gastrointestinal hemorrhage
Hemorrhoids
Hepatic failure
Intestinal infection
Intestinal obstruction and
ileus
Noninfectious
gastroenteritis
Noninfectious hepatitis
Other specified and
unspecified disorders of the
stomach and duodenum
Other specified and
unspecified gastrointestinal
disorders
Other specified and
unspecified liver disease
Pancreatic disorders
(excluding diabetes)
Peritonitis and intraabdominal abscess
Postprocedural and
postoperative digestive
system complication
Regional enteritis and
ulcerative colitis

NAS
Diagnosis
67.98%

Exposure
Diagnosis
64.32%

Comparator
Group
62.53%

62.84%

9.05%
0.79%
Supp.

10.42%
1.14%
Supp.

7.15%
1.01%
0.05%

7.35%
1.01%
Supp.

0.46%
31.54%

0.46%
31.00%

0.25%
28.37%

0.26%
28.61%

20.60%

17.29%

16.70%

16.89%

Supp.

Supp.

Supp.

Supp.

26.94%
0.95%
Supp.
Supp

21.99%
1.06%
Supp.
Supp.

22.38%
0.96%
0.02%
0.08%

22.56%
0.97%
Supp.
Supp.

1.88%
Supp.
Supp.
14.29%
1.72%

2.01%
0.29%
0.23%
12.47%
1.82%

2.14%
0.25%
0.06%
13.89%
1.04%

2.12%
Supp.
Supp.
13.86%
1.10%

12.98%

9.59%

11.24%

11.25%

Supp.

Supp.

Supp.

Total

Supp.

1.46%

1.16%

0.84%

0.88%

26.66%

28.16%

27.61%

27.59%

0.48%

0.89%

0.30%

0.33%

Supp.

Supp.

0.09%

Supp.

0.31%

Supp.

0.27%

Supp.

1.26%

1.68%

0.71%

0.77%

Supp.

Supp.

0.02%

Supp.
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Table 5.3 Number of diagnoses in the categories of respiratory conditions of children born
on Kentucky Medicaid between 2016 and 2019, stratified by opioid exposure status.

Any respiratory diagnosis
Acute and chronic tonsilitis
Acute bronchitis
Aspiration pneumonia
Asthma
Chronic obstructive pulmonary
disease and bronchiectasis
Influenza
Lung disease due to external
agents
Mediastinal disorders
Other specified or unspecified
lower respiratory diseases
Other specified or unspecified
upper respiratory diseases
Other specified upper respiratory
infections
Pleurisy, pleural effusion, and
pulmonary collapse
Pneumonia (except caused by
tuberculosis)
Pneumothorax
Postprocedural or postoperative
respiratory system complication
Respiratory failure;
insufficiency; arrest
Sinusitis

NAS
Diagnosis
(n=5,472)
4,708
458
4,548
17
1,352
117

Exposure
Diagnosis
(n=4,829)
4,056
417
3,247
14
1,006
81

Comparator
Group
(n=117,182)
95,934
9,526
70,943
206
18,132
1,143

(N=127,483)
104,698
10,401
78,738
237
20,490
1,341

1,706
15

1,487
12

37,288
205

40,481
232

Supp.
904

Supp.
824

35
15,572

Supp.
17,300

3,478

2,614

58,442

64,534

7,670

6,209

153,584

167,463

269

246

3,274

3,789

931

772

16,279

18,000

39
50

26
64

391
831

456
945

481

466

5,549

6,496

812

738

18,123

19,673
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Total

Table 5.4 Proportion of diagnoses in the categories of respiratory conditions to children
born on Kentucky Medicaid between 2016 and 2019, stratified by opioid exposure status,
expressed as percentages.
Any respiratory diagnosis
Acute and chronic tonsilitis
Acute bronchitis
Aspiration pneumonia
Asthma
Chronic obstructive pulmonary
disease and bronchiectasis
Influenza
Lung disease due to external
agents
Mediastinal disorders
Other specified or unspecified
lower respiratory diseases
Other specified or unspecified
upper respiratory diseases
Other specified upper respiratory
infections
Pleurisy, pleural effusion, and
pulmonary collapse
Pneumonia (except caused by
tuberculosis)
Pneumothorax
Postprocedural or postoperative
respiratory system complication
Respiratory failure;
insufficiency; arrest
Sinusitis

NAS
Diagnosis
86.04%
8.37%
83.11%
0.31%
24.71%
2.14%

Exposure
Diagnosis
83.99%
8.64%
67.24%
0.29%
20.83%
1.68%

Comparator
Group
81.87%
8.13%
60.54%
0.18%
15.47%
0.98%

82.13%
8.16%
61.76%
0.19%
16.07%
1.05%

31.18%
0.27%

30.79%
0.25%

31.82%
0.17%

31.75%
0.18%

Supp.
16.52%

Supp.
17.06%

0.03%
13.29%

Supp.
13.57%

63.56%

54.13%

49.87%

50.62%

140.17%

128.58%

131.06%

131.36%

4.92%

5.09%

2.79%

2.97%

17.01%

15.99%

13.89%

14.12%

0.71%
0.91%

0.54%
1.33%

0.33%
0.71%

0.36%
0.74%

8.79%

9.65%

4.74%

5.10%

14.84%

15.28%

15.47%

15.43%
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Total

Table 5.5 Population demographics for the study population consisting of birth year
cohorts 2016 through 2019 in the Kentucky Medicaid population, stratified by opioid
exposure status.
Characteristic
Sex at Birth
Male
Female
Race
White
Black
Other
Maternal
Smoking at
Birth
Yes
No
Unknown
Missing
Appalachian at
Beginning of
Year
Metropolitan
Status
Metro
Non-Metro
Gestational
Age, mean
(S.D.)
Asthma

NAS Diagnosis
(n = 5,472)

Exposure
Diagnosis
(n=4,829)

Comparator
Group
(n=117,182)

Total

(N=127,482)

2,943 (53.78%)
2,528 (46.20%)

2,470 (51.15%)
2,359 (48.85%)

59,979 (51.18%)
57,202 (48.81%)

65,392 (51.29%)
62,089 (48.70%)

4,162 (76.06%)
137 (2.50%)
1,173 (21.44%)

3,195 (66.16%)
570 (11.80%)
1,054 (22.03%)

75,980 (64.85%)
14,249 (12.15%)
26,953 (23.00%)

83,337 (65.37%)
14,956 (11.73%)
29,190 (22.90%)

3,856 (70.47%)
981 (17.93%)
77 (1.41%)
558 (10.20%)
3,065 (56.01%)

2,869 (59.41%)
1,570 (32.51%)
27 (0.56%)
363 (7.52%)
1,455 (30.13%)

27,904 (23.81%)
80,033 (68.30%)
925 (0.79%)
8,320 (7.10%)
34,472 (29.42%)

34,629 (27.16%)
82,584 (64.78%)
1,029 (0.81%)
9,241 (7.25%)
38,992 (30.59%)

P-Value
<0.0001
<0.0001

<0.0001

<0.0001
<0.0001

2,034 (37.13%)
3,438 (62.83%)
38.43 (1.75)

2,784 (57.65%)
2,045 (42.35%)
38.24 (2.16)

64,243 (54.82%)
52,948 (45.18%)
38.64 (1.73)

69,052 (54.17%)
58,431 (45.83%)
38.61 (1.75)

<0.0001

807 (14.75%)

568 (11.76%)

10,424 (8.90%)

11,799 (9.26%)

<0.0001
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Table 5.6 Demographics of the population of children born on Kentucky Medicaid
between 2016 and 2019, stratified by asthma diagnosis.
Characteristic

Race
White
Black
Other
Sex at Birth
Male
Female
Appalachian at
Birth
Metropolitan Status
at Birth
Metro
Non-Metro
Gestational Age,
mean (S.D.)**
Maternal Smoking
Yes
No
Unknown

Asthma Diagnosis

Total Population

n=11,799

No Asthma
Diagnosis
n=115,684

7,879 (66.78%)
1,711 (14.50%)
2,209 (18.72%)

75,458 (65.73%)
13,245 (11.45%)
26,981 (23.32%)

83,337 (65.37%)
14,956 (11.73%)
29,190 (22.90%)

7,184 (60.89%)
4,615 (39.11%)
4,782 (40.53%)

58,208 (50.32%)
57,474 (49.68%)
34,210 (29.57%)

65,392 (51.29%)
62,089 (48.70%)
38,992 (30.59%)

N=127,483

P-Value
<0.0001

<0.0001
<0.0001
<0.0001

5,576 (47.26%)
6,223 (52.74%)
38.31 (2.20)
3,953 (33.50%)
6,980 (59.16%)
88 (0.75%)

63,476 (54.87%)
52,206 (45.13%)
38.65 (1.70)
30,676 (26.52%)
75,604 (65.35%)
941 (0.81%)
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69,052 (54.17%)
58,431 (45.83%)
38.61 (1.74)
34,629 (27.16%)
82,584 (64.78%)
1,029 (0.81%)

<0.0001
<0.0001

Table 5.7 Logistic regression analysis of the odds that a child born on Kentucky
Medicaid between 2016 and 2019 with prenatal exposure to opioids received an asthma
diagnosis.
Strata
Opioid
Exposure Level
NAS Diagnosis
Opioid Exposure
Race
Black
Other
Sex at Birth
Female
Appalachian
Metro Status
Non-Metro
Gestational Age
Maternal
Smoking
Yes
Unknown

Unadjusted
Odds Ratio
95% CI

Adjusted*
Odds Ratio
95% CI

1.77
1.34

(1,64, 1.91)
(1.25, 1.49)

1.40
1.19

(1.29, 1.53)
(1.08, 1.31)

1.24
0.78

(1.17, 1.31)
(0.75, 0.82)

1.63
0.88

(1.53, 1.73)
(0.84, 0.93)

0.65
1.62

(0.63, 0.65)
(1.56, 1.69)

0.65
1.58

(0.62, 0.68)
(1.50, 1.67)

1.36
0.91

(1.31, 1.41)
(0.90, 0.92)

1.06
0.91

(1.00, 1.12)
(0.91, 0.92)

1.40
1.01

(1.34, 1.46)
(0.81, 1.26)

1.30
1.01

(1.24, 1.36)
(0.83, 1.26)

*Adjusted for race, sex, Appalachian status, metropolitan status, gestational age,
and maternal smoking status.
**The reference group for prenatal opioid exposure was the comparator group; for
race, White; for sex at birth, male; for Appalachian status, non-Appalachian; for
metropolitan status, metropolitan; for maternal smoking, no maternal smoking.
Gestational age was analyzed as a continuous variable within the regression.
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Table 5.8 Mental health conditions identified by Sherman et al. and Conner et al. in
their respective articles in Psychiatric Services, applied to the population of children
born on Kentucky Medicaid in 2014 and 2015.*
Diagnosis
NAS
Prenatal
Comparator
Total
(ICD-9 Code)
Diagnosis
Exposure
Group
Population
Diagnosis
n=2,760
n=1,025
n=61,111
N=64,896
Any mental
233 (8.44%)
52 (5.07%)
2,010 (3.29%) 2,295 (3.54%)
health condition
Psychoses with
origin specific to
childhood (299)
Neurotic
disorders (300)
Special
symptoms of
syndromes (307)
Acute reaction
to stress (308)
Adjustment
reaction (309)
Disturbance of
conduct (312)
Disturbance of
emotion specific
to childhood and
adolescence
(313)
Hyperkinetic
syndrome of
childhood (314)
Specific delays
in development
(315)
Intellectual
disabilities (317318)

Supp.

Supp.

Supp.

Supp.

Supp.

Supp.

80 (0.13%)

Supp.

16 (0.58%)

Supp.

253 (0.41%)

275 (0.42%)

Supp.

Supp.

11 (0.02%)

Supp.

Supp.

Supp.

12 (0.02%)

Supp.

58 (2.10%)

Supp.

190 (0.31%)

Supp.

Supp.

Supp.

12 (0.02%)

Supp.

Supp.

Supp.

14 (0.02%)

Supp.

186 (6.74%)

43 (4.20%)

1,536 (2.51%)

1,765 (2.72%)

Supp.

Supp.

Supp.

Supp.

*Cell counts less than 10 were suppressed per the Memorandum of Understanding to
minimize the potential for the reidentification of data. Cell counts of zero were also
suppressed to minimize potential for reidentification of data.
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Table 5.9 Population demographics for the study population consisting of birth year cohort
2014 in the Kentucky Medicaid population, continuously enrolled for the first year of life,
stratified by opioid exposure status.
Characteristic
Race
White
Black
Other
Sex at Birth
Male
Female
Appalachian at
Beginning of
Year
Metropolitan
Status
Metropolitan
Non-Metro
Foster Care
Different
Household
Mother on
Medicaid
Sibling on
Medicaid
Gestational
Age
Sibling with
NAS
Mental Health
Conditions

NAS Diagnosis
(n = 1,227)

Exposure
Diagnosis
(n=366)

Comparator
Group
(n = 27,474)

Total

(N = 29,067)

971 (79.14%)
45 (3.67%)
211 (17.20%)

256 (69.95%)
29 (7.92%)
81 (22.13%)

18,954 (68.99%)
3,248 (11.82%)
5,272 (19.19%)

20,181 (69.43%)
3,322 (11.43%)
5,564 (19.14%)

646 (52.65%)
581 (47.35%)
647 (52.73%)

199 (54.37%)
167 (45.63%)
127 (34.70%)

14,150 (51.50%)
13,324 (48.50%)
8,566 (31.18%)

14,995 (51.59%)
14,072 (48.41%)
9,340 (32.13%)

P-Value
<0.0001

0.41
<0.0001
<0.0001

506 (41.24%)
721 (58.76%)
170 (13.85%)
683 (55.66%)

220 (60.11%)
146 (39.89%)
30 (8.20%)
211 (57.65%)

14,583 (53.08%)
12,891 (46.92%)
386 (1.40%)
8,360 (30.43%)

15,309 (52.67%)
13,758 (47.33%)
586 (2.02%)
9,254 (31.84%)

<0.0001
<0.0001

1,174 (95.68%)

348 (95.08%)

26,213 (95.41%)

27,735 (95.42%)

0.86

568 (46.29%)

164 (44.81%)

12,732 (46.34%)

13,464 (46.32%)

0.84

38.27 (1.78)

37.48 (2.76)

38.58 (1.75)

38.56 (1.77)

<0.0001

335 (27.30%)

95 (25.96%)

864 (3.14%)

1,294 (4.45%)

<0.0001

140 (11.41%)

37 (10.11%)

1,104 (4.02%)

1,281 (4.41%)

<0.0001
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Table 5.10 Factors identified by the DAG, proxy variables available within the data,
justification, and models the variables were included in for the linear mixed model
of the association between prenatal opioid exposure and mental health condition
diagnoses at an early age.
Item in the DAG

Proxy
Variable(s)

Justification

Full Adjusted
Model

Sociodemographic
factors

Appalachian
status;
metropolitan
status; race;
sex
Foster care;
different
household
than the
mother

Sociodemographic factors, such
as location, sex, and race, often
are vital social determinants of
health that impact many health
outcomes.200
Children’s cognitive
development depends upon the
home environment in which
they are raised.201 Instability in
the household can lead to
adverse cognitive
development.202
Families provide some of the
earliest relationships to children
and are thus vital components
of their cognitive
development.29,131,132
Gestational age can be
indicative of developmental
delays as babies born preterm
emerge before full development
in utero is completed.203
Adverse childhood events have
known associations with
cognitive development in
children.204

X

DAG*
Adjusted
Model
X

X

X

X

X

X

X

Home
environment

Family structure

Mother on
Medicaid;
sibling on
Medicaid

Gestational age

Gestational
age

Adverse
childhood events
(ACEs)

Sibling with
NAS; foster
care

*Code for the DAG described above can be found in the Appendix.
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Table 5.11 Logistic regression analysis for the association between mental health condition
diagnoses at an early age and in utero opioid exposure among children born on Kentucky
Medicaid in 2014 with continuous enrollment for the first year of life.

Opioid Exposure
Level
NAS Diagnosis
Opioid Exposure
Race
Black
Other
Sex
Female
Metropolitan
Status
Non-Metro
Appalachian
Foster Care
Different
Household than
the Mother
No Mother on
Medicaid
No Sibling on
Medicaid
Gestational Age
No Sibling with
NAS

Unadjusted
Odds
95% CI
Ratio

Fully Adjusted*
Odds
95% CI
Ratio

DAG Adjusted**
Odds Ratio
95% CI

3.08
2.69

(2.55, 3.71)
(1.90, 3.79)

1.46
1.39

(1.16, 1.84)
(0.94, 2.06)

1.42
1.34

(1.13, 1.77)
(0.91, 1.97)

0.67
1.15
0.81

(0.54, 0.82)
(0.998, 1.31)
(0.72, 0.90)

0.77
1.04
0.81

(0.62, 0.97)
(0.89, 1.21)
(0.72, 0.92)

0.78
1.04
0.81

(0.62, 0.97)
(0.89, 1.21)
(0.72, 0.91)

1.13

(1.01, 1.26)

0.89

(0.76, 1.05)

0.89

(0.76, 1.05)

1.40
14.41
2.25

(1.25, 1.57)
(12.05, 17.25)
(2.01, 2.52)

1.53
9.79
1.63

(1.30, 1.80)
(7.91, 12.11)
(1.43, 1.86)

1.52
9.72
1.62

(1.30, 1.79)
(7.85, 12.02)
(1.42, 1.84)

1.27

(0.999, 1.62)

1.06

(0.56, 2.00)

1.06

(0.56, 2.00)

0.69

(0.61, 0.77)

0.64

(0.57, 0.73)

0.65

(0.58, 0.74)

0.80
1.93

(0.79, 0.82)
(1.56, 2.38)

0.80
0.87

(0.79, 0.82)
(0.79, 0.82)

0.80
--

(0.77, 0.82)
--

*Adjusted for race, sex, metropolitan status, Appalachian status, foster care, different
household, mother on Medicaid, sibling on Medicaid, gestational age, sibling with NAS,
and foster care. Model c-statistic=0.72.
**Adjusted for race, sex, metropolitan status, Appalachian status, foster care, different
household, mother on Medicaid, sibling on Medicaid, and gestational age. Model cstatistic=0.72.
***Reference for opioid exposure level was the Comparator group; race was White; for
sex, male, metropolitan status, metropolitan county at birth; Appalachian status, nonAppalachian county at birth; foster care, no foster care; different household, same
household; mother on Medicaid, having a mother on Medicaid; sibling on Medicaid,
having a sibling on Medicaid; and sibling with NAS, no sibling with NAS.
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Table 5.12 Backwards selected logistic regression model of the predictors of mental
health conditions among children born on Kentucky Medicaid in 2014 with
continuous enrollment for the first year of life.
Odds Ratio
95% Confidence Interval
Prenatal Opioid
Exposure Level
1.42
(1.14, 1.78)
NAS
Prenatal Exposure
1.36
(0.92, 1.99)
0.81
(0.72, 0.91)
Female Sex at Birth
1.46
(1.29, 1.65)
Appalachian at Birth
9.80
(7.93, 12.11)
Foster Care
1.64
(1.44, 1.86)
Different Household than
the Mother
0.66
(0.58, 0.74)
No Sibling on Medicaid
0.80
(0.79, 0.82)
Gestational Age

*Reference for opioid exposure level was the Comparator group; for sex, male;
Appalachian status, non-Appalachian county at birth; foster care, no foster care; different
household, same household; sibling on Medicaid, having a sibling on Medicaid.
**Model c-statistic=0.72
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Table 5.13 Demographics of children involved with the foster care system among the
children born on Kentucky Medicaid in 2014 with continuous enrollment.
Characteristic
Count (Percentage)
Prenatal Opioid Exposure Level
NAS
170 (29.01%)
Prenatal Opioid Exposure
30 (5.12%)
Comparator Group
386 (65.87%)
Sex at Birth
Male
314 (53.58%)
Female
272 (46.42%)
Race
White
340 (58.02%)
Black
49 (8.36%)
Other
197 (33.62%)
Metropolitan Status
Metropolitan
342 (58.36%)
Non-Metro
244 (41.64%)
Appalachian
160 (27.30%)
Mental Health Condition
211 (36.01%)
Mental Health and Prenatal Exposure
NAS
72 (42.35% of 170 children)
Exposure
Supp.
Comparator
132 (34.20% of 386 children)
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Figure 5.1 Directed acyclic graph (DAG) hypothesizing the relationship between
prenatal opioid exposure and an asthma diagnosis. (Code in the Appendix.)
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Figure 5.2 Directed acyclic graph (DAG) hypothesizing the relationship between
prenatal opioid exposure and cognitive development. (Code in the Appendix.)
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CHAPTER 6. STRUCTURAL IMPACT: HEALTHCARE UTILIZATION AND EXPENDITURES IN
NEONATAL ABSTINENCE SYNDROME
6.1

Background
Children traditionally have low healthcare utilization205, as children tend to be

healthier individuals than most adults. Overall, children have increased physical activity
compared to adults and tend to consume healthier diets. As such, healthy children tend to
be relatively low-risk individuals for companies to insure. The current well-child visit
schedules recommended by the American Academy of Pediatrics, between ages 1 and 5,
that a child see a pediatrician for a checkup within the 3 to 5 days of birth, at 1 month, 2
month, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 2 years, 2 ½
years, 3 years, 4 years, and 5 years.206 These well child visits are typically low complexity
outpatient office visits with relatively low costs to the healthcare system.
Increased utilization of healthcare in this population typically implies increased
adverse health outcomes207, as children do not necessarily obtain care when it is not needed.
The healthcare utilization of the child is linked to the caregiver’s capability and capacity
to identify and fulfill the need for healthcare services to be obtained.208 This role of a parent
then becomes a filter; less serious healthcare issues may not necessarily warrant an office
visit. When a child obtains and utilizes healthcare, it is safe to assume the utilization of the
services was necessary for the child. As such, the investigation of healthcare utilization of
NAS children then becomes an important proxy to understanding the difference in health
outcomes associated with NAS compared to children born without the condition.
Medicaid has become an important stakeholder as rates of NAS rise. Anticipating
the economic impact the system will face assists in preparing state Medicaid agencies for
the healthcare these children will need as they grow older. Two seminal studies, one by
Taylor et al.60 and one by Corr et al.42, have previously been conducted in this area, with
Medicaid as the targeted population. Taylor et al. examined expenditures through the
second year of life, finding significant differences.60 Corr et al. examined an eleven year
cohort, finding that differences persist through the first few years of life, but those
differences begin deteriorating around age 4 for all health services.42
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Uncovering differences in healthcare utilization in these early periods of a child’s
life could provide impetus for Medicaid systems to provide additional oversight and
investment in the needs of these children to reduce overall burden and improve the
efficiency of the services used by the children. Healthcare utilization here will be analyzed
as the number of services obtained, the cost of the services obtained, the number and cost
of inpatient visits, the number of pharmacy prescriptions, and the number of unique
pharmacy prescriptions. The intent of this chapter is to analyze whether differences exist
and provide a model of total healthcare expenditures as they relate to the Medicaid system
to assess whether costs associated with prenatal opioid exposure decrease over time.
6.2

Methods
The entire study population identified in Chapter Three was utilized in the analysis.

The entire study population was used in this instance due to the nature of the outcomes
analyzed. The outcomes assessed within the chapter were composite annual summations
of various types of healthcare expenditures available within the Kentucky Medicaid
administrative claims database and were longitudinal in nature, permitting the investigation
of changes over time for this group of children. From this overall population of children,
the population was subset to include only children with one or more claim within a given
year of life as well as expenditures totaling at least $1 for a year of life. Observations with
missing information for any of the variables were removed from the analysis in the
modeling step.
Additionally, children were included in the analysis for each year of life these criteria
were met; if a child obtained no healthcare utilization in one year, but did in the following
year, the child was included in the following year, but their information was excluded for
the year in which they had no healthcare expenditures. The intent of this was to identify
the total impact of NAS to the Medicaid system, not necessarily quantify the degree to
which NAS alters the mean expenditures for a child; to mimic a more realistic environment
for the Medicaid system, children could pop in and out of the system and healthcare
utilization and contribute only a small percentage of utilization and observations, yet still
compound annual costs that are relevant to the Medicaid system. To subset the population
to only consist of the children who were consistently utilizing services changes the overall
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interpretation of the information being modeled. As the intent was to approach the analysis
from the perspective of the Medicaid system and not necessarily the child, the entire study
population was utilized.
6.2.1

Statistical Analyses

Frequency analyses were conducted to identify differences among the strata, with
chi square analyses being utilized to identify statistically significant differences among the
strata for categorical variables. ANOVA analyses were run to ascertain differences
between the strata for the continuous variables within this study.
A linear mixed effects model was utilized to assess total expenditures based on
prenatal opioid exposure level and year of life. A DAG was utilized to identify potential
main effects for the model. The DAG was created using DAGitty v3.0. Main effects for
each of these variables, as well as time, were utilized in the analysis; an interaction term
accounting for the influence of time on prenatal opioid status was also included in the
analysis as the intent of the model was to assess changes in NAS expenditures over time.
The working mean structure was chosen based on the AIC selection criteria after
the application of the covariance structure to a saturated means model based on the items
identified by the DAG. Covariance parameters were estimated using restricted maximum
likelihood (or REML) estimators. REML was utilized because REML tends to produce less
biased estimates of the variance compared to maximum likelihood (ML) estimators.
Model-based standard errors were utilized in this analysis. The overall population had
many observations, which could result in inconsistencies in the empirical standard error
estimates. Also, because of the large number of subjects and multiple observations from
most subjects (minimum 1, maximum 6), no small-sample corrections were utilized in this
analysis.
Two-sided F-tests were utilized ascertain statistical significance for all variables in
the analysis; statistical inference was drawn from the parameter estimates given by the
model. A significance level of 0.05 was utilized in the analysis; a p-value less than 0.05
indicated a statistically significant result. All analyses were conducted using SAS v9.4.
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6.3

Results
6.3.1

Children with No Healthcare Utilization within a Given Year

With the establishment of the study population with the exclusion criteria of one
claim and at least $1 of healthcare expenditures during the study period, a population of
children that did not utilize any healthcare services within a given year of life were
discovered. These children contributed 36,786 observations to the study period. The
frequency of children with no healthcare expenditures, stratified by year of life and birth
year cohort, are shown in Table 6.1. Among these children, it did seem that most children
did obtain healthcare services while enrolled in Medicaid within the first year of life, with
only around 200 children in each birth year cohort not utilizing any services or acquiring
any expenditures. An exception to this is in birth year cohort 2014, in which over 400
children, approximately double the other years, met this criterion. From there, at each age
and among each birth year cohort, the children seemed rather evenly dispersed, not
suggesting any birth cohort and age effects contributing to this phenomenon.
Demographic details of these children were explored in Table 6.2. Though these
children contributed over 36,700 observations to the study, meaning they were enrolled at
Medicaid at some point in the year but did not utilize any services, the unique population
of children was only composed of 27,029. This suggests that there is a group of children in
this analysis enrolled in Medicaid in multiple successive years that are not receiving any
healthcare services. The demographics of this population were also largely reflective of the
larger population identified in Chapter 3, with one notable exception: this group of children
was considerably less Appalachian than the overall population. This is an interesting
finding from the data: despite access to care being a known issue in Appalachia162, the data
suggests that children in Appalachia are largely receiving healthcare services.
6.3.2

Children with Healthcare Utilization

Table 6.3 presents a table providing the number of observations contributed by each
age and each birth year cohort among the entire population of children, once the exclusion
criteria was applied to the data. In total, the number of observations contributed by the
study population reduced to 583,845 qualifying observations. While there are reductions
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in the total number of observations for each birth cohort over time, the drop-out rate is
rather constant for each of the birth year cohorts, providing a steady stream of data to
analyze among all the children. Demographics for the study population are also presented
in Table 6.4. As expected, because few children and few observations were eliminated for
this analysis, the population is largely reflective of the overall population identified in
Chapter 3.
Measures of central tendency as they relate to several determinations of healthcare
utilization are shown in Table 6.5 for healthcare services and Table 6.6 for pharmacyrelated claims. In Table 6.5, significant differences were found for overall healthcare
expenditures, overall number of claims, and overall inpatient expenditures. Outpatient
expenditures, however, did not obtain statistical significance, and thus do not provide
evidence of differences in outpatient costs.
Table 6.7 presents a repeated measures ANOVA of the difference in total healthcare
expenditures among each age group. Consistent with the findings of Taylor et al.60 and
Corr et al.42, these expenditures were significantly different through the third year of life.
After age four, however, these costs ceased being statistically different.42
These findings identify several areas for improvement for other models of healthcare
expenditures as they relate to children with prenatal opioid exposure. First, there does seem
to be a lessening of statistically significant differences over time, as was suggested by Corr
et al.42 This suggests that there may be cause to examine for the importance of an
interaction between prenatal opioid exposure level and year of life in models of total
healthcare expenditures over time. Secondly, it is reasonable to assume that a year’s
healthcare expenditures are related to a previous year’s healthcare expenditures, thus
presenting a need to account for within-subject variability in a created statistical model.
6.3.3

Modeling Total Annual Healthcare Expenditures

A linear mixed model was proposed to accommodate all the improvements noted
above. A linear mixed model was targeted as the outcome of interest, healthcare
expenditures, is a continuous, real number outcome, meaning that the number can be any
number that is part of the real numbers. Linear mixed models require this type of number
as a dependent variable. It is worth noting that a lower bound of one was applied to the
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dependent outcome of interest, thus preventing the data from dipping below one. However,
the range of the data and the size of the population is sufficient to the degree that this should
not matter or alter findings of the model.
First, a DAG was utilized to establish a saturated means model for analysis. The
DAG for the study is shown in Figure 6.1, with additional explanation for the inclusion of
each of the variables available in Table 6.8. The variables and proxy variables identified
will be utilized in the determination of the covariance matrix with a saturated means model,
meaning a model that is potentially overfit, as well as a more parsimonious model, which,
here, will be identified as a model adjusted for the variables considered to be the minimal
sufficient adjustment set through the utilization of the DAG.
Next, a linear mixed model assumes that the dependent variable is normally
distributed. Figure 6.2 shows an untransformed distribution of total healthcare
expenditures, which shows an extreme left skew in the data. To correct this, a natural log
transformation was attempted, as shown in Figure 6.3, with goodness of fit statistics
assessing the model fit to a normal distribution shown in Table 6.9. Visually, assessing
Figure 6.3, the natural log transformation seemed to benefit the distribution immensely,
though the fit does vary from a normal distribution in several locations as data clustered
around a certain area. The model fit statistics in Table 6.9 also indicated that the model
does likely deviate from a normal distribution.
To attempt to correct this, two additional transformations were attempted, with a
second and third natural log applied to the variable, producing transformations of
𝑙𝑙𝑙𝑙(𝑙𝑙𝑙𝑙(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) and 𝑙𝑙𝑙𝑙(𝑙𝑙𝑙𝑙(𝑙𝑙𝑙𝑙(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒))) to be assessed. The

model fit statistics for these models continued producing results consistent with the
distribution being significantly different than a normal distribution. Visually, as shown in
Figures 6.4 and 6.5, the distributions began to skew to the right with additional applications
of the log transformation. Thus, the transformation of 𝑙𝑙𝑙𝑙(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) was
applied to the dependent variable in the final model.

The saturated means model was first used to determine a working covariance

structure. The design in this study was unbalanced, meaning that all subjects did not
contribute equal numbers of time points, which means that many covariance structures
were invalid out-of-hand and were thus not included in the analysis. Covariance structures
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that work with unbalanced designs include compound symmetry and exponential power
decay covariance structures. Usually, whenever possible, an unstructured covariance
matrix should be utilized, as this covariance matrix does not force the data to follow any
specific pattern as far as the within-subject variability. However, unstructured matrices
generally only work with balanced designs; because the study design here is unbalanced,
an unstructured covariance matrix was not considered for analysis.
The results of the tests to determine the working covariance matrix are shown in
Table 6.10. The AIC was utilized in this analysis to select a model. Of note, when a
compound symmetry covariance structure with heterogenous variance was attempted, SAS
returned that the model had infinite likelihood and would not complete the analysis. This
is likely due to many subjects with only one observation contributing to the analysis;
because SAS could not locate additional observations, SAS could not determine the
variance between the observations, as a variance inherently assumes more than one
repeated measure for each subject. To fix this, the population would need to be filtered
down to those observations for which a minimum of two observations contributed to the
analysis. Nonetheless, the results in Table 6.10 indicated than an exponential power decay
model may be the best fit for the data. Inherently, this may be sensible; an exponential
power decay model assumes that the variability decreases over time, as is shown by the
decreasing ranges in Table 6.7, though the rate at which these variances decrease in an
exponential power decay structure may be faster than what is realistically possible.
However, because this covariance structure was inherently more sensible than a compound
symmetry covariance structure, this was the working covariance structure selected to be
included in the remaining analyses.
The saturated means model used to determine the covariance structure is provided in
Table 6.11, with the parsimonious model presented in Table 6.12. A post hoc additional
adjusted model is also provided in Table 6.13, where the model only kept in the statistically
significant variables. All three of these models point to the same conclusion, though the
quantification of the amount varies between the models due to the additions and
subtractions from the model adjustment: total expenditures for the population of children
with NAS and children with prenatal opioid exposure are higher than the comparator group.
Annually, expenditures for all children decrease as the children grow older. However, when
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considering the interaction between the opioid exposure variable and the age variable, the
rate at which total expenditures for the population of children with NAS and with prenatal
opioid exposure decrease over time is faster than that of the comparator group. This
suggests that, as time continues and if the trend continues, expenditures for children with
some level of prenatal opioid exposure will eventually reach an inflection point and equal
out to the expenditures accrued by the comparator group.
Additionally, within the adjustment, foster care children also have a higher rate of
healthcare utilization than children not in foster care. Conversely, children that are enrolled
as female have lower expenditures than children that are enrolled as male. Increasing
gestational age also appears to decrease total expenditures. Conversely, while residing in a
rural area does decrease total expenditures, residing in Appalachia increases expenditures.
One interesting finding is prenatal care; it appears that increased amounts of prenatal
care also increase the total expenditures for a child; however, this may be because mothers
that obtain prenatal care are also more likely to use other healthcare services for her
children, such as well-child visits. It is also worth noting that the amount by which prenatal
care increases total expenditures is negligible and does not provide an argument against
advocating for prenatal care for mothers and babies.
Model fit statistics via the AIC are shown in Table 6.14 for all three of these models.
AIC was chosen as the model fit comparison because BIC values tend to favor simpler
models and AICC values are best utilized in small samples.143 When using AIC values to
select models, the smallest value represents the best fit.143 Here, the smallest AIC value
actually belonged to the largest model, the saturated means model, thus producing a final
model from this analysis of
𝑙𝑙𝑙𝑙(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒)

= 8.84 + 0.99𝑥𝑥1 + 0.84𝑥𝑥2 − 0.32𝑥𝑥3 − 0.24𝑥𝑥1 𝑥𝑥3 − 0.27𝑥𝑥2 𝑥𝑥3 + 0.7𝑥𝑥4

where

− 0.3𝑥𝑥5 + 0.02𝑥𝑥6 + 0.0002𝑥𝑥7 − 0.05𝑥𝑥8 + 0.1𝑥𝑥9 + 0.05𝑥𝑥10 + 0.3𝑥𝑥11
+ 0.03𝑥𝑥12 − 0.04𝑥𝑥13 + 0.0005𝑥𝑥14

x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS,
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal
opioid exposure,
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x3 is a continuous variable indicating the year of life for a child,
x4 is a dichotomous variable indicating whether a child began the year in an
Appalachian county,
x5 is a dichotomous variable indicating whether a child began the year in a nonmetropolitan county,
x6 is a dichotomous variable indicating whether a child’s race was identified as
Black,
x7 is a dichotomous variable indicating whether a child’s race was identified as
Other,
x8 is a dichotomous variable indicating whether a child’s sex was identified as
female,
x9 is a dichotomous variable indicating whether a child’s mother was in the
Medicaid database,
x10 is a dichotomous variable indicating whether a child had a sibling born after
2014 identified in the Medicaid database,
x11 is a dichotomous variable indicating whether a child was in foster care for that
year of life,
x12 is a continuous variable indicating the number of claims a child accrued for that
year of life,
x13 is a continuous variable indicating the gestational age identified on the birth
certificate for the child,
and x14 is a continuous variable indicating the number of prenatal visits the child’s
mother obtained during pregnancy for the child.
6.4

Discussion
While many of the findings reached statistical significance, the actual meaningful

difference of the values must be considered. For example, the mean values for unique
pharmacy prescriptions for the three strata of children in Table 6.6 were 1.31, 1,42, and
1.40; median values for this were 1 for all strata. Functionally, these values do not represent
a great difference, though the analysis determined that these differences were statistically
significant.
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Statistical power is driven by both the effect size and the population size, and is
calculated as 1-β, or one minus the probability of a true positive.146 As sample size
increases, the probability that we will reject the null hypothesis also increases, thus creating
the phenomenon in administrative claims-based analyses of results that are wildly
statistically significant or wildly statistically insignificant. Thus, when considering
findings that are statistically significant in these types of analyses, functional (or clinical)
meaningfulness of the differences must be considered.
Many of our statistically significant differences in Table 6.5 and Table 6.6 are likely
due to the large sample size alone rather than the effect size, as the actual difference
between the groups for many of these figures are quite small. Therefore, though statistically
significant findings were discovered, those differences should be approached with caution
in interpretation.
Table 6.7 looked at overall total healthcare expenditures by year of life, as they apply
to the Medicaid system. In this table, we found results consistent with the findings of Corr
et al.42, finding that expenditures ceased being statistically different around ages four and
five for the population of children born on Kentucky Medicaid between 2014 and 2015.
There are many reasons this could be the case. One reason could be the introduction of
school into the child’s life around this time, leading to less contact with the parent and
therefore less time to obtain healthcare utilization. Additionally, many school systems have
nurses on staff, and small healthcare needs may be handled and brought to the caretaker’s
attention by the school nurse rather than by a billable physician. Another reason could be
the end of services such as NICU graduate programs that children with NAS may have
been involved with, where developmental screenings and enhanced attention and followup to these children were previously established. Nonetheless, this presents an interesting
pattern for Medicaid to consider when planning for expenditures in the future, and an area
where policies, such as enhancing managed care oversight for these children, could prove
beneficial in ensuring that no healthcare waste is being obtained and that caretakers have
adequate information on when care should be sought for children.
Conversely, in Table 6.1 and Table 6.2, it was determined that there is a population
of children that are not receiving any healthcare within a year of life in which they are, at
some point, enrolled in the Medicaid system. While a reason for this could be that the child
118

was not enrolled long enough during that year of life to utilize healthcare services, it is also
probable that the child simply did not receive any healthcare services for that year.
Considering both the years of life examined and the American Academy of Pediatrics wellchild visit schedule, this is a deviation from the standards established by that group of
practitioners. Medicaid then should prompt managed care organizations to intervene when
children are not receiving their recommended well-child visits to ensure that children are
having healthy childhoods.

6.4.1

Limitations and Future Directions

This chapter provides two novel approaches to economic analyses for this population
within the literature: first, the utilization of a non-Gaussian model to account for withinsubject variability, as a previous year’s healthcare expenditures are likely related to the
current year’s expenditures, as well as the utilization of an intercept variable for NAS and
time, indicating the rate at which expenditures for NAS and prenatal opioid exposure are
decreasing when compared to the comparator group. The utilization of the non-Gaussian
model and model-based standard errors does present the possibility that the covariance
structure was mis-specified in the model, thus creating inaccurate inference. One way to
protect against this in future analyses would be through the utilization of robust standard
errors as opposed to model-based standard errors; robust standard errors would act as a
protective measure ensuring that inference that is approximately correct while
acknowledging that the covariance matrix utilized in the analysis is likely mis-specified.
A sensitivity analysis was therefore conducted using the fully adjusted model to
ascertain whether inference from the model-based standard errors was approximately
unbiased by utilizing robust empirical standard error estimates. The results from this
sensitivity analysis are shown in Table 6.15 and given by the equation
𝑙𝑙𝑙𝑙(𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒)

= 8.84 + 0.99𝑥𝑥1 + 0.84𝑥𝑥2 − 0.32𝑥𝑥3 − 0.24𝑥𝑥1 𝑥𝑥3 − 0.27𝑥𝑥2 𝑥𝑥3 + 0.07𝑥𝑥4
− 0.03𝑥𝑥5 + 0.02𝑥𝑥6 + 0.002𝑥𝑥7 − 0.05𝑥𝑥8 + 0.10𝑥𝑥9 + 0.05𝑥𝑥10 + 0.05𝑥𝑥11
+ 0.03𝑥𝑥12 − 0.04𝑥𝑥13 + 0.0005𝑥𝑥14 + 𝜖𝜖
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where
x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS,
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal
opioid exposure,
x3 is a continuous variable indicating the year of life for a child,
x4 is a dichotomous variable indicating whether a child began the year in an
Appalachian county,
x5 is a dichotomous variable indicating whether a child began the year in a nonmetropolitan county,
x6 is a dichotomous variable indicating whether a child’s race was identified as
Black,
x7 is a dichotomous variable indicating whether a child’s race was identified as Other,
x8 is a dichotomous variable indicating whether a child’s sex was identified as
female,
x9 is a dichotomous variable indicating whether a child’s mother was in the Medicaid
database,
x10 is a dichotomous variable indicating whether a child had a sibling born after 2014
identified in the Medicaid database,
x11 is a dichotomous variable indicating whether a child was in foster care for that
year of life,
x12 is a continuous variable indicating the number of claims a child accrued for that
year of life,
x13 is a continuous variable indicating the gestational age identified on the birth
certificate for the child,
and x14 is a continuous variable indicating the number of prenatal visits the child’s
mother obtained during pregnancy for the child.
This equation is approximately equal to the final equation given by the results in
Table 6.11, indicating that the inference based on the final model is likely approximately
correct. The standard errors also showed minimal correction. While it remains true that the
covariance structure utilized within the scope of the analysis may possibly be mis-
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specified, the results of the sensitivity analysis indicate that the inference likely was not
impact by the error.
Another significant limitation to the findings of these analyses was the lack of
information surrounding diagnoses or reasons for the utilization of healthcare. The
comparator group population consisted of all children without evidence of prenatal opioid
exposure; while the group did, by definition, consist of children without any evidence of
prenatal opioid exposure, the group could have contained children with pediatric cancer
diagnoses, congenital defects, and children that were involved with traumatic automobile
accidents. However, the intent of this analysis was not to ascertain whether a child with
NAS accrued more healthcare costs than a child without evidence of health complications,
but to ascertain whether the average cost of a child with NAS varied from that of their
peers. That peer group does consist of both children with no evidence of health issues and
children with severe health issues. Additionally, having a diagnosis of NAS does not
necessarily pre-empt a child from experiencing a congenital defect, as was established by
Wen et al.,41 a cancer diagnosis, or an automobile accident, which may lead to increased
expenditures for those children as well. Additionally, children who died during the study
period were not identified or examined within the context of this work.
Given these limitations, future directions for this work would be to partner with an
economist to optimize the model utilized within this dissertation. The model produced here
was a mixed linear model as established by an epidemiologist; the model could benefit
significantly through consultations with an economist to understand more of the
econometrics required to accurate model such a relationship. Additionally, insight into
reasons for healthcare utilization should be examined in the future. Finally, additional
insight into the death rate of children on Kentucky Medicaid is an area of need.
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Table 6.1 Year of life and birth year cohort for children with no healthcare
expenditures during a year of life among the children born on Kentucky Medicaid
between 2014 and 2019.
Year of
Life
Birth to 1
1 to 2
2 to 3
3 to 4
4 to 5
5 to 6
Total

2014

2015

2016

2017

2018

2019

Total

416
2,113
2,512
2,748
2,035
2,467
12,291

287
1,976
2,387
2,552
2,620
-9,822

244
1,928
2,172
3,166
--7,510

198
1,772
2,592
---4,562

229
2,111
----2,340

261
-----261

1,635
9,900
9,663
8,466
4,655
2,467
36,786
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Table 6.2 Demographics of the children born on Kentucky Medicaid between 2014
and 2019 who had at least one year of no healthcare expenditures.
Characteristic
Number of
Percent among
Percent among
Children
Children with No
Children in the
Healthcare
Overall
Expenditures
Population
n=27,029
N=192,379
Prenatal Opioid
Exposure
NAS
1,088
4.03%
13.22%
Opioid Exposure
775
2.87%
13.24%
Comparator
25,166
93.11%
14.13%
Race
White
16,871
62.42%
13.31%
Black
3,476
12.86%
15.67%
Other
6,682
24.72%
15.37%
Sex
Male
13,743
49.15%
13.93%
Female
13,286
50.85%
14.17%
876
3.24%
10.52%
Foster Care
7,079
26.19%
11.89%
Appalachian
Metropolitan
Status
Metro
Non-Metro

15,960
11,069

59.05%
40.95%
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15.42%
12.45%

Table 6.3 Number of observations for each birth year cohort and year of life for the
population of children with at least $1 in healthcare expenditures and 1 paid claim
among the children born on Kentucky Medicaid between 2014 and 2019. N=583,845.
Year of
Life
Birth to 1
1 to 2
2 to 3
3 to 4
4 to 5
5 to 6
Total

2014

2015

2016

2017

2018

2019

Total

31,502
28,387
26,255
24,929
24,381
22,513
157,967

32,643
29,652
27,117
25,519
23,815
-138,746

31,981
28,890
26,278
23,569
--110,718

32,120
28,941
25,106
---86,167

31,579
27,861
----59,440

30,807
-----30,807

190,632
143,731
104,756
74,017
48,196
22,513
583,845
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Table 6.4 Demographics of the study population of children born on Kentucky
Medicaid between 2014 and 2019 with at least $1 of healthcare expenditures and 1
claim, stratified by opioid exposure status. N=191,156.
Characteristic
Sex at Birth*
Male
Female
Race
White
Black
Other
Appalachian at
Beginning of
Earliest
Observation
Metropolitan
Status
Metro
Non-Metro
Gestational
Age, mean
(S.D.)
Foster Care

NAS Diagnosis
n = 8,231

Exposure
Diagnosis
n=5,852

Comparator
Group
n=177,073

Total

N=191,156

4,387 (53.30%)
3,843 (46.69%)

3,017 (51.56%)
2,835 (48.44%)

90,609 (51.17%)
86,463 (48.83%)

98,013 (51.27%)
93,141 (48.73%)

6,323 (76.82%)
218 (2.65%)
1,690 (20.53%)
4,607 (55.93%)

3,909 (66.80%)
659 (11.26%)
1,284 (21.94%)
1,818 (31.07%)

115,922 (65.47%)
21,181 (11.96%)
39,970 (22.57%)
52,862 (29.85%)

126,154 (66.00%)
22,058 (11.54%)
42,944 (22.47%)
59,284 (31.01%)

P-Value
<0.0001
<0.0001

<0.0001

<0.0001
3,125 (37.97%)
5,106 (62.03%)
38.40 (1.75)

3,372 (57.62%)
2,480 (42.38%)
38.14 (2.26)

96,173 (54.31%)
80,900 (45.69%)
38.63 (1.73)

102,670 (53.71%)
88,486 (46.29%)
38.61 (1.75)

<0.0001

1,612 (19.58%)

905 (15.46%)

5,750 (3.25%)

8,267 (4.32%)

<0.0001

*A suppressed number of observations (n ≤10) are missing from these tallies; to minimize the potential for
reidentification, the missing figures are not reported here.
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Table 6.5 Measures of central tendency for select health utilization figures for the
population of children born on Kentucky Medicaid between 2014 to 2019 with at
least one claim and $1 of healthcare expenditures in each year of life, stratified by
opioid exposure status. N=583,845.
TOTAL HEALTHCARE EXPENDITURES
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
10,580.02
8,967.70

Median
2,284
2,180

Stan. Dev.
38,465.12
32,099.08

Minimum
2
1

Maximum
3,479,574
1,079,300

4,446.95
4,844.26

1,457
1,489

23,557.61
24,772.57

1
1

3,305,638
3,479,574

TOTAL HEALTHCARE UTILIZATION
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
31.50
27.52

Median
17
18

Stan. Dev.
36.34
34.78

Minimum
1
1

Maximum
670
656

31.50
24.68

22
17

28.47
29.09

1
1

907
907

TOTAL INPATIENT EXPENDITURES
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
22,366.89
15,582.03

Median
19,262
7,158

Stan. Dev.
59,590.21
41,565.50

Minimum
50
86

Maximum
3,370,499
1,007,445

7,518.46
8,521.18

1,269
1,410

37,086.58
38,801.82

1
1

3,216,231
3,370,499

TOTAL OUTPATIENT EXPENDITURES
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
868.84
916.35

Median
360.50
387

Stan. Dev.
2,070.11
1,892.93

Minimum
1
1

Maximum
118,378
53,062

827.25
831.66

364
365

5,835.07
5,643.44

1
1

2,155,788
2,155,788
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P-Value
<0.0001

P-Value
<0.0001

P-Value
<0.0001

P-Value
0.21

Table 6.6 Measures of central tendency for select pharmacy utilization figures and
components for the population of children born on Kentucky Medicaid, 2014 to
2019, stratified by opioid exposure status.
TOTAL PHARMACY EXPENDITURES
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
376.52
593.26

Median
80
60

Stan. Dev.
3,344.82
6,988.94

Minimum
1
1

Maximum
197,064
381,706

316.19
326.64

62
63

4,269.38
4,330.30

1
1

1,544,841
1,544,841

TOTAL NUMBER OF PRESCRIPTIONS
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
7.21
5.80

Median
5
4

Stan. Dev.
9.32
8.29

Minimum
0
0

Maximum
154
115

5.60
6.04

4
4

7.74
7.95

0
0

433
433

NUMBER OF UNIQUE PRESCRIPTIONS
NAS
Prenatal
Exposure
Comparator
Total
Population

Mean
1.40
1.42

Median
1
1

Stan. Dev.
0.66
0.65

Minimum
1
1

Maximum
8
12

1.31
1.32

1
1

0.54
0.55

1
1

14
14
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P-Value
<0.0001

P-Value
<0.0001

P-Value
<0.0001

Table 6.7 Measures of central tendency for overall healthcare expenditures for the
population of children born on Kentucky Medicaid, 2014 to 2019, stratified by
opioid exposure status and year of life.
Year
Mean
Median
Minimum Maximum P-Value
of
Life
NAS
22,036
9
3,479,574
<0.0001*
26,209.68
Birth
Opioid Exposed
8,969
28
1,079,300
19,001.90
to 1
Comparator
1 to 2

2 to 3

3 to 4

4 to 5

5 to 6

Total Population
NAS
Opioid Exposed
Comparator
Total Population
NAS
Opioid Exposed
Comparator
Total Population
NAS
Opioid Exposed
Comparator
Total Population
NAS
Opioid Exposed
Comparator
Total Population
NAS
Opioid Exposed
Comparator
Total Population

8,847.00
9,907.32
3,774.37
3,756.12
2,663.87
2,747.05
3,561.57
3,253.17
2,245.20
2,333.81
2,789.84
2,670.69
1,989.57
2,042.08
2,525.85
2,642.74
2,132.65
2,158.55
2,429.56
2,778.23
1,973.21
2,005.29

3,120
3,350
1,286
1,110
1,049
1,059
975.50
814
789
797
884
733.50
728
733
989
791
823
829.50
886
992
784
792

1
1
2
1
1
1
2
2
1
1
2
2
1
1
2
2
1
1
3
35
1
1

3,305,638
3,479,574
425,793
335,420
2,201,698
2,201,698
442,993
395,209
1,002,928
1,002,928
246,861
286,661
1,028,624
1,028,624
115,570
135,768
2,551,759
2,551,759
165,191
132,737
410,361
410,361

<0.0001*

<0.0001*

<0.0001*

0.27

0.04

*To account for multiple comparisons, a Bonferroni adjustment was applied to the
α threshold, creating an adjusted α threshold of 0.008. An asterisk denotes a
statistically significant finding.
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Table 6.8 Factors identified by the DAG, proxy variables available within the data,
justification, and models the variables were included in for the linear mixed model
of the association between prenatal opioid exposure and healthcare expenditures.
Item in the
DAG
Access to care

Proxy
Variable(s)
Appalachian
status;
metropolitan
status

Race

Race

Sex

Sex

Caretaker
efficacy

Mother on
Medicaid;
sibling on
Medicaid;
foster care
involvement
Number of
claims;
gestational
age; prenatal
care

Clinical
characteristics

Justification

The ability to obtain healthcare
depends upon the proximity to
healthcare.209 Known shortages of
doctors in rural areas of the
United States.210 Appalachian
Kentucky has traditionally
struggled with access to care.211
Race often determines the care
one can access, as well as the care
received in a healthcare setting.212
There may be gender differences
in healthcare utilization in
children.213,214 Male sex has been
associated with NAS.65
Parents determine when a child
gets healthcare.215 Foster care
children have unique healthcare
needs.115
Best indicator of sickness in a
child available in the dataset is
the utilization of healthcare
resources. Gestational age has
been associated with increased
healthcare utilization.216 Prenatal
care is vital for a healthy birth,
though long-term effects are still
in question.217

*Code for the DAG described above can be found in the Appendix.
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Saturated
Means Model
X

Parsimonious
Means Model
X

X

X

X

X

X

X

Table 6.9 Goodness of fit tests for a normal distribution of the transformation
ln(Total Expenditures).
Test
Statistic
P-Value
Kolmogorov-Smirnov
0.03
<0.01
Cramer-von Mises
84.22
<0.005
Anderson-Darling
537.40
<0.005
*The results in Table 6.9 indicate that the distribution shown in Figure 6.3 is significantly
different from the normal distribution, indicating that the normality assumption may be
violated.
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Table 6.10 Covariance structure selection criteria following the fitting of a saturated
means model into a linear mixed effects model.
Covariance Structure
AIC**
Compound symmetry, common variance
1,555,282
Exponential power decay, common
1,543,380
variance

*The observational study in Chapter 6 is an unbalanced design, therefore, testing unstructured covariance structures,
Toeplitz covariance structures, AR-1 covariance structures, and banded covariance structures were considered
impractical and inappropriate for the model and therefore excluded from consideration.
**AIC selection criterion dictates that the model with the smallest AIC value is the most efficient estimate of the
covariance structure of the model. In Table 6.9, the AIC selected exponential power decay as the working covariance
structure.
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Table 6.11 Results of the linear mixed effects model modeling differences in overall
healthcare expenditures for children with prenatal opioid exposure over time,
saturated means model.
Variable
Parameter
Standard
95%
95%
P-Value
Estimate
Error
Confidence Confidence
Estimate
Interval
Interval
Lower
Upper
Bound
Bound
Intercept
8.84
0.042
8.76
8.92
<.0001
Opioid
<.0001
Exposure
NAS
0.99
0.015
0.96
1.02
<.0001
Prenatal
0.84
0.018
0.80
0.88
<.0001
Exposure
Year
-0.32
0.001
-0.32
-0.32
<.0001
Interaction
<.0001
NAS*Year
-0.24
0.001
-0.24
-0.24
<.0001
Exp*Year
-0.27
0.005
-0.28
-0.26
<.0001
Appalachian
0.07
0.004
0.06
0.08
<.0001
Status
Metropolitan
<.0001
Status
Non-Metro
-0.03
0.004
-0.04
-0.02
<.0001
0.0003
Race
0.02
0.005
-0.03
-0.01
<.0001
Black
Other
0.0002
0.004
-0.008
0.0008
0.97
Female at
-0.05
0.003
-0.06
-0.04
<.0001
Birth
Mother on
0.10
0.020
0.06
0.14
<.0001
Medicaid
Sibling on
0.05
0.003
0.04
0.06
<.0001
Medicaid
Foster Care
0.30
0.008
0.28
0.32
<.0001
Involvement
Number of
0.03
0.00006
0.03
0.03
<.0001
Claims
Gestational
-0.04
0.001
-0.04
-0.04
<.0001
Age
Prenatal
0.0005
0.00009
-0.001
0.002
<.0001
Care
*175,731 subjects composed the model population. Of the 583,845 observations
read, 546,000 were utilized. 37,845 observations were excluded for missing data.
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Table 6.12 Results of the linear mixed effects model modeling differences in overall
healthcare expenditures for children with prenatal opioid exposure over time,
parsimonious means model.
Variable
Parameter
Standard
95%
95%
P-Value
Estimate
Error
Confidence Confidence
Estimate
Interval
Interval
Lower
Upper
Bound
Bound
Intercept
8.38
0.005
8.37
8.39
<.0001
Opioid
<.0001
Exposure
NAS
1.49
0.019
1.45
1.53
<.0001
Prenatal
1.14
0.023
1.09
1.19
<.0001
Exposure
Year
-0.45
0.001
-0.45
-0.45
<.0001
Exposure
<.0001
and Year
Interaction
NAS*Year
-0.33
0.006
-0.34
-0.32
<.0001
Exp*Year
-0.34
0.009
-0.36
-0.32
<.0001
Appalachian
0.23
0.006
0.22
0.24
<.0001
Status
Metropolitan
Status
Non-Metro
0.03
0.005
0.02
0.04
<.0001
0.70
Race
-0.001
0.007
-0.01
0.01
0.84
Black
Other
0.004
0.006
-0.01
0.02
0.45
Female at
-0.13
0.004
-0.14
-0.12
<.0001
Birth
*191,154 subjects composed the model population. Of the 583,845 observations
read, 583,843 were utilized. 2 observations were excluded for missing data.
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Table 6.13 Results of the linear mixed effects model modeling differences in overall
healthcare expenditures for children with prenatal opioid exposure over time,
parsimonious means model, additional adjustment.
Variable
Parameter
Standard
95%
95%
P-Value
Estimate
Error
Confidence Confidence
Estimate
Interval
Interval
Lower
Upper
Bound
Bound
Intercept
8.39
0.005
8.37
8.39
<.0001
Opioid
<.0001
Exposure
NAS
1.49
0.019
1.45
1.53
<.0001
Prenatal
1.14
0.023
1.09
1.19
<.0001
Exposure
Year
-0.45
0.001
-0.45
-0.45
<.0001
Exposure
<.0001
and Year
Interaction
NAS*Year
-0.33
0.006
-0.34
-0.32
<.0001
Exp*Year
-0.34
0.009
-0.36
-0.32
<.0001
Appalachian
0.22
0.006
0.22
0.24
<.0001
Status
Metropolitan
Status
Non-Metro
0.03
0.005
0.02
0.04
<.0001
Female at
-0.13
0.004
-0.14
-0.12
<.0001
Birth
*191,154 subjects composed the model population. Of the 583,845 observations
read, 583,843 were utilized. 2 observations were excluded for missing data.
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Table 6.14 Model comparison following the fitting of three different models into a
linear mixed effects model with an exponential power decay covariance structure.
Means Model
AIC*
Saturated means model (Table 6.11)
1,543,380
Parsimonious means model (Table 6.12)
1,915,859
Parsimonious means model, additional
1,915,843
adjustment (Table 6.13)
*AIC selection criterion dictates that the model with the smallest AIC value is the
most efficient estimate of the covariance structure of the model. The AIC selection
criteria identified the saturated means model as the final model.
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Table 6.15 Results of the linear mixed effects model modeling differences in overall
healthcare expenditures for children with prenatal opioid exposure over time,
robust empirical standard error estimates.
Variable
Parameter
Standard Error
P-Value
Estimate
Estimate
Intercept
8.84
0.062
<.0001
Opioid Exposure
<.0001
NAS
0.99
0.018
<.0001
Prenatal Exposure
0.84
0.021
<.0001
Year
-0.32
0.002
<.0001
Interaction
<.0001
NAS*Year
-0.24
0.006
<.0001
Exp*Year
-0.27
0.009
<.0001
Appalachian Status
0.07
0.004
<.0001
Metropolitan Status
<.0001
Non-Metro
-0.03
0.004
<.0001
0.0005
Race
0.02
0.005
0.0001
Black
Other
0.0002
0.004
0.97
Female at Birth
-0.05
0.003
<.0001
Mother on Medicaid
0.10
0.021
<.0001
Sibling on Medicaid
0.05
0.003
<.0001
Foster Care
0.30
0.009
<.0001
Involvement
Number of Claims
0.03
0.0003
<.0001
Gestational Age
-0.04
0.001
<.0001
Prenatal Care
0.0005
0.00001
<.0001
*175,731 subjects composed the model population. Of the 583,845 observations
read, 546,000 were utilized. 37,845 observations were excluded for missing data.
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Figure 6.1 Directed acyclic graph (DAG) illustrating the relationship between
prenatal opioid exposure and healthcare expenditures.
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Figure 6.2 Distribution of all total expenditures for the population of children born
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures
and 1 claim for a given year, untransformed.
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Figure 6.3 Distribution of all total expenditures for the population of children born
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures
and 1 claim for a given year, following the transformation ln(total expenditures).
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Figure 6.4 Distribution of all total expenditures for the population of children born
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures
and 1 claim for a given year, following the transformation ln(ln(total expenditures)).
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Figure 6.5 Distribution of all total expenditures for the population of children born
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures
and 1 claim for a given year, following the transformation ln(ln(ln(total
expenditures))).
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CHAPTER 7. CONCLUSION
7.1

Summary
In an American healthcare context, it is impossible to separate the provision of

healthcare from a person’s insurance coverage. One of the largest strides in healthcare
coverage occurred in 2012 with the passage of the Affordable Care Act.88 Kentucky was
one of the first states to expand their state Medicaid program.88 Prior to this expansion,
back in 1990s, Kentucky made the decision to house their CHIP program within Medicaid.
In 1990, the passage of KRS 205.592 mandated Medicaid coverage for the duration of the
first year of a child’s life.38 All these items in tandem, along with the creation of OHDA as
a “data hub” in existence to provide analytics for the Kentucky Department for Medicaid
Services, permitted the Kentucky Medicaid MMIS to be an optimal dataset to use in the
examination of childhood outcomes for NAS.
The literature synthesis in Chapter 2 identified significant gaps in the published
literature, as well as validated the ICD-9 and ICD-10 codes used to ascertain a diagnosis
of NAS in the literature using Tennessee Medicaid data linked to medical records.59
Additionally, many of these studies identified factors that would be important
considerations in the work of later chapters.
Chapter 3 contained the methodology and demographics for the study population
utilized within the chapters in this dissertation. Consistent with most of the published
literature, the population of children with a diagnosis of NAS were largely White, mostly
male, and the majority resided in non-metropolitan counties and/or Appalachian counties
within Kentucky. Additionally, retention to Kentucky Medicaid and HEDIS continuous
enrollment were assessed, showing a long retention to the Kentucky Medicaid system for
the study population utilized within this dissertation.
Chapter 4 presented evidence that family units (i.e., mothers and children) are
frequently covered in tandem within the Medicaid system and that a significant number of
opioid exposed children are involved with the foster care system. Additionally, a large
percentage of children with evidence of placental transference of opioids seem to be living
apart from their mother.
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The studies in Chapter 5 determined that, while differences identified were
considered statistically different, there may not be clinically meaningful differences in
gastrointestinal conditions for the population of children with NAS. Asthma, however, did
present a significant signal that is consistent with other prior published work in this
area.42,79 Mental health conditions, however, consistent with the findings of Sherman et
al.78 and Conner et al.79, appeared to be elevated for one- and two-year-old children
diagnosed with NAS in the study population. As was hypothesized in Chapter 1, these were
largely driven by developmental delays. Foster care also seemed to be an important driver
within this analysis.
Finally, the study of healthcare utilization in Chapter 6 found results consistent with
the seminal studies conducted by Taylor et al.60 and Corr et al.42 in this area. In this analysis,
total expenditures were found to be significantly different between the strata of children
through age three, with the differences ceasing at ages 4 and 5. Finally, in the modeled
analysis, while total expenditures for NAS and prenatal opioid exposure were higher than
the comparator group and while costs did decrease over time, the costs decreased at a faster
rate over time than the comparator group, suggesting that, eventually, if the trend continues,
there should be an inflection point where the expenditures of the children with a diagnosis
of NAS and the expenditures of the children with a diagnosis of prenatal opioid exposure
would eventually reach the level of their peers.
7.1.1

Policy Recommendations

This dissertation identifies several options for Medicaid policy to be enacted to
stimulate better health outcomes for this population. First, because of the large number of
families on Medicaid coupled with the long retention of children to the Medicaid system,
Medicaid would stand to benefit from investing in prophylactic measures for this
population. Additionally, all children in the Kentucky Medicaid system are currently
managed by one managed care organization (MCO). By taking advantage of the MCO
structure, families could be pressed when children are not meeting well-child visit
thresholds or are accumulating excess expenditures.
Second, Medicaid also has a responsibility to ensure the health and safety of
children involved with the foster care system. Foster care was identified within this
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dissertation as an important factor in all analyses surrounding NAS. As shown in Chapter
5, the group of children with a diagnosis of NAS involved in the foster care system is
largely driving the diagnoses of mental health conditions. As identified in Chapter 4,
children entering foster care between these ages are most commonly doing so within the
first year of that child’s life, when the well-child visit schedule for an infant is more
demanding than for other ages.206 Medicaid should monitor whether this group of children
is meeting this schedule and Medicaid should seek interventions and reminders when a
child has missed several well-child visit milestones. As developmental delays are driving
the diagnoses obtained by these children in these early years of life, ensuring that children
are meeting those well-child visits in early childhood is critical to ensuring that adequate
child development is occurring and that children are receiving proper health interventions
when needed to ensure happy and healthy childhoods.
Third, participation in prophylactic measures and well-child visits should be
incentivized for families, as are already being offered by some health insurance coverage
plans.218 By offering rewards and perks for adherence to the schedule, such as car seats218,
Medicaid could offset some of the healthcare expenditures that could arise because of
accumulated healthcare problems that become urgent medical needs when the situation
could have been handled at a routine care visit prior to becoming an issue. The Medicaid
system also stands to benefit from an investment in prophylaxis given the long retention to
the system for children born on Kentucky Medicaid due to the long duration of retention
to the Kentucky Medicaid system, as established in Chapter 3. As children are maintaining
their Medicaid enrollment for relatively long durations of time, Medicaid has the potential
to see a benefit from such measures being implemented within the next decade as the
children assessed progress into adolescence and then finally into adulthood.
7.1.2

Future Directions

The creation of this dataset identified several areas for future research. One of the
most opportunistic areas that should be further examined with this population is the
creation of mother-baby dyads and sibling-dyads among children with evidence of prenatal
opioid exposure. Because almost a quarter of children with NAS in this population have a

144

sibling with some sort of prenatal opioid exposure, both children could be followed in
tandem to see how their life course differs over time.
Additionally, more extensive examination of physical health outcomes related to
NAS is warranted. NAS impacts an extensive number of body systems of an infant; little
information exists on the result of this assault later in the child’s life.
Finally, additional examination of the economic impact of NAS on the Medicaid
system should be conducted. As these children grow and develop, more information will
come to light as the years move forward. Moreover, the Opioid Epidemic continues shifting
and moving; the state and the drugs at the center of the epidemic in 2014 differ from those
at the center of the Epidemic today. There is growing evidence that methamphetamine, for
which no medication assisted therapy exists as of the time of writing, is a growing problem
within the United States. The influence these changes have on the results of these analyses
should not be dismissed; though these findings are accurate to the best of the author’s
knowledge as of the time of writing, the results may differ as changes occur within the
Medicaid system and within the culture in the years to come. These analyses should be
returned to in a few years to see if any differences in the findings arisen.
7.2

Conclusion
Between ages 1 to 5, this dissertation provides evidence that prenatal exposure to

opioids continues to have a lasting impact on a child’s life. Placental transference of opioids
is associated with residing in a different household than the mother, with increased asthma
diagnoses, and increased mental health condition diagnoses within this population, and has
a lasting fiscal impact that diminishes over time. Special attention and additional policy
considerations should be given to these children to ensure the children have safe, strong
environments to grow and develop within.
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APPENDICES

APPENDIX 1. DATA ELEMENTS OBTAINED FROM THE OFFICE OF HEALTH
DATA AND ANALYTICS WITHIN THE KENTUCKY DEPARTMENT FOR
MEDICAID SERVICES.
Variable Obtained

Explanation

Subject-level deidentified
identifier

Utilized to be able to link
successive years of claims
together
An indicator variable
identifying whether a child
was diagnosed with ICD-9
codes 779.5 or 760.72 or
ICD-10 codes P96.1 or
P04.49.
The exact prenatal opioid
exposure diagnosis code
the child was diagnosed
with at birth; in instances
where the child obtained
both, the withdrawal code
was preferred.
The year the child was
born

Prenatal opioid exposure
identifier

Prenatal opioid exposure
diagnosis code

Birth year cohort
Year of life

A variable indicating the
year of life the variables
applied to for an
observation for each child

Race

The race of the child
provided on the enrollment
form
The sex of the child
provided on the enrollment
form

Sex
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Information on the
Variable
Random character variable,
unique for each child in the
analysis
Dichotomous variable (1 –
Yes; 0 – No)

Character variable of five
levels: 7795, 76072, P961,
P0449, or 0

Categorical variable
ranging between 2014 and
2019
Categorical variable
ranging between 1
(meaning the time from
birth to the day before the
child’s first birthday, or the
child’s first full year of
life) to 6 (meaning the time
from the child’s fifth
birthday to the day before
the child’s sixth birthday,
or the child’s sixth year of
life)
Character variable of three
levels: WHITE, BLACK,
OTHER
Character variable of three
levels: M, F, U. U was
recoded to missing in the
analysis.

County of residence at the
beginning of the child’s
year of life

The county of residence
provided on the enrollment
form at the beginning of
the year of life

County of residence at the
end of the child’s year of
life

The county of residence
provided on the enrollment
form at the end of the year
of life

RUC code at the beginning
of the child’s year of life

The RUC code associated
with the child’s county of
residence at the beginning
of the year of life
RUC code at the end of the The RUC code associated
child’s year of life
with the child’s county of
residence at the beginning
of the year of life
Foster care flag
A longitudinal variable
indicating whether the
child was involved with the
foster care system during
that year of life
Continuous enrollment flag
A variable indicating
whether the child was
continuously enrolled by
HEDIS standards for that
year of life
Mother on Medicaid
A variable indicating
whether the child’s mother
could be identified in the
MMIS system
Sibling on Medicaid
A variable indicating
whether a sibling for the
child (born between 2014
and the end of the study
period) could be identified
in the MMIS system
Sibling with NAS
A variable indicating
whether an identified
sibling was diagnosed with
one of the prenatal opioid
exposure codes at birth
Same household as the
A variable indicating
mother
whether a child was always
enrolled in the Medicaid
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Categorical variable
ranging from 1 to 120, with
a few outliers indicating a
child resided outside
Kentucky
Categorical variable
ranging from 1 to 120, with
a few outliers indicating a
child resided outside
Kentucky
Categorical variable
ranging from 1 to 9
Categorical variable
ranging from 1 to 9
Dichotomous variable (1 –
Yes, 0 – No)

Dichotomous variable (Y –
yes; N – no)

Dichotomous variable (1 –
Yes; 0 – No)
Dichotomous variable (1 –
Yes; 0 – No)

Dichotomous variable (1 –
Yes; 0 – No)

Dichotomous variable (1 –
Yes; 0 – No)

Maternal smoking

Gestational diabetes
mellitus

Gestational hypertension

Multigravida

Infant hepatitis C

Number of prenatal visits

Gestational age

Mental health conditions
indicator

Gastrointestinal conditions
indicator

system at the same address
as the mother
A variable obtained from
the birth certificate
indicating whether the
mother was a smoker at
birth
A variable obtained from
the birth certificate
indicating whether the
mother was diagnosed with
gestational diabetes
A variable obtained from
the birth certificate
indicating whether the
mother was diagnosed with
gestational hypertension
A variable obtained from
the birth certificate
indicating whether this was
the mother’s first child
A variable obtained from
the birth certificate
indicating whether the
infant was exposed to
hepatitis C in utero
A variable obtained from
the birth certificate
indicating the number of
prenatal visits the mother
acquired
A variable obtained from
the birth certificate
estimating the gestational
age of the child at birth
A variable identifying if
the child had been
diagnosed with one of the
diagnosis codes indicating
a mental health condition
A variable identifying if
the child had been
diagnosed with one of the
diagnosis codes indicating
a gastrointestinal condition
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Categorical variable: 1 –
Yes; 0 – No; 9 – Unknown

Categorical variable: 1 –
Yes; 0 – No; 9 – Unknown

Categorical variable: 1 –
Yes; 0 – No; 9 – Unknown

Categorical variable: 1 –
Yes; 0 – No; 9 – Unknown
Categorical variable: 1 –
Yes; 0 – No; 9 – Unknown

Continuous variable, with
99 coded as missing

Continuous, bounded
variable with 99 coded as
missing
Dichotomous variable (1 –
Yes; 0 – No)

Dichotomous variable (1 –
Yes; 0 – No)

Respiratory conditions
indicator

Total expenditures
Total number of claims
Well child expenditures
Number of well child
claims
Outpatient expenditures
Number of outpatient
claims
Inpatient expenditures
Number of inpatient claims
Birth total

Behavioral health claims
Pharmacy expenditures
Number of pharmacy
claims
Unique pharmacy drugs

A variable identifying if
the child had been
diagnosed with one of the
diagnosis codes indicating
a respiratory condition
A variable summing the
annual expenditures for a
child
A variable summing the
annual number of claims
for a child
The total cost of the well
child visits for a child
The total number of claims
for a well child visit each
year for a child
The total cost of the
outpatient claims each year
for a child
The total number of the
outpatient claims each year
for a child
The total cost of the
inpatient claims each year
for a child
The total number of the
inpatient claims each year
for a child
The estimated total cost of
the birth event as a child,
defined as time from birth
to first 48-hour gap
The total number of
behavioral health claims
each year for a child
The total cost of all
pharmacy claims each year
for a child
The total number of
pharmacy claims each year
for a child
The total number of unique
drugs each year for a child
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Dichotomous variable (1 –
Yes; 0 – No)

Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric
Continuous numeric

In theory, continuous
numeric; here, all 0
Continuous numeric
Continuous numeric
Continuous numeric

APPENDIX 2. COUNTIES IDENTIFIED AS APPALACHIAN COUNTIES BY THE
APPALACHIAN REGIONAL COMMISSION. 111

APPENDIX 3. COUNTIES IDENTIFIED AS METROPOLITAN OR NONMETROPOLITAN BASED ON THE RURAL URBAN CONTINUUM CODES
PROVIDED BY THE UNITED STATES DEPARTMENT OF AGRICULTURE.110
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APPENDIX 4. KENTUCKY 2010 POPULATION DISTRIBUTION BASED ON
NUMBERS AVAILABLE WITHIN THE .SHP FILE FROM THE KENTUCKY GIS
SERVER

APPENDIX 5. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE
AND BEING LOCATED IN A DIFFERENT HOUSEHOLD IN CHAPTER 4.
dag {
"Birth Year" [pos="0.058,-0.800"]
"Continued Substance Use" [pos="0.599,-0.006"]
"Different Household" [outcome,pos="0.433,0.505"]
"Foster Care" [pos="-0.295,0.054"]
"Gestational Age" [pos="-0.557,1.124"]
"Physical Location" [pos="-1.153,-0.122"]
"Prenatal Opioid Exposure" [exposure,pos="-1.055,0.498"]
Abuse [pos="-0.440,-0.846"]
Poverty [pos="0.035,1.089"]
Race [pos="0.425,-0.540"]
Sex [pos="-0.815,-0.619"]
"Birth Year" -> "Different Household"
"Birth Year" -> "Foster Care"
"Birth Year" -> "Prenatal Opioid Exposure"
"Continued Substance Use" -> "Different Household"
"Continued Substance Use" -> "Foster Care"
"Continued Substance Use" -> "Prenatal Opioid Exposure"
"Continued Substance Use" -> Abuse
"Foster Care" -> "Different Household"
"Foster Care" <-> "Physical Location"
"Gestational Age" -> Abuse
"Physical Location" -> "Continued Substance Use"
"Physical Location" -> "Different Household"
"Physical Location" -> "Prenatal Opioid Exposure"
"Physical Location" -> Poverty
"Physical Location" -> Race
"Prenatal Opioid Exposure" -> "Different Household"
"Prenatal Opioid Exposure" -> "Foster Care"
"Prenatal Opioid Exposure" -> "Gestational Age"
"Prenatal Opioid Exposure" -> Abuse
Abuse -> "Different Household"
Abuse -> "Foster Care"
Poverty -> "Different Household"
Poverty -> "Foster Care"
Poverty -> "Gestational Age"
Poverty -> "Prenatal Opioid Exposure"
Poverty -> Abuse
Poverty -> Race
Race -> "Continued Substance Use"
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Race -> "Different Household"
Race -> "Foster Care"
Race -> "Gestational Age"
Race -> "Prenatal Opioid Exposure"
Race -> Abuse
Sex -> "Different Household"
Sex -> "Prenatal Opioid Exposure"
}
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APPENDIX 6. HISTOGRAM SHOWING THE DISTRIBUTION OF GESTATIONAL
AGE FOR THE STUDY POPULATION UTILIZED IN CHAPTER 4.
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APPENDIX 7. CHECKING FOR LINEARITY IN THE LOG ODDS OF THE
ASSOCIATION BETWEEN GESTATIONAL AGE AND A CHILD ENROLLING IN
MEDICAID AT A DIFFERENT ADDRESS THAN THE MOTHER’S.
Odds Ratio Estimates
Effect

Point Estimate

95% Wald
Confidence Limits

23 Weeks vs 40

16.667

7.658

36.275

24 Weeks vs 40

5.601

3.761

8.342

25 Weeks vs 40

5.113

3.544

7.374

26 Weeks vs 40

4.632

3.301

6.499

27 Weeks vs 40

3.006

2.147

4.208

28 Weeks vs 40

3.120

2.310

4.214

29 Weeks vs 40

2.891

2.175

3.844

30 Weeks vs 40

1.998

1.558

2.563

31 Weeks vs 40

1.267

1.001

1.603

32 Weeks vs 40

1.682

1.404

2.016

33 Weeks vs 40

1.420

1.211

1.665

34 Weeks vs 40

1.260

1.114

1.425

35 Weeks vs 40

1.356

1.232

1.492

36 Weeks vs 40

1.176

1.096

1.260

37 Weeks vs 40

1.069

1.019

1.122

38 Weeks vs 40

1.093

1.050

1.139

39 Weeks vs 40

0.984

0.952

1.017

41 Weeks vs 40

0.990

0.930

1.053

42 Weeks vs 40

0.981

0.753

1.279

43 Weeks vs 40

1.132

0.422

3.032

44 Weeks vs 40

2.151

0.394

11.744

45 Weeks vs 40

<0.001 <0.001 >999.999

47 Weeks vs 40

<0.001 <0.001 >999.999
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APPENDIX 8. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE
AND ASTHMA IN CHAPTER 5.
dag {
"Gestational Age" [pos="-0.253,0.843"]
"Maternal Smoking" [pos="-1.515,-0.200"]
"Physical Environment" [pos="-0.290,-0.298"]
"Prenatal Opioid Exposure" [exposure,pos="-1.222,0.512"]
Asthma [outcome,pos="0.569,0.505"]
Genetics [latent,pos="1.113,0.462"]
Race [pos="0.721,-0.221"]
Sex [pos="-0.719,-0.981"]
"Gestational Age" -> "Prenatal Opioid Exposure"
"Gestational Age" -> Asthma
"Maternal Smoking" -> "Gestational Age"
"Maternal Smoking" -> "Prenatal Opioid Exposure"
"Maternal Smoking" -> Asthma
"Maternal Smoking" <-> "Physical Environment"
"Physical Environment" -> "Gestational Age"
"Physical Environment" -> "Prenatal Opioid Exposure"
"Physical Environment" -> Asthma
"Prenatal Opioid Exposure" -> Asthma
Genetics -> Asthma
Race -> "Gestational Age"
Race -> "Physical Environment"
Race -> "Prenatal Opioid Exposure"
Race -> Asthma
Sex -> "Gestational Age"
Sex -> "Prenatal Opioid Exposure"
Sex -> Asthma
}
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APPENDIX 9. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE
AND COGNITIVE DEVELOPMENT IN CHAPTER 5.
dag {
"Cognitive Development" [outcome,pos="0.642,0.646"]
"Family Structure" [pos="0.674,-0.016"]
"Gestational Age" [pos="-0.295,-0.826"]
"Home Environment" [pos="-0.285,-0.326"]
"Prenatal Opioid Exposure" [exposure,pos="-1.159,0.610"]
"Socioedemographic Factors" [pos="-1.358,-0.207"]
ACEs [pos="-0.280,0.962"]
"Family Structure" -> "Cognitive Development"
"Family Structure" -> "Prenatal Opioid Exposure"
"Family Structure" -> ACEs
"Gestational Age" -> "Cognitive Development"
"Gestational Age" -> "Prenatal Opioid Exposure"
"Home Environment" -> "Cognitive Development"
"Home Environment" -> "Family Structure"
"Home Environment" -> "Prenatal Opioid Exposure"
"Home Environment" -> ACEs
"Prenatal Opioid Exposure" -> "Cognitive Development"
"Prenatal Opioid Exposure" -> ACEs
"Socioedemographic Factors" -> "Cognitive Development"
"Socioedemographic Factors" -> "Home Environment"
"Socioedemographic Factors" -> "Prenatal Opioid Exposure"
"Socioedemographic Factors" -> ACEs
ACEs -> "Cognitive Development"
}
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APPENDIX 10. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE
AND HEALTHCARE EXPENDITURES IN CHAPTER 6.
dag {
"Access to Care" [pos="-1.107,-0.312"]
"Caretaker Efficacy" [pos="-0.363,0.223"]
"Clinical Characteristics" [pos="-0.217,0.934"]
"Healthcare Expenditures" [outcome,pos="0.496,0.575"]
"Prenatal Opioid Exposure" [exposure,pos="-1.049,0.582"]
Genetics [latent,pos="0.621,-0.045"]
Race [pos="-0.248,-0.664"]
Sex [pos="-0.253,-0.221"]
"Access to Care" -> "Clinical Characteristics"
"Access to Care" -> "Healthcare Expenditures"
"Access to Care" -> "Prenatal Opioid Exposure"
"Access to Care" <-> "Caretaker Efficacy"
"Caretaker Efficacy" -> "Clinical Characteristics"
"Caretaker Efficacy" -> "Healthcare Expenditures"
"Clinical Characteristics" -> "Healthcare Expenditures"
"Prenatal Opioid Exposure" -> "Caretaker Efficacy"
"Prenatal Opioid Exposure" -> "Clinical Characteristics"
"Prenatal Opioid Exposure" -> "Healthcare Expenditures"
Genetics -> "Clinical Characteristics"
Genetics -> "Healthcare Expenditures"
Race -> "Access to Care"
Race -> "Healthcare Expenditures"
Race -> "Prenatal Opioid Exposure"
Sex -> "Healthcare Expenditures"
Sex -> "Prenatal Opioid Exposure"
}
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